id
stringlengths 1
5
| document_id
stringlengths 5
8
| passages
list | entities
list | events
sequence | coreferences
sequence | relations
sequence |
|---|---|---|---|---|---|---|
79440 | 663366 | [
{
"id": "79441",
"type": "document",
"text": [
"[ Maintaining sinus rhythm with quinidine and amiodarone after electric cardioversion ] ."
],
"offsets": [
[
0,
89
]
]
}
] | [
{
"id": "79442",
"type": "Intervention_Pharmacological",
"text": [
"quinidine"
],
"offsets": [
[
32,
41
]
],
"normalized": []
},
{
"id": "79443",
"type": "Intervention_Pharmacological",
"text": [
"amiodarone"
],
"offsets": [
[
46,
56
]
],
"normalized": []
},
{
"id": "79444",
"type": "Participant_Condition",
"text": [
"after electric cardioversion ]"
],
"offsets": [
[
57,
87
]
],
"normalized": []
}
] | [] | [] | [] |
79445 | 6650773 | [
{
"id": "79446",
"type": "document",
"text": [
"Bovine carotid artery heterografts versus polytetrafluoroethylene grafts . A prospective , randomized study . A prospective , randomized comparison of BCAH and PTFE vascular access grafts resulted in no statistically significant difference when analyzed for survival rates of complications , types of complications , reasons for failure , and clot salvageability . The results in diabetic patients were similar to those in nondiabetic patients . The majority of retrospective studies and subjective experiences favor PTFE grafts over BCAHs . The explanation may be part that BCAH preceded PTFE grafts into clinical use , and inexperience in the operating room and in the dialysis unit had an effect on BCAH results . A review of impressions of the graft materials indicated a decided preference for PTFE grafts ."
],
"offsets": [
[
0,
812
]
]
}
] | [
{
"id": "79447",
"type": "Intervention_Surgical",
"text": [
"Bovine carotid artery heterografts versus polytetrafluoroethylene grafts ."
],
"offsets": [
[
0,
74
]
],
"normalized": []
},
{
"id": "79448",
"type": "Intervention_Surgical",
"text": [
"BCAH"
],
"offsets": [
[
151,
155
]
],
"normalized": []
},
{
"id": "79449",
"type": "Intervention_Surgical",
"text": [
"PTFE vascular access grafts"
],
"offsets": [
[
160,
187
]
],
"normalized": []
},
{
"id": "79450",
"type": "Intervention_Surgical",
"text": [
"PTFE grafts"
],
"offsets": [
[
517,
528
]
],
"normalized": []
},
{
"id": "79451",
"type": "Intervention_Surgical",
"text": [
"BCAHs"
],
"offsets": [
[
534,
539
]
],
"normalized": []
},
{
"id": "79452",
"type": "Intervention_Surgical",
"text": [
"BCAH"
],
"offsets": [
[
151,
155
]
],
"normalized": []
},
{
"id": "79453",
"type": "Intervention_Surgical",
"text": [
"PTFE grafts"
],
"offsets": [
[
517,
528
]
],
"normalized": []
},
{
"id": "79454",
"type": "Intervention_Surgical",
"text": [
"PTFE grafts"
],
"offsets": [
[
517,
528
]
],
"normalized": []
},
{
"id": "79455",
"type": "Outcome_Mortality",
"text": [
"survival rates of complications"
],
"offsets": [
[
258,
289
]
],
"normalized": []
},
{
"id": "79456",
"type": "Outcome_Adverse-effects",
"text": [
"types of complications"
],
"offsets": [
[
292,
314
]
],
"normalized": []
},
{
"id": "79457",
"type": "Outcome_Other",
"text": [
"reasons for failure"
],
"offsets": [
[
317,
336
]
],
"normalized": []
},
{
"id": "79458",
"type": "Outcome_Physical",
"text": [
"clot salvageability"
],
"offsets": [
[
343,
362
]
],
"normalized": []
},
{
"id": "79459",
"type": "Participant_Condition",
"text": [
"Bovine carotid artery heterografts"
],
"offsets": [
[
0,
34
]
],
"normalized": []
},
{
"id": "79460",
"type": "Participant_Condition",
"text": [
"polytetrafluoroethylene"
],
"offsets": [
[
42,
65
]
],
"normalized": []
},
{
"id": "79461",
"type": "Participant_Condition",
"text": [
"diabetic"
],
"offsets": [
[
380,
388
]
],
"normalized": []
},
{
"id": "79462",
"type": "Participant_Condition",
"text": [
"nondiabetic"
],
"offsets": [
[
423,
434
]
],
"normalized": []
}
] | [] | [] | [] |
79463 | 6653648 | [
{
"id": "79464",
"type": "document",
"text": [
"Diazoxide and labetalol in acute hypertension during haemodialysis . The antihypertensive effect of the peripheral vasodilator diazoxide in 13 patients and the alpha-beta adrenoceptor blocking agent labetalol in 12 patients were compared in 46 severe acute hypertensive episodes during haemodialysis . A single dose of diazoxide 150 mg or labetalol 50 mg was effective in 74 % and 70 % of the hypertensive episodes , respectively . In the diazoxide-treated patients blood pressure fell from 192 +/- 3/115 +/- 4 mmHg to 141 +/- 8/85 +/- 4 mmHg 2 h after injection . In 7 hypertensive episodes a second dose of diazoxide 150 mg was given 60 +/- 11 min after the first injection . The reduction in mean arterial blood pressure at the end of haemodialysis was 21.5 +/- 2.6 % in patients treated with a single dose and 24.8 +/- 3.5 % in patients treated with the repeated dose of diazoxide . In the labetalol-treated patients blood pressure in 17 instances fell from 198 +/- 5/104 +/- 4 mmHg to 143 +/- 7/89 +/- 5 mmHg 180 min following injection of labetalol 50 mg . In 6 episodes a second dose labetalol 50 mg was given 41 +/- 9 min after the first injection . At the end of haemodialysis the decrease in mean arterial blood pressure was 17.2 % in patients treated with a single dose and 18 +/- 5 % in patients given the repeated dose of labetalol . The reduction in blood pressure caused by diazoxide was slightly greater than that due to labetalol . At the end of haemodialysis the percentage reduction in mean arterial blood pressure was 23 +/- 2 % in the diazoxide-treated group and 17 +/- 2 % after labetalol . ( ABSTRACT TRUNCATED AT 250 WORDS )"
],
"offsets": [
[
0,
1648
]
]
}
] | [
{
"id": "79465",
"type": "Intervention_Pharmacological",
"text": [
"Diazoxide"
],
"offsets": [
[
0,
9
]
],
"normalized": []
},
{
"id": "79466",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "79467",
"type": "Intervention_Pharmacological",
"text": [
"peripheral vasodilator diazoxide"
],
"offsets": [
[
104,
136
]
],
"normalized": []
},
{
"id": "79468",
"type": "Intervention_Pharmacological",
"text": [
"alpha-beta adrenoceptor blocking agent labetalol"
],
"offsets": [
[
160,
208
]
],
"normalized": []
},
{
"id": "79469",
"type": "Intervention_Pharmacological",
"text": [
"diazoxide 150 mg"
],
"offsets": [
[
319,
335
]
],
"normalized": []
},
{
"id": "79470",
"type": "Intervention_Pharmacological",
"text": [
"labetalol 50 mg"
],
"offsets": [
[
339,
354
]
],
"normalized": []
},
{
"id": "79471",
"type": "Intervention_Pharmacological",
"text": [
"diazoxide-treated"
],
"offsets": [
[
439,
456
]
],
"normalized": []
},
{
"id": "79472",
"type": "Intervention_Pharmacological",
"text": [
"diazoxide"
],
"offsets": [
[
127,
136
]
],
"normalized": []
},
{
"id": "79473",
"type": "Intervention_Pharmacological",
"text": [
"diazoxide"
],
"offsets": [
[
127,
136
]
],
"normalized": []
},
{
"id": "79474",
"type": "Intervention_Pharmacological",
"text": [
"labetalol-treated"
],
"offsets": [
[
894,
911
]
],
"normalized": []
},
{
"id": "79475",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "79476",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "79477",
"type": "Intervention_Pharmacological",
"text": [
"labetalol"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "79478",
"type": "Intervention_Pharmacological",
"text": [
"diazoxide"
],
"offsets": [
[
127,
136
]
],
"normalized": []
},
{
"id": "79479",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
466,
480
]
],
"normalized": []
},
{
"id": "79480",
"type": "Outcome_Physical",
"text": [
"mean arterial blood pressure"
],
"offsets": [
[
695,
723
]
],
"normalized": []
},
{
"id": "79481",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
466,
480
]
],
"normalized": []
},
{
"id": "79482",
"type": "Outcome_Physical",
"text": [
"mean arterial blood pressure"
],
"offsets": [
[
695,
723
]
],
"normalized": []
},
{
"id": "79483",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
466,
480
]
],
"normalized": []
}
] | [] | [] | [] |
79484 | 6667628 | [
{
"id": "79485",
"type": "document",
"text": [
"Comparison of the hypotensive effects of bendrofluazide , bumetanide and xipamide . A randomized , triple crossover study was carried out in 24 elderly patients requiring chronic diuretic therapy to assess the different hypotensive effects of a fixed daily dose of 5 mg bendrofluazide , 1 mg bumetanide and 40 mg xipamide . Each treatment was given for 3 months . The results showed that no significant weight change took place during the study period . There was , however , a significant ( p less than 0.001 ) decrease compared to baseline values both in systolic and diastolic blood pressure during the xipamide period and a decrease in diastolic blood pressure ( p less than 0.05 ) when taking bumetanide . Only minor side-effects were reported ."
],
"offsets": [
[
0,
750
]
]
}
] | [
{
"id": "79486",
"type": "Intervention_Pharmacological",
"text": [
"bendrofluazide"
],
"offsets": [
[
41,
55
]
],
"normalized": []
},
{
"id": "79487",
"type": "Intervention_Pharmacological",
"text": [
"bumetanide"
],
"offsets": [
[
58,
68
]
],
"normalized": []
},
{
"id": "79488",
"type": "Intervention_Pharmacological",
"text": [
"xipamide"
],
"offsets": [
[
73,
81
]
],
"normalized": []
},
{
"id": "79489",
"type": "Intervention_Pharmacological",
"text": [
"chronic diuretic therapy"
],
"offsets": [
[
171,
195
]
],
"normalized": []
},
{
"id": "79490",
"type": "Intervention_Pharmacological",
"text": [
"5 mg bendrofluazide"
],
"offsets": [
[
265,
284
]
],
"normalized": []
},
{
"id": "79491",
"type": "Intervention_Pharmacological",
"text": [
"1 mg bumetanide"
],
"offsets": [
[
287,
302
]
],
"normalized": []
},
{
"id": "79492",
"type": "Intervention_Pharmacological",
"text": [
"40 mg xipamide"
],
"offsets": [
[
307,
321
]
],
"normalized": []
},
{
"id": "79493",
"type": "Intervention_Pharmacological",
"text": [
"bumetanide"
],
"offsets": [
[
58,
68
]
],
"normalized": []
},
{
"id": "79494",
"type": "Outcome_Physical",
"text": [
"weight change"
],
"offsets": [
[
403,
416
]
],
"normalized": []
},
{
"id": "79495",
"type": "Outcome_Physical",
"text": [
"baseline values both in systolic and diastolic blood pressure"
],
"offsets": [
[
533,
594
]
],
"normalized": []
},
{
"id": "79496",
"type": "Outcome_Physical",
"text": [
"diastolic blood pressure"
],
"offsets": [
[
570,
594
]
],
"normalized": []
},
{
"id": "79497",
"type": "Outcome_Adverse-effects",
"text": [
"minor side-effects"
],
"offsets": [
[
716,
734
]
],
"normalized": []
},
{
"id": "79498",
"type": "Participant_Sample-size",
"text": [
"24"
],
"offsets": [
[
141,
143
]
],
"normalized": []
},
{
"id": "79499",
"type": "Participant_Age",
"text": [
"elderly"
],
"offsets": [
[
144,
151
]
],
"normalized": []
},
{
"id": "79500",
"type": "Participant_Condition",
"text": [
"requiring chronic diuretic therapy"
],
"offsets": [
[
161,
195
]
],
"normalized": []
}
] | [] | [] | [] |
79501 | 6686808 | [
{
"id": "79502",
"type": "document",
"text": [
"Effect of antacids on intragastric pH in healthy subjects and duodenal ulcer patients . Influence of the size of the antacid dose and of anticholinergics . Different doses of two liquid antacids , alone and combined with an anticholinergic agent , were studied with respect to the duration of antacid action . The studies were performed in healthy subjects with MAO less than 30 mmol/h and in duodenal ulcer patients with MAO greater than 35 mmol/h . Gastric pH was recorded using radiotelemetric technique ( Heidelberg capsule ) . In the healthy subjects , there was no significant difference in the duration of action with the different doses but in duodenal ulcer patients a tenfold increase of the antacid dose resulted in a doubling of the duration of action . Combined treatment with an anticholinergic and antacids enhanced the antacid effects in both groups . It is concluded that an antacid dose should be so great that it binds secreted acid before the dose leaves the stomach . Further increase of the dose will not increase the duration . Concomitant use of an anticholinergic agent increases the duration of antacid action ."
],
"offsets": [
[
0,
1137
]
]
}
] | [
{
"id": "79503",
"type": "Intervention_Pharmacological",
"text": [
"antacids"
],
"offsets": [
[
10,
18
]
],
"normalized": []
},
{
"id": "79504",
"type": "Intervention_Pharmacological",
"text": [
"antacid dose"
],
"offsets": [
[
117,
129
]
],
"normalized": []
},
{
"id": "79505",
"type": "Intervention_Pharmacological",
"text": [
"anticholinergics ."
],
"offsets": [
[
137,
155
]
],
"normalized": []
},
{
"id": "79506",
"type": "Intervention_Pharmacological",
"text": [
"antacids"
],
"offsets": [
[
10,
18
]
],
"normalized": []
},
{
"id": "79507",
"type": "Intervention_Pharmacological",
"text": [
"anticholinergic"
],
"offsets": [
[
137,
152
]
],
"normalized": []
},
{
"id": "79508",
"type": "Intervention_Pharmacological",
"text": [
"antacid"
],
"offsets": [
[
10,
17
]
],
"normalized": []
},
{
"id": "79509",
"type": "Intervention_Pharmacological",
"text": [
"anticholinergic"
],
"offsets": [
[
137,
152
]
],
"normalized": []
},
{
"id": "79510",
"type": "Intervention_Pharmacological",
"text": [
"antacids"
],
"offsets": [
[
10,
18
]
],
"normalized": []
},
{
"id": "79511",
"type": "Intervention_Pharmacological",
"text": [
"anticholinergic agent"
],
"offsets": [
[
224,
245
]
],
"normalized": []
},
{
"id": "79512",
"type": "Outcome_Other",
"text": [
"Effect"
],
"offsets": [
[
0,
6
]
],
"normalized": []
},
{
"id": "79513",
"type": "Outcome_Physical",
"text": [
"intragastric pH"
],
"offsets": [
[
22,
37
]
],
"normalized": []
},
{
"id": "79514",
"type": "Outcome_Other",
"text": [
"duration of antacid action"
],
"offsets": [
[
281,
307
]
],
"normalized": []
},
{
"id": "79515",
"type": "Outcome_Physical",
"text": [
"Gastric pH"
],
"offsets": [
[
451,
461
]
],
"normalized": []
},
{
"id": "79516",
"type": "Outcome_Physical",
"text": [
"radiotelemetric"
],
"offsets": [
[
481,
496
]
],
"normalized": []
},
{
"id": "79517",
"type": "Outcome_Other",
"text": [
"duration of action"
],
"offsets": [
[
601,
619
]
],
"normalized": []
},
{
"id": "79518",
"type": "Outcome_Other",
"text": [
"duration of action"
],
"offsets": [
[
601,
619
]
],
"normalized": []
},
{
"id": "79519",
"type": "Outcome_Other",
"text": [
"antacid effects"
],
"offsets": [
[
835,
850
]
],
"normalized": []
},
{
"id": "79520",
"type": "Outcome_Other",
"text": [
"duration"
],
"offsets": [
[
281,
289
]
],
"normalized": []
},
{
"id": "79521",
"type": "Outcome_Other",
"text": [
"duration of antacid action"
],
"offsets": [
[
281,
307
]
],
"normalized": []
},
{
"id": "79522",
"type": "Participant_Condition",
"text": [
"healthy subjects"
],
"offsets": [
[
41,
57
]
],
"normalized": []
},
{
"id": "79523",
"type": "Participant_Condition",
"text": [
"duodenal ulcer"
],
"offsets": [
[
62,
76
]
],
"normalized": []
},
{
"id": "79524",
"type": "Participant_Condition",
"text": [
"duodenal ulcer"
],
"offsets": [
[
62,
76
]
],
"normalized": []
},
{
"id": "79525",
"type": "Participant_Condition",
"text": [
"duodenal ulcer"
],
"offsets": [
[
62,
76
]
],
"normalized": []
}
] | [] | [] | [] |
79526 | 6721970 | [
{
"id": "79527",
"type": "document",
"text": [
"General anaesthesia for caesarean section in severe pre-eclampsia . Comparison of the renal and hepatic effects of enflurane and halothane . In a randomized study of patients undergoing Caesarean section , either enflurane ( mean 0.24 MAC-h ) or halothane ( mean 0.23 MAC-h ) and 50 % nitrous oxide in oxygen were administered to women ( n = 12 ) with severe pre-eclampsia-eclampsia and to 16 healthy pregnant patients with normal renal and hepatic function . No evidence of nephrotoxicity was found in any pre-eclamptic or normal patient . Metabolism of enflurane resulted in plasma inorganic fluoride concentrations ( max 15 mumol litre -1 ) which were well below the toxic value . Postoperative liver function tests showed no important changes from preoperative values , although reductive metabolites of halothane were not measured . In patients with severe pre-eclampsia there appears no contraindication to enflurane or , probably , halothane as volatile supplements during general anaesthesia ."
],
"offsets": [
[
0,
1001
]
]
}
] | [
{
"id": "79528",
"type": "Intervention_Pharmacological",
"text": [
"General anaesthesia"
],
"offsets": [
[
0,
19
]
],
"normalized": []
},
{
"id": "79529",
"type": "Intervention_Pharmacological",
"text": [
"enflurane"
],
"offsets": [
[
115,
124
]
],
"normalized": []
},
{
"id": "79530",
"type": "Intervention_Pharmacological",
"text": [
"halothane"
],
"offsets": [
[
129,
138
]
],
"normalized": []
},
{
"id": "79531",
"type": "Intervention_Pharmacological",
"text": [
"enflurane"
],
"offsets": [
[
115,
124
]
],
"normalized": []
},
{
"id": "79532",
"type": "Intervention_Pharmacological",
"text": [
"halothane"
],
"offsets": [
[
129,
138
]
],
"normalized": []
},
{
"id": "79533",
"type": "Intervention_Pharmacological",
"text": [
"nitrous oxide in oxygen"
],
"offsets": [
[
285,
308
]
],
"normalized": []
},
{
"id": "79534",
"type": "Intervention_Pharmacological",
"text": [
"enflurane"
],
"offsets": [
[
115,
124
]
],
"normalized": []
},
{
"id": "79535",
"type": "Intervention_Pharmacological",
"text": [
"halothane"
],
"offsets": [
[
129,
138
]
],
"normalized": []
},
{
"id": "79536",
"type": "Intervention_Pharmacological",
"text": [
"enflurane"
],
"offsets": [
[
115,
124
]
],
"normalized": []
},
{
"id": "79537",
"type": "Intervention_Pharmacological",
"text": [
"halothane"
],
"offsets": [
[
129,
138
]
],
"normalized": []
},
{
"id": "79538",
"type": "Intervention_Pharmacological",
"text": [
"general anaesthesia"
],
"offsets": [
[
980,
999
]
],
"normalized": []
},
{
"id": "79539",
"type": "Outcome_Adverse-effects",
"text": [
"nephrotoxicity"
],
"offsets": [
[
475,
489
]
],
"normalized": []
},
{
"id": "79540",
"type": "Outcome_Physical",
"text": [
"plasma inorganic fluoride concentrations"
],
"offsets": [
[
577,
617
]
],
"normalized": []
},
{
"id": "79541",
"type": "Outcome_Physical",
"text": [
"liver function"
],
"offsets": [
[
698,
712
]
],
"normalized": []
},
{
"id": "79542",
"type": "Outcome_Adverse-effects",
"text": [
"contraindication to enflurane"
],
"offsets": [
[
893,
922
]
],
"normalized": []
},
{
"id": "79543",
"type": "Participant_Condition",
"text": [
"caesarean section in severe pre-eclampsia ."
],
"offsets": [
[
24,
67
]
],
"normalized": []
},
{
"id": "79544",
"type": "Participant_Condition",
"text": [
"patients undergoing Caesarean section , either enflurane ( mean 0.24 MAC-h ) or halothane ( mean 0.23 MAC-h ) and 50 % nitrous oxide in oxygen"
],
"offsets": [
[
166,
308
]
],
"normalized": []
},
{
"id": "79545",
"type": "Participant_Condition",
"text": [
"women ( n = 12 ) with severe pre-eclampsia-eclampsia and to 16 healthy pregnant patients with normal renal and hepatic function ."
],
"offsets": [
[
330,
459
]
],
"normalized": []
}
] | [] | [] | [] |
79546 | 6729651 | [
{
"id": "79547",
"type": "document",
"text": [
"High-dose weekly fractionation radiotherapy in advanced cancer of the uterine cervix . A trial comparing two different radiotherapy techniques and schedules in the treatment of 83 patients with advanced cancer of the uterine cervix ( stage IIIB ) employing external irradiation alone is described . The one technique , used routinely in this department , employed a conventional daily fractionation schedule while the other used a high-dose weekly fractionation regimen . The techniques are described . The aim of the trial was to compare the efficacy and morbidity of these two methods of treatment . Dose distribution curves in cross-section and midsagittal planes are shown and calculations or equivalent doses at various selected points using Ellis 's nominal single-dose formula are tabulated . The 2-year survival figures were 33 % for the daily fractionation technique and 22 % for the weekly regimen . Serious late complication rates were 6 % for the daily regimen and 22 % for the weekly schedule . These differences are not statistically significant . Late complication rates in the weekly fractionation regimen appeared to be lower than figures quoted by other authors . Local control within the irradiated volume was better in the group treated by the daily fractionation method ."
],
"offsets": [
[
0,
1292
]
]
}
] | [
{
"id": "79548",
"type": "Intervention_Physical",
"text": [
"High-dose weekly fractionation radiotherapy"
],
"offsets": [
[
0,
43
]
],
"normalized": []
},
{
"id": "79549",
"type": "Intervention_Physical",
"text": [
"external irradiation"
],
"offsets": [
[
257,
277
]
],
"normalized": []
},
{
"id": "79550",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
543,
551
]
],
"normalized": []
},
{
"id": "79551",
"type": "Outcome_Other",
"text": [
"morbidity"
],
"offsets": [
[
556,
565
]
],
"normalized": []
},
{
"id": "79552",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
811,
819
]
],
"normalized": []
},
{
"id": "79553",
"type": "Outcome_Adverse-effects",
"text": [
"Serious late complication rates"
],
"offsets": [
[
910,
941
]
],
"normalized": []
},
{
"id": "79554",
"type": "Outcome_Adverse-effects",
"text": [
"Late complication rates"
],
"offsets": [
[
1062,
1085
]
],
"normalized": []
},
{
"id": "79555",
"type": "Participant_Condition",
"text": [
"advanced cancer of the uterine cervix"
],
"offsets": [
[
47,
84
]
],
"normalized": []
},
{
"id": "79556",
"type": "Participant_Sample-size",
"text": [
"83"
],
"offsets": [
[
177,
179
]
],
"normalized": []
}
] | [] | [] | [] |
79557 | 6734073 | [
{
"id": "79558",
"type": "document",
"text": [
"Short-term studies on the use of glycerol as an osmotic agent in continuous ambulatory peritoneal dialysis ( CAPD ) . The use of glycerol as an osmotic agent in two different concentrations ( 92 mmol/l and 272 mmol/l ) in peritoneal dialysis fluid was investigated over 3 days in six patients on continuous ambulatory peritoneal dialysis and compared with two concentrations of glucose ( 76 mmol/l and 215 mmol/l ) in the same patients . The calorific value of the absorbed osmotic agent was lower , by 19 % with isotonic and 22 % with hypertonic solutions , when glycerol was used in place of glucose . However , glycerol provided significantly lower total ultrafiltration than glucose at each concentration , despite a higher initial osmotic pressure of the glycerol-based solutions . Thus , the higher concentration of glycerol required to provide equal ultrafiltration may offset any calorific advantage . Equilibration of creatinine and urea was slower and creatinine clearance lower with glycerol . Solutions containing glycerol were initially less acid ( pH 6.5 ) than those containing glucose ( pH 5.1 ) . Blood glycerol levels , which were in the physiological range with glucose as the osmotic agent , reached a peak 80-fold greater at 4.3 +/- 0.8 mmol/l during dialysis with fluid containing glycerol at 272 mmol/l and eightfold higher at 0.42 +/- 0.09 mmol/l with glycerol at 92 mmol/l . There was no evidence of haemolysis or other toxic effect despite these levels . The rise in blood glucose and insulin noted during the use of glucose-based solutions was not found with glycerol . Circulating levels of lactate , pyruvate , alanine , non-esterified fatty acids and the ketone bodies were similar with the two agents . Although these short-term studies have shown no conclusive advantage of glycerol over glucose , long-term effects of glycerol , particularly on circulating lipid levels , will determine its future role as an osmotic agent in continuous ambulatory peritoneal dialysis ."
],
"offsets": [
[
0,
2002
]
]
}
] | [
{
"id": "79559",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79560",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79561",
"type": "Intervention_Control",
"text": [
"glucose"
],
"offsets": [
[
378,
385
]
],
"normalized": []
},
{
"id": "79562",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79563",
"type": "Intervention_Control",
"text": [
"glucose"
],
"offsets": [
[
378,
385
]
],
"normalized": []
},
{
"id": "79564",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79565",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79566",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79567",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79568",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79569",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79570",
"type": "Intervention_Control",
"text": [
"glucose"
],
"offsets": [
[
378,
385
]
],
"normalized": []
},
{
"id": "79571",
"type": "Intervention_Pharmacological",
"text": [
"glycerol"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "79572",
"type": "Outcome_Other",
"text": [
"calorific value"
],
"offsets": [
[
442,
457
]
],
"normalized": []
},
{
"id": "79573",
"type": "Outcome_Physical",
"text": [
"total ultrafiltration"
],
"offsets": [
[
652,
673
]
],
"normalized": []
},
{
"id": "79574",
"type": "Outcome_Other",
"text": [
"equal ultrafiltration"
],
"offsets": [
[
851,
872
]
],
"normalized": []
},
{
"id": "79575",
"type": "Outcome_Physical",
"text": [
"Equilibration of creatinine and urea"
],
"offsets": [
[
910,
946
]
],
"normalized": []
},
{
"id": "79576",
"type": "Outcome_Physical",
"text": [
"creatinine clearance"
],
"offsets": [
[
962,
982
]
],
"normalized": []
},
{
"id": "79577",
"type": "Outcome_Physical",
"text": [
"Blood glycerol levels"
],
"offsets": [
[
1114,
1135
]
],
"normalized": []
},
{
"id": "79578",
"type": "Outcome_Adverse-effects",
"text": [
"haemolysis"
],
"offsets": [
[
1425,
1435
]
],
"normalized": []
},
{
"id": "79579",
"type": "Outcome_Adverse-effects",
"text": [
"toxic effect"
],
"offsets": [
[
1445,
1457
]
],
"normalized": []
},
{
"id": "79580",
"type": "Outcome_Physical",
"text": [
"blood glucose and insulin"
],
"offsets": [
[
1493,
1518
]
],
"normalized": []
},
{
"id": "79581",
"type": "Outcome_Physical",
"text": [
"Circulating levels of lactate"
],
"offsets": [
[
1597,
1626
]
],
"normalized": []
},
{
"id": "79582",
"type": "Outcome_Physical",
"text": [
"pyruvate"
],
"offsets": [
[
1629,
1637
]
],
"normalized": []
},
{
"id": "79583",
"type": "Outcome_Physical",
"text": [
"alanine , non-esterified fatty acids"
],
"offsets": [
[
1640,
1676
]
],
"normalized": []
},
{
"id": "79584",
"type": "Outcome_Physical",
"text": [
"the ketone bodies"
],
"offsets": [
[
1681,
1698
]
],
"normalized": []
},
{
"id": "79585",
"type": "Outcome_Physical",
"text": [
"circulating lipid levels"
],
"offsets": [
[
1878,
1902
]
],
"normalized": []
},
{
"id": "79586",
"type": "Participant_Condition",
"text": [
"continuous ambulatory peritoneal dialysis"
],
"offsets": [
[
65,
106
]
],
"normalized": []
},
{
"id": "79587",
"type": "Participant_Condition",
"text": [
"CAPD"
],
"offsets": [
[
109,
113
]
],
"normalized": []
},
{
"id": "79588",
"type": "Participant_Sample-size",
"text": [
"six"
],
"offsets": [
[
280,
283
]
],
"normalized": []
},
{
"id": "79589",
"type": "Participant_Condition",
"text": [
"continuous ambulatory peritoneal dialysis"
],
"offsets": [
[
65,
106
]
],
"normalized": []
}
] | [] | [] | [] |
79590 | 6740101 | [
{
"id": "79591",
"type": "document",
"text": [
"A comparison of the serologic responses to oral and injectable trivalent poliovirus vaccines . United States children two months of age were randomly assigned to two groups that received either the commercially available oral trivalent poliovirus vaccine ( OPV ) or an injectable ( inactivated ) trivalent poliovirus vaccine ( IPV ) with a confirmed minimum D-antigen content of 27 , 3.5 , and 29 units for poliovirus types 1 , 2 , and 3 , respectively . Vaccine was given at two , four , and 18 months of age . Sera obtained from 439 children at two , four , and six months of age and from 85 children at 18 and 20 months of age were examined for neutralizing antibodies . The percentage of children with detectable antibodies and the reciprocal geometric mean titers were similar for both groups at two months of age for antibodies to all three poliovirus types . At 20 months of age , all children but one had detectable antibodies to all three poliovirus types . Significantly higher geometric mean titers against types 2 and 3 were noted at 20 months of age for the IPV group ."
],
"offsets": [
[
0,
1082
]
]
}
] | [
{
"id": "79592",
"type": "Intervention_Pharmacological",
"text": [
"trivalent poliovirus vaccines"
],
"offsets": [
[
63,
92
]
],
"normalized": []
},
{
"id": "79593",
"type": "Intervention_Pharmacological",
"text": [
"oral trivalent poliovirus vaccine ( OPV )"
],
"offsets": [
[
221,
262
]
],
"normalized": []
},
{
"id": "79594",
"type": "Intervention_Pharmacological",
"text": [
"injectable ( inactivated ) trivalent poliovirus vaccine ( IPV )"
],
"offsets": [
[
269,
332
]
],
"normalized": []
},
{
"id": "79595",
"type": "Intervention_Pharmacological",
"text": [
"IPV"
],
"offsets": [
[
327,
330
]
],
"normalized": []
},
{
"id": "79596",
"type": "Outcome_Physical",
"text": [
"neutralizing antibodies"
],
"offsets": [
[
648,
671
]
],
"normalized": []
},
{
"id": "79597",
"type": "Outcome_Physical",
"text": [
"percentage of children with detectable antibodies and the reciprocal geometric mean titers"
],
"offsets": [
[
678,
768
]
],
"normalized": []
},
{
"id": "79598",
"type": "Outcome_Physical",
"text": [
"geometric mean titers against types 2 and 3"
],
"offsets": [
[
988,
1031
]
],
"normalized": []
},
{
"id": "79599",
"type": "Participant_Age",
"text": [
"children two months"
],
"offsets": [
[
109,
128
]
],
"normalized": []
},
{
"id": "79600",
"type": "Participant_Sample-size",
"text": [
"439"
],
"offsets": [
[
531,
534
]
],
"normalized": []
},
{
"id": "79601",
"type": "Participant_Age",
"text": [
"children at two , four , and six months of age"
],
"offsets": [
[
535,
581
]
],
"normalized": []
},
{
"id": "79602",
"type": "Participant_Sample-size",
"text": [
"85"
],
"offsets": [
[
591,
593
]
],
"normalized": []
},
{
"id": "79603",
"type": "Participant_Age",
"text": [
"children at 18 and 20 months of age"
],
"offsets": [
[
594,
629
]
],
"normalized": []
}
] | [] | [] | [] |
79604 | 6751144 | [
{
"id": "79605",
"type": "document",
"text": [
"Epidural morphine in the elderly . A controlled trial after upper abdominal surgery . The effectiveness of epidurally administered morphine in the relief of pain after upper abdominal surgery was assessed in a controlled study involving 20 patients aged 61 to 78 years . Analgesia provided by epidural morphine was comparable to that obtained in matched patients given an intramuscular regime . The total dose required by the epidural route was less than one-fifth that required intramuscularly , and sedation was correspondingly reduced . Postoperative respiratory mechanics , however , were not significantly improved and delayed respiratory depression was observed in one patient . It is concluded that in elderly patients undergoing upper abdominal surgery the risks related to the use of morphine by the epidural route outweigh the marginal advantages it may offer over conventional analgesic techniques ."
],
"offsets": [
[
0,
910
]
]
}
] | [
{
"id": "79606",
"type": "Intervention_Pharmacological",
"text": [
"Epidural morphine"
],
"offsets": [
[
0,
17
]
],
"normalized": []
},
{
"id": "79607",
"type": "Intervention_Pharmacological",
"text": [
"epidurally administered morphine"
],
"offsets": [
[
107,
139
]
],
"normalized": []
},
{
"id": "79608",
"type": "Intervention_Pharmacological",
"text": [
"epidural morphine"
],
"offsets": [
[
293,
310
]
],
"normalized": []
},
{
"id": "79609",
"type": "Intervention_Pharmacological",
"text": [
"intramuscular regime"
],
"offsets": [
[
372,
392
]
],
"normalized": []
},
{
"id": "79610",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
9,
17
]
],
"normalized": []
},
{
"id": "79611",
"type": "Outcome_Pain",
"text": [
"relief of pain"
],
"offsets": [
[
147,
161
]
],
"normalized": []
},
{
"id": "79612",
"type": "Outcome_Pain",
"text": [
"Analgesia"
],
"offsets": [
[
271,
280
]
],
"normalized": []
},
{
"id": "79613",
"type": "Outcome_Pain",
"text": [
"Postoperative respiratory mechanics"
],
"offsets": [
[
540,
575
]
],
"normalized": []
},
{
"id": "79614",
"type": "Outcome_Pain",
"text": [
"delayed respiratory depression"
],
"offsets": [
[
624,
654
]
],
"normalized": []
},
{
"id": "79615",
"type": "Participant_Age",
"text": [
"elderly"
],
"offsets": [
[
25,
32
]
],
"normalized": []
},
{
"id": "79616",
"type": "Participant_Sample-size",
"text": [
"20"
],
"offsets": [
[
237,
239
]
],
"normalized": []
},
{
"id": "79617",
"type": "Participant_Age",
"text": [
"aged 61 to 78 years"
],
"offsets": [
[
249,
268
]
],
"normalized": []
},
{
"id": "79618",
"type": "Participant_Condition",
"text": [
"undergoing upper abdominal surgery"
],
"offsets": [
[
726,
760
]
],
"normalized": []
}
] | [] | [] | [] |
79619 | 6752752 | [
{
"id": "79620",
"type": "document",
"text": [
"[ Treatment of the hyperkinetic response to exercise after myocardial infarct . Results of a randomized ergometric study ] ."
],
"offsets": [
[
0,
124
]
]
}
] | [
{
"id": "79621",
"type": "Intervention_Physical",
"text": [
"Treatment of the hyperkinetic response to exercise"
],
"offsets": [
[
2,
52
]
],
"normalized": []
}
] | [] | [] | [] |
79622 | 6753091 | [
{
"id": "79623",
"type": "document",
"text": [
"A randomized trial of intranasal beclomethasone dipropionate after polypectomy . Beneficial effects of intranasal beclomethasone dipropionate ( Bdp ) in patients with nasal polyposis have been reported earlier . This study was carried out to investigate whether long-term treatment with Bdp after polypectomy could prevent formation of new polyps and reduce the number of surgical removals . Forty consecutive patients without laboratory or other clinical signs of allergy but with severe nasal polyposis were included in the study . Twenty patients were treated with intranasal Bdp and twenty patients received no treatment after polypectomy . All patients were followed for at least 2.5 years . The size of the polyps that recurred was estimated at different time-intervals by the examining doctor . After six months there was already a significant difference in favour of the group treated with intranasal Bdp . Further results of the study and the clinical implications are discussed ."
],
"offsets": [
[
0,
989
]
]
}
] | [
{
"id": "79624",
"type": "Intervention_Pharmacological",
"text": [
"beclomethasone dipropionate"
],
"offsets": [
[
33,
60
]
],
"normalized": []
},
{
"id": "79625",
"type": "Intervention_Pharmacological",
"text": [
"intranasal beclomethasone dipropionate ( Bdp )"
],
"offsets": [
[
103,
149
]
],
"normalized": []
},
{
"id": "79626",
"type": "Intervention_Pharmacological",
"text": [
"Bdp"
],
"offsets": [
[
144,
147
]
],
"normalized": []
},
{
"id": "79627",
"type": "Intervention_Pharmacological",
"text": [
"intranasal Bdp"
],
"offsets": [
[
568,
582
]
],
"normalized": []
},
{
"id": "79628",
"type": "Intervention_Surgical",
"text": [
"polypectomy"
],
"offsets": [
[
67,
78
]
],
"normalized": []
},
{
"id": "79629",
"type": "Intervention_Pharmacological",
"text": [
"Bdp"
],
"offsets": [
[
144,
147
]
],
"normalized": []
},
{
"id": "79630",
"type": "Outcome_Physical",
"text": [
"size of the polyps that recurred"
],
"offsets": [
[
701,
733
]
],
"normalized": []
},
{
"id": "79631",
"type": "Outcome_Other",
"text": [
"difference"
],
"offsets": [
[
851,
861
]
],
"normalized": []
},
{
"id": "79632",
"type": "Participant_Condition",
"text": [
"nasal polyposis"
],
"offsets": [
[
167,
182
]
],
"normalized": []
},
{
"id": "79633",
"type": "Participant_Sample-size",
"text": [
"Forty"
],
"offsets": [
[
392,
397
]
],
"normalized": []
},
{
"id": "79634",
"type": "Participant_Condition",
"text": [
"severe nasal polyposis"
],
"offsets": [
[
482,
504
]
],
"normalized": []
},
{
"id": "79635",
"type": "Participant_Sample-size",
"text": [
"Twenty"
],
"offsets": [
[
534,
540
]
],
"normalized": []
},
{
"id": "79636",
"type": "Participant_Condition",
"text": [
"intranasal Bdp"
],
"offsets": [
[
568,
582
]
],
"normalized": []
},
{
"id": "79637",
"type": "Participant_Sample-size",
"text": [
"twenty"
],
"offsets": [
[
587,
593
]
],
"normalized": []
},
{
"id": "79638",
"type": "Participant_Condition",
"text": [
"polypectomy"
],
"offsets": [
[
67,
78
]
],
"normalized": []
}
] | [] | [] | [] |
79639 | 6753858 | [
{
"id": "79640",
"type": "document",
"text": [
"Comparative efficacy and safety of lofexidine and clonidine given alone or concomitantly with hydrochlorothiazide in hypertensive outpatients ."
],
"offsets": [
[
0,
143
]
]
}
] | [
{
"id": "79641",
"type": "Intervention_Pharmacological",
"text": [
"lofexidine and clonidine"
],
"offsets": [
[
35,
59
]
],
"normalized": []
},
{
"id": "79642",
"type": "Intervention_Pharmacological",
"text": [
"hydrochlorothiazide"
],
"offsets": [
[
94,
113
]
],
"normalized": []
},
{
"id": "79643",
"type": "Outcome_Other",
"text": [
"Comparative efficacy and safety"
],
"offsets": [
[
0,
31
]
],
"normalized": []
},
{
"id": "79644",
"type": "Participant_Condition",
"text": [
"hypertensive outpatients"
],
"offsets": [
[
117,
141
]
],
"normalized": []
}
] | [] | [] | [] |
79645 | 6756508 | [
{
"id": "79646",
"type": "document",
"text": [
"Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer . Eighty-eight postmenopausal women with metastatic breast cancer , in whom estrogen receptors ( ER ) were positive or unknown , were treated on a controlled trial to determine the effectiveness of tamoxifen and to assess the therapeutic advantage of sequentially adding low-dose cyclophosphamide-methotrexate-5-fluorouracil ( CMF ) chemotherapy in tamoxifen responders . Patients with known ER negative status were not studied . After the initial 12-week treatment with tamoxifen alone , 60 % of ER positive patients achieved complete or partial response as did 35 % in whom ER were unknown . Response status further improved in 18 % randomized to continue tamoxifen alone vs 31 % in whom CMF was added to tamoxifen . There were no statistically significant differences in time to the development of progressive disease or survival between the ER positive and ER unknown patients or between the tamoxifen and tamoxifen plus CMF groups . We conclude that inability to determine ER status should not prejudice against the use of tamoxifen in postmenopausal patients with advanced breast cancer . No benefit has been demonstrated from the addition of CMF chemotherapy in tamoxifen responders ."
],
"offsets": [
[
0,
1338
]
]
}
] | [
{
"id": "79647",
"type": "Intervention_Pharmacological",
"text": [
"tamoxifen"
],
"offsets": [
[
29,
38
]
],
"normalized": []
},
{
"id": "79648",
"type": "Intervention_Pharmacological",
"text": [
"low-dose cyclophosphamide-methotrexate-5-fluorouracil ( CMF ) chemotherapy in tamoxifen responders"
],
"offsets": [
[
418,
516
]
],
"normalized": []
},
{
"id": "79649",
"type": "Intervention_Pharmacological",
"text": [
"tamoxifen alone"
],
"offsets": [
[
79,
94
]
],
"normalized": []
},
{
"id": "79650",
"type": "Outcome_Other",
"text": [
"effectiveness"
],
"offsets": [
[
328,
341
]
],
"normalized": []
},
{
"id": "79651",
"type": "Outcome_Other",
"text": [
"therapeutic advantage"
],
"offsets": [
[
373,
394
]
],
"normalized": []
},
{
"id": "79652",
"type": "Outcome_Other",
"text": [
"complete or partial response"
],
"offsets": [
[
674,
702
]
],
"normalized": []
},
{
"id": "79653",
"type": "Outcome_Physical",
"text": [
"development of progressive disease"
],
"offsets": [
[
933,
967
]
],
"normalized": []
},
{
"id": "79654",
"type": "Outcome_Other",
"text": [
"or"
],
"offsets": [
[
238,
240
]
],
"normalized": []
},
{
"id": "79655",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
971,
979
]
],
"normalized": []
},
{
"id": "79656",
"type": "Participant_Condition",
"text": [
"postmenopausal"
],
"offsets": [
[
98,
112
]
],
"normalized": []
},
{
"id": "79657",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
113,
118
]
],
"normalized": []
},
{
"id": "79658",
"type": "Participant_Condition",
"text": [
"advanced breast cancer"
],
"offsets": [
[
124,
146
]
],
"normalized": []
},
{
"id": "79659",
"type": "Participant_Sample-size",
"text": [
"Eighty-eight"
],
"offsets": [
[
149,
161
]
],
"normalized": []
},
{
"id": "79660",
"type": "Participant_Condition",
"text": [
"estrogen receptors ( ER ) were positive or unknown"
],
"offsets": [
[
223,
273
]
],
"normalized": []
}
] | [] | [] | [] |
79661 | 6758263 | [
{
"id": "79662",
"type": "document",
"text": [
"[ The analgetic effect of intramuscular pethidine compared with epidural morphine in upper abdominal laparotomies ] ."
],
"offsets": [
[
0,
117
]
]
}
] | [
{
"id": "79663",
"type": "Intervention_Pharmacological",
"text": [
"pethidine"
],
"offsets": [
[
40,
49
]
],
"normalized": []
},
{
"id": "79664",
"type": "Intervention_Pharmacological",
"text": [
"epidural morphine"
],
"offsets": [
[
64,
81
]
],
"normalized": []
},
{
"id": "79665",
"type": "Participant_Condition",
"text": [
"upper abdominal laparotomies ]"
],
"offsets": [
[
85,
115
]
],
"normalized": []
}
] | [] | [] | [] |
79666 | 6761890 | [
{
"id": "79667",
"type": "document",
"text": [
"Platelet inhibitory drugs : an in vivo method of evaluation in patients . The measurement of platelet deposition in human thrombi is essential for the evaluation of platelet-inhibitory drugs and prosthetic materials for use in patients . The rate of 111Indium-labelled platelet accumulation on Dacron arterial grafts was measured in 27 patients randomised to take either aspirin and dipyridamole ( ASA + DPM ) or placebo . Autologous platelets were labelled and re-injected seven days following surgery and the graft thrombogenicity index calculated as the daily rise in the ratio of emissions from the graft over a reference site . The mean ( +/- SD ) thrombogenicity index in 12 patients undergoing femoro-popliteal bypass was 0.25 +/- 0.09 on placebo and 0.16 +/- 0.07 on ASA + DPM started pre-operatively ( p less than 0.05 ) . Post-operative ASA + DPM therapy started two days following platelet labelling in 15 patients with aorto-femoral grafts also significantly reduce thrombogenicity to 0.12 +/- 0.05 compared with 0.25 +/- 0.08 on placebo ( p less than 0.01 ) . In the latter patients the ratio of emissions from the graft over reference fell significantly on starting ASA + DPM , suggesting a net loss of platelets from the graft . These results indicate that the rate of in vivo platelet accumulation on Dacron grafts can be quantitated and that ASA + DPM reduced this rate in man ."
],
"offsets": [
[
0,
1395
]
]
}
] | [
{
"id": "79668",
"type": "Intervention_Pharmacological",
"text": [
"Platelet inhibitory drugs"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "79669",
"type": "Intervention_Pharmacological",
"text": [
"platelet-inhibitory drugs"
],
"offsets": [
[
165,
190
]
],
"normalized": []
},
{
"id": "79670",
"type": "Intervention_Pharmacological",
"text": [
"aspirin and dipyridamole ( ASA + DPM )"
],
"offsets": [
[
371,
409
]
],
"normalized": []
},
{
"id": "79671",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
413,
420
]
],
"normalized": []
},
{
"id": "79672",
"type": "Intervention_Pharmacological",
"text": [
"ASA"
],
"offsets": [
[
398,
401
]
],
"normalized": []
},
{
"id": "79673",
"type": "Intervention_Pharmacological",
"text": [
"DPM"
],
"offsets": [
[
404,
407
]
],
"normalized": []
},
{
"id": "79674",
"type": "Intervention_Pharmacological",
"text": [
"ASA + DPM"
],
"offsets": [
[
398,
407
]
],
"normalized": []
},
{
"id": "79675",
"type": "Intervention_Pharmacological",
"text": [
"ASA + DPM"
],
"offsets": [
[
398,
407
]
],
"normalized": []
},
{
"id": "79676",
"type": "Outcome_Other",
"text": [
"method of evaluation"
],
"offsets": [
[
39,
59
]
],
"normalized": []
},
{
"id": "79677",
"type": "Outcome_Physical",
"text": [
"platelet deposition"
],
"offsets": [
[
93,
112
]
],
"normalized": []
},
{
"id": "79678",
"type": "Outcome_Physical",
"text": [
"evaluation of platelet-inhibitory drugs"
],
"offsets": [
[
151,
190
]
],
"normalized": []
},
{
"id": "79679",
"type": "Outcome_Physical",
"text": [
"prosthetic materials"
],
"offsets": [
[
195,
215
]
],
"normalized": []
},
{
"id": "79680",
"type": "Outcome_Physical",
"text": [
"platelet accumulation"
],
"offsets": [
[
269,
290
]
],
"normalized": []
},
{
"id": "79681",
"type": "Outcome_Physical",
"text": [
"ratio of emissions"
],
"offsets": [
[
575,
593
]
],
"normalized": []
},
{
"id": "79682",
"type": "Outcome_Physical",
"text": [
"thrombogenicity index"
],
"offsets": [
[
517,
538
]
],
"normalized": []
},
{
"id": "79683",
"type": "Outcome_Physical",
"text": [
"thrombogenicity"
],
"offsets": [
[
517,
532
]
],
"normalized": []
},
{
"id": "79684",
"type": "Outcome_Other",
"text": [
"emissions"
],
"offsets": [
[
584,
593
]
],
"normalized": []
},
{
"id": "79685",
"type": "Outcome_Physical",
"text": [
"rate of in vivo platelet accumulation"
],
"offsets": [
[
1276,
1313
]
],
"normalized": []
},
{
"id": "79686",
"type": "Participant_Condition",
"text": [
"Platelet inhibitory drugs :"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "79687",
"type": "Participant_Condition",
"text": [
"platelet deposition in human thrombi"
],
"offsets": [
[
93,
129
]
],
"normalized": []
},
{
"id": "79688",
"type": "Participant_Sample-size",
"text": [
"27 patients"
],
"offsets": [
[
333,
344
]
],
"normalized": []
}
] | [] | [] | [] |
79689 | 6762195 | [
{
"id": "79690",
"type": "document",
"text": [
"Immunotherapy maintenance in acute non-lymphocytic leukaemia . Between January 1975 and December 1977 , 264 adult patients with acute non-lymphocytic leukaemia entered the Australian National Leukaemia Trial . Of 251 evaluable patients , three induction regimens achieved similar complete response ( CR ) rates . CROP ( cytosine arabinoside , daunorubicin , vincristine , prednisolone ) produced CR in 41 % of patients , 7 and 3 ( cytosine arabinoside , daunorubicin ) in 42 % and 7 and 3 plus hydroxyurea in 52 % . Remission duration and survival were similar when induction regimens were compared . Forty-five patients reaching maintenance therapy were randomised to either chemo-immunotherapy ( BCG plus intradermal leukaemic blast cells ) or chemotherapy alone . The duration of CR in these two groups was almost identical , though patients receiving chemotherapy alone had prolonged survival ( median 161 weeks ) when compared to the chemo-immunotherapy group ( 84 weeks , p = 0 . 07 ) . Institutions with less developed supportive facilities reported lower CR rates ( p = 0 . 04 ) . Leucocytosis ( greater than 100 X 10 ( 9 ) /1 ) and older age ( greater than 50 years ) were associated with shortened survival . The Trial has failed to show any advantage for this form of immunotherapy ."
],
"offsets": [
[
0,
1294
]
]
}
] | [
{
"id": "79691",
"type": "Intervention_Pharmacological",
"text": [
"Immunotherapy"
],
"offsets": [
[
0,
13
]
],
"normalized": []
},
{
"id": "79692",
"type": "Intervention_Pharmacological",
"text": [
"CROP"
],
"offsets": [
[
313,
317
]
],
"normalized": []
},
{
"id": "79693",
"type": "Intervention_Pharmacological",
"text": [
"cytosine arabinoside"
],
"offsets": [
[
320,
340
]
],
"normalized": []
},
{
"id": "79694",
"type": "Intervention_Pharmacological",
"text": [
"daunorubicin"
],
"offsets": [
[
343,
355
]
],
"normalized": []
},
{
"id": "79695",
"type": "Intervention_Pharmacological",
"text": [
"vincristine"
],
"offsets": [
[
358,
369
]
],
"normalized": []
},
{
"id": "79696",
"type": "Intervention_Pharmacological",
"text": [
"prednisolone"
],
"offsets": [
[
372,
384
]
],
"normalized": []
},
{
"id": "79697",
"type": "Intervention_Pharmacological",
"text": [
"cytosine arabinoside"
],
"offsets": [
[
320,
340
]
],
"normalized": []
},
{
"id": "79698",
"type": "Intervention_Pharmacological",
"text": [
"daunorubicin"
],
"offsets": [
[
343,
355
]
],
"normalized": []
},
{
"id": "79699",
"type": "Intervention_Pharmacological",
"text": [
"hydroxyurea"
],
"offsets": [
[
494,
505
]
],
"normalized": []
},
{
"id": "79700",
"type": "Intervention_Pharmacological",
"text": [
"maintenance therapy"
],
"offsets": [
[
630,
649
]
],
"normalized": []
},
{
"id": "79701",
"type": "Intervention_Pharmacological",
"text": [
"chemo-immunotherapy"
],
"offsets": [
[
676,
695
]
],
"normalized": []
},
{
"id": "79702",
"type": "Intervention_Pharmacological",
"text": [
"BCG"
],
"offsets": [
[
698,
701
]
],
"normalized": []
},
{
"id": "79703",
"type": "Intervention_Pharmacological",
"text": [
"intradermal leukaemic blast cells"
],
"offsets": [
[
707,
740
]
],
"normalized": []
},
{
"id": "79704",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy"
],
"offsets": [
[
746,
758
]
],
"normalized": []
},
{
"id": "79705",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy"
],
"offsets": [
[
746,
758
]
],
"normalized": []
},
{
"id": "79706",
"type": "Intervention_Pharmacological",
"text": [
"chemo-immunotherapy"
],
"offsets": [
[
676,
695
]
],
"normalized": []
},
{
"id": "79707",
"type": "Intervention_Pharmacological",
"text": [
"immunotherapy"
],
"offsets": [
[
682,
695
]
],
"normalized": []
},
{
"id": "79708",
"type": "Outcome_Physical",
"text": [
"complete response ( CR ) rates"
],
"offsets": [
[
280,
310
]
],
"normalized": []
},
{
"id": "79709",
"type": "Outcome_Physical",
"text": [
"Remission duration"
],
"offsets": [
[
516,
534
]
],
"normalized": []
},
{
"id": "79710",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
539,
547
]
],
"normalized": []
},
{
"id": "79711",
"type": "Outcome_Other",
"text": [
"duration of CR"
],
"offsets": [
[
771,
785
]
],
"normalized": []
},
{
"id": "79712",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
539,
547
]
],
"normalized": []
},
{
"id": "79713",
"type": "Outcome_Physical",
"text": [
"Leucocytosis"
],
"offsets": [
[
1089,
1101
]
],
"normalized": []
},
{
"id": "79714",
"type": "Participant_Condition",
"text": [
"acute non-lymphocytic leukaemia ."
],
"offsets": [
[
29,
62
]
],
"normalized": []
}
] | [] | [] | [] |
79715 | 6764321 | [
{
"id": "79716",
"type": "document",
"text": [
"Two blind randomized cross-over trials in the treatment of primary open angle glaucoma . We present the results of two blind randomized trials comparing both guanethidine 3 per cent and adrenaline 0.5 per cent ( Ganda 3.0/0.5 ) and guanethidine 1 per cent and adrenaline 0.2 per cent ( Ganda 1.0/0.2 ) in single drop form with Timolol ( Timoptol ) 0.25 per cent . Results of 48-hour phasing at the end of one month 's treatment demonstrated a significantly greater fall in intraocular pressure with Ganda 3.0/0.5 ( 9.8 mm Hg ) than with Timolol 0.25 per cent ( 7.67 mm Hg ) P less than 0.001 . There was no significant difference in the fall in intraocular pressure between Ganda 1.0/0.2 ( 8.87 mm Hg ) and Timolol 0.25 per cent ( 8.24 mm Hg ) ."
],
"offsets": [
[
0,
745
]
]
}
] | [
{
"id": "79717",
"type": "Intervention_Pharmacological",
"text": [
"guanethidine 3 per cent and adrenaline 0.5 per cent ( Ganda 3.0/0.5 )"
],
"offsets": [
[
158,
227
]
],
"normalized": []
},
{
"id": "79718",
"type": "Intervention_Pharmacological",
"text": [
"guanethidine 1 per cent"
],
"offsets": [
[
232,
255
]
],
"normalized": []
},
{
"id": "79719",
"type": "Intervention_Pharmacological",
"text": [
"adrenaline 0.2 per cent ( Ganda 1.0/0.2 )"
],
"offsets": [
[
260,
301
]
],
"normalized": []
},
{
"id": "79720",
"type": "Intervention_Pharmacological",
"text": [
"Timolol ( Timoptol ) 0.25 per cent"
],
"offsets": [
[
327,
361
]
],
"normalized": []
},
{
"id": "79721",
"type": "Intervention_Pharmacological",
"text": [
"Ganda 3.0/0.5"
],
"offsets": [
[
212,
225
]
],
"normalized": []
},
{
"id": "79722",
"type": "Intervention_Pharmacological",
"text": [
"Timolol 0.25 per cent"
],
"offsets": [
[
537,
558
]
],
"normalized": []
},
{
"id": "79723",
"type": "Intervention_Pharmacological",
"text": [
"Ganda 1.0/0.2"
],
"offsets": [
[
286,
299
]
],
"normalized": []
},
{
"id": "79724",
"type": "Intervention_Pharmacological",
"text": [
"Timolol 0.25 per cent"
],
"offsets": [
[
537,
558
]
],
"normalized": []
},
{
"id": "79725",
"type": "Outcome_Physical",
"text": [
"primary open angle glaucoma"
],
"offsets": [
[
59,
86
]
],
"normalized": []
},
{
"id": "79726",
"type": "Outcome_Physical",
"text": [
"fall in intraocular pressure"
],
"offsets": [
[
465,
493
]
],
"normalized": []
},
{
"id": "79727",
"type": "Outcome_Physical",
"text": [
"fall in intraocular pressure"
],
"offsets": [
[
465,
493
]
],
"normalized": []
},
{
"id": "79728",
"type": "Participant_Condition",
"text": [
"treatment of primary open angle glaucoma ."
],
"offsets": [
[
46,
88
]
],
"normalized": []
}
] | [] | [] | [] |
79729 | 6807568 | [
{
"id": "79730",
"type": "document",
"text": [
"Treatment of stable angina of effort with verapamil : a double-blind , placebo-controlled randomized crossover study . The effects of verapamil were assessed in 26 patients with stable exertional angina pectoris in a double-blind , placebo-controlled , randomized crossover protocol using serial treadmill tests . Verapamil , 480 mg/day , reduced anginal frequency from 5.6 +/- 7.3 to 2.2 +/- 3.9 attacks per week ( p less than 0.001 ) and nitroglycerin consumption from 3.4 +/- 4.9 to 1.2 +/- 2.5 tablets per week ( p less than 0.05 ) compared with placebo . Treadmill time increased from 6.4 +/- 2.1 minutes during the placebo phase to 7.5 +/- 1.8 minutes during the verapamil phase ( p less than 0.001 ) . Verapamil 's beneficial effect appeared to be related , in part , to a 10 % reduction of the rate-pressure product at rest ( p less than 0.05 ) and a 12 % reduction during submaximal exercise ( p less than 0.001 ) . Verapamil also caused less marked ST-segment depressions at peak exercise ( p less than 0.05 ) at a similar rate-pressure product , suggesting a favorable redistribution of coronary blood flow to the ischemic zone . Side effects from verapamil were minimal , consisting mainly of constipation ( six patients ) . Verapamil appears to be a safe and effective drug for treating angina of effort ."
],
"offsets": [
[
0,
1318
]
]
}
] | [
{
"id": "79731",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "79732",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
71,
89
]
],
"normalized": []
},
{
"id": "79733",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "79734",
"type": "Intervention_Pharmacological",
"text": [
"Verapamil"
],
"offsets": [
[
314,
323
]
],
"normalized": []
},
{
"id": "79735",
"type": "Intervention_Pharmacological",
"text": [
"nitroglycerin"
],
"offsets": [
[
440,
453
]
],
"normalized": []
},
{
"id": "79736",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
71,
78
]
],
"normalized": []
},
{
"id": "79737",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
71,
78
]
],
"normalized": []
},
{
"id": "79738",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "79739",
"type": "Intervention_Pharmacological",
"text": [
"Verapamil 's"
],
"offsets": [
[
709,
721
]
],
"normalized": []
},
{
"id": "79740",
"type": "Intervention_Pharmacological",
"text": [
"Verapamil"
],
"offsets": [
[
314,
323
]
],
"normalized": []
},
{
"id": "79741",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "79742",
"type": "Intervention_Pharmacological",
"text": [
"Verapamil"
],
"offsets": [
[
314,
323
]
],
"normalized": []
},
{
"id": "79743",
"type": "Outcome_Physical",
"text": [
"anginal frequency"
],
"offsets": [
[
347,
364
]
],
"normalized": []
},
{
"id": "79744",
"type": "Outcome_Other",
"text": [
"nitroglycerin consumption"
],
"offsets": [
[
440,
465
]
],
"normalized": []
},
{
"id": "79745",
"type": "Outcome_Physical",
"text": [
"Treadmill time"
],
"offsets": [
[
560,
574
]
],
"normalized": []
},
{
"id": "79746",
"type": "Outcome_Physical",
"text": [
"rate-pressure product"
],
"offsets": [
[
802,
823
]
],
"normalized": []
},
{
"id": "79747",
"type": "Outcome_Physical",
"text": [
"ST-segment depressions at peak exercise"
],
"offsets": [
[
959,
998
]
],
"normalized": []
},
{
"id": "79748",
"type": "Outcome_Physical",
"text": [
"coronary blood flow"
],
"offsets": [
[
1098,
1117
]
],
"normalized": []
},
{
"id": "79749",
"type": "Outcome_Adverse-effects",
"text": [
"constipation"
],
"offsets": [
[
1205,
1217
]
],
"normalized": []
},
{
"id": "79750",
"type": "Outcome_Other",
"text": [
"safe and effective"
],
"offsets": [
[
1263,
1281
]
],
"normalized": []
},
{
"id": "79751",
"type": "Participant_Condition",
"text": [
"stable angina of effort"
],
"offsets": [
[
13,
36
]
],
"normalized": []
},
{
"id": "79752",
"type": "Participant_Condition",
"text": [
"angina"
],
"offsets": [
[
20,
26
]
],
"normalized": []
}
] | [] | [] | [] |
79753 | 6836750 | [
{
"id": "79754",
"type": "document",
"text": [
"Pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion . A pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion was carried out . All patients received total abdominal hysterectomy and bilateral salpingo-oophorectomy plus complementary radium therapy on the vaginal stump . After the conventional treatment , patients were randomly allocated to adjuvant hormone therapy or no further treatment . Hormone therapy consisted of gestonorone caproate ( 17 alpha-hydroxy-19-norpregn-4-en 3 , 20 dione caproate ) administered i.m . at the dose of 200 mg/week for 1 year . Of the 62 patients who entered the study , 51 were considered evaluable ( 24 with adjuvant hormone therapy and 27 with no further treatment ) . Five patients had a relapse : four of these were in the group with no further treatment . Actuarial relapse-free survival analysis at 5 years was 95.7 % in the group of adjuvant-treated patients and 82.8 % in the control group . Although there is no statistical significance , adjuvant therapy appears to result in an increase in relapse-free survival in the group of patients with deep myometrial invasion and undifferentiated carcinoma . Further studies are necessary to assess the effectiveness of hormone adjuvant treatment in FIGO stage I endometrial carcinoma with myometrial invasion ."
],
"offsets": [
[
0,
1403
]
]
}
] | [
{
"id": "79755",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant hormone therapy"
],
"offsets": [
[
17,
41
]
],
"normalized": []
},
{
"id": "79756",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant hormone therapy"
],
"offsets": [
[
17,
41
]
],
"normalized": []
},
{
"id": "79757",
"type": "Intervention_Physical",
"text": [
"total abdominal hysterectomy"
],
"offsets": [
[
254,
282
]
],
"normalized": []
},
{
"id": "79758",
"type": "Intervention_Physical",
"text": [
"bilateral salpingo-oophorectomy"
],
"offsets": [
[
287,
318
]
],
"normalized": []
},
{
"id": "79759",
"type": "Intervention_Physical",
"text": [
"complementary radium therapy on the vaginal stump"
],
"offsets": [
[
324,
373
]
],
"normalized": []
},
{
"id": "79760",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant hormone therapy or no further treatment"
],
"offsets": [
[
447,
495
]
],
"normalized": []
},
{
"id": "79761",
"type": "Intervention_Pharmacological",
"text": [
"gestonorone caproate ( 17 alpha-hydroxy-19-norpregn-4-en 3 , 20 dione caproate ) administered i.m"
],
"offsets": [
[
527,
624
]
],
"normalized": []
},
{
"id": "79762",
"type": "Intervention_Pharmacological",
"text": [
"at the dose of 200 mg/week for 1 year"
],
"offsets": [
[
627,
664
]
],
"normalized": []
},
{
"id": "79763",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant hormone therapy"
],
"offsets": [
[
17,
41
]
],
"normalized": []
},
{
"id": "79764",
"type": "Intervention_Other",
"text": [
"no further treatment"
],
"offsets": [
[
475,
495
]
],
"normalized": []
},
{
"id": "79765",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant therapy"
],
"offsets": [
[
1088,
1104
]
],
"normalized": []
},
{
"id": "79766",
"type": "Intervention_Pharmacological",
"text": [
"hormone adjuvant treatment"
],
"offsets": [
[
1312,
1338
]
],
"normalized": []
},
{
"id": "79767",
"type": "Outcome_Physical",
"text": [
"relapse"
],
"offsets": [
[
831,
838
]
],
"normalized": []
},
{
"id": "79768",
"type": "Outcome_Other",
"text": [
"no further treatment"
],
"offsets": [
[
475,
495
]
],
"normalized": []
},
{
"id": "79769",
"type": "Outcome_Mortality",
"text": [
"Actuarial relapse-free survival"
],
"offsets": [
[
901,
932
]
],
"normalized": []
},
{
"id": "79770",
"type": "Outcome_Mortality",
"text": [
"relapse-free survival"
],
"offsets": [
[
911,
932
]
],
"normalized": []
},
{
"id": "79771",
"type": "Participant_Condition",
"text": [
"FIGO stage I endometrial carcinoma"
],
"offsets": [
[
45,
79
]
],
"normalized": []
},
{
"id": "79772",
"type": "Participant_Condition",
"text": [
"myometrial invasion"
],
"offsets": [
[
85,
104
]
],
"normalized": []
},
{
"id": "79773",
"type": "Participant_Condition",
"text": [
"FIGO stage I endometrial carcinoma"
],
"offsets": [
[
45,
79
]
],
"normalized": []
},
{
"id": "79774",
"type": "Participant_Condition",
"text": [
"myometrial invasion"
],
"offsets": [
[
85,
104
]
],
"normalized": []
},
{
"id": "79775",
"type": "Participant_Sample-size",
"text": [
"62"
],
"offsets": [
[
674,
676
]
],
"normalized": []
},
{
"id": "79776",
"type": "Participant_Condition",
"text": [
"FIGO stage I endometrial carcinoma"
],
"offsets": [
[
45,
79
]
],
"normalized": []
},
{
"id": "79777",
"type": "Participant_Condition",
"text": [
"myometrial invasion"
],
"offsets": [
[
85,
104
]
],
"normalized": []
}
] | [] | [] | [] |
79778 | 6839001 | [
{
"id": "79779",
"type": "document",
"text": [
"Human platelet response to three salicylate dosage forms . Acetylsalicylic acid ( ASA ) inhibition of platelet aggregation as evaluated by collagen-induced 14C-serotonin release , has been measured in 12 healthy male subjects . Each subject received a single oral dose ( 650 mg ) of enteric-coated ASA ( ecASA ) and compressed ASA tablets ( cASA ) , or ecASA and sodium salicylate ( 578 mg ) separated by a minimum of 5 weeks . The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography . Both ecASA and cASA inhibited 14C-serotonin release ; no significant difference was observed in the maximum effect between these two products ( p less than 0.05 ) . No relationship was found between the maximum observed plasma ASA level and the maximum effect . Further , no correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations ."
],
"offsets": [
[
0,
1058
]
]
}
] | [
{
"id": "79780",
"type": "Intervention_Pharmacological",
"text": [
"salicylate"
],
"offsets": [
[
33,
43
]
],
"normalized": []
},
{
"id": "79781",
"type": "Intervention_Pharmacological",
"text": [
"Acetylsalicylic acid"
],
"offsets": [
[
59,
79
]
],
"normalized": []
},
{
"id": "79782",
"type": "Intervention_Pharmacological",
"text": [
"enteric-coated ASA"
],
"offsets": [
[
283,
301
]
],
"normalized": []
},
{
"id": "79783",
"type": "Intervention_Pharmacological",
"text": [
"compressed ASA tablets ( cASA )"
],
"offsets": [
[
316,
347
]
],
"normalized": []
},
{
"id": "79784",
"type": "Intervention_Pharmacological",
"text": [
"ecASA"
],
"offsets": [
[
304,
309
]
],
"normalized": []
},
{
"id": "79785",
"type": "Intervention_Pharmacological",
"text": [
"sodium salicylate"
],
"offsets": [
[
363,
380
]
],
"normalized": []
},
{
"id": "79786",
"type": "Intervention_Pharmacological",
"text": [
"ecASA"
],
"offsets": [
[
304,
309
]
],
"normalized": []
},
{
"id": "79787",
"type": "Intervention_Pharmacological",
"text": [
"cASA"
],
"offsets": [
[
305,
309
]
],
"normalized": []
},
{
"id": "79788",
"type": "Intervention_Pharmacological",
"text": [
"ASA"
],
"offsets": [
[
82,
85
]
],
"normalized": []
},
{
"id": "79789",
"type": "Intervention_Pharmacological",
"text": [
"ASA"
],
"offsets": [
[
82,
85
]
],
"normalized": []
},
{
"id": "79790",
"type": "Outcome_Other",
"text": [
"maximum effect"
],
"offsets": [
[
648,
662
]
],
"normalized": []
},
{
"id": "79791",
"type": "Outcome_Physical",
"text": [
"plasma ASA level and the maximum effect"
],
"offsets": [
[
768,
807
]
],
"normalized": []
},
{
"id": "79792",
"type": "Participant_Sample-size",
"text": [
"12"
],
"offsets": [
[
201,
203
]
],
"normalized": []
},
{
"id": "79793",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
212,
216
]
],
"normalized": []
}
] | [] | [] | [] |
79794 | 6841763 | [
{
"id": "79795",
"type": "document",
"text": [
"Modifying the Type A coronary-prone behavior pattern ."
],
"offsets": [
[
0,
54
]
]
}
] | [
{
"id": "79796",
"type": "Intervention_Educational",
"text": [
"Type A coronary-prone behavior pattern"
],
"offsets": [
[
14,
52
]
],
"normalized": []
},
{
"id": "79797",
"type": "Outcome_Mental",
"text": [
"Modifying the Type A coronary-prone behavior pattern"
],
"offsets": [
[
0,
52
]
],
"normalized": []
},
{
"id": "79798",
"type": "Participant_Condition",
"text": [
"Type A coronary-prone behavior"
],
"offsets": [
[
14,
44
]
],
"normalized": []
}
] | [] | [] | [] |
79799 | 6844471 | [
{
"id": "79800",
"type": "document",
"text": [
"Breathlessness and psychiatric morbidity in chronic bronchitis and emphysema : a study of psychotherapeutic management . This paper describes a study of the outcome of psychotherapy with patients disabled by chronic obstructive airways disease giving rise to dyspnoea . Forty-three men and 22 women with severe COAD were randomly allocated for 8 weeks to one of three types of psychotherapy or to an untreated control group , and were followed up six months later . The group treated by a medical nurse without training in psychotherapy experienced sustained relief of dyspnoea but tended to undergo less psychodynamic change ; psychiatric symptoms were reduced in those receiving supportive , but not analytical , psychotherapy . The psychosomatic mechanisms involved and the implications for medical and nursing practice and for liaison psychotherapy are discussed ."
],
"offsets": [
[
0,
868
]
]
}
] | [
{
"id": "79801",
"type": "Intervention_Educational",
"text": [
"psychotherapeutic management"
],
"offsets": [
[
90,
118
]
],
"normalized": []
},
{
"id": "79802",
"type": "Intervention_Psychological",
"text": [
"psychotherapy"
],
"offsets": [
[
168,
181
]
],
"normalized": []
},
{
"id": "79803",
"type": "Intervention_Educational",
"text": [
"psychotherapy"
],
"offsets": [
[
168,
181
]
],
"normalized": []
},
{
"id": "79804",
"type": "Intervention_Control",
"text": [
"untreated control"
],
"offsets": [
[
400,
417
]
],
"normalized": []
},
{
"id": "79805",
"type": "Intervention_Psychological",
"text": [
"psychotherapy"
],
"offsets": [
[
168,
181
]
],
"normalized": []
},
{
"id": "79806",
"type": "Intervention_Psychological",
"text": [
"psychotherapy"
],
"offsets": [
[
168,
181
]
],
"normalized": []
},
{
"id": "79807",
"type": "Outcome_Physical",
"text": [
"dyspnoea"
],
"offsets": [
[
259,
267
]
],
"normalized": []
},
{
"id": "79808",
"type": "Outcome_Mental",
"text": [
"psychodynamic change ; psychiatric symptoms"
],
"offsets": [
[
605,
648
]
],
"normalized": []
},
{
"id": "79809",
"type": "Participant_Sample-size",
"text": [
"Forty-three"
],
"offsets": [
[
270,
281
]
],
"normalized": []
},
{
"id": "79810",
"type": "Participant_Sex",
"text": [
"men"
],
"offsets": [
[
114,
117
]
],
"normalized": []
},
{
"id": "79811",
"type": "Participant_Sample-size",
"text": [
"and 22"
],
"offsets": [
[
286,
292
]
],
"normalized": []
},
{
"id": "79812",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
293,
298
]
],
"normalized": []
},
{
"id": "79813",
"type": "Participant_Condition",
"text": [
"severe COAD"
],
"offsets": [
[
304,
315
]
],
"normalized": []
}
] | [] | [] | [] |
79814 | 6849726 | [
{
"id": "79815",
"type": "document",
"text": [
"Interactions of morphine and methotrimeprazine in mouse and man with respect to analgesia , respiration and sedation . Interactions between morphine and methotrimeprazine have been studied in mice and man with respect to analgesia or antinociceptive activity , respiratory effects and sedation . The volunteer study was a double-blind cross-over trial with 10 volunteers . In mice , methotrimeprazine only possessed antinociceptive activity in doses which caused marked sedation . However , small non-sedative doses of methotrimeprazine potentiated the analgesic action of morphine . The volunteer study did not confirm this finding in man . Methotrimeprazine 7.5 mg i.m . caused significant sedation , but did not alter the effects of morphine 5 mg on pain threshold or ventilatory response to carbon dioxide ."
],
"offsets": [
[
0,
811
]
]
}
] | [
{
"id": "79816",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
16,
24
]
],
"normalized": []
},
{
"id": "79817",
"type": "Intervention_Pharmacological",
"text": [
"methotrimeprazine"
],
"offsets": [
[
29,
46
]
],
"normalized": []
},
{
"id": "79818",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
16,
24
]
],
"normalized": []
},
{
"id": "79819",
"type": "Intervention_Pharmacological",
"text": [
"methotrimeprazine"
],
"offsets": [
[
29,
46
]
],
"normalized": []
},
{
"id": "79820",
"type": "Intervention_Pharmacological",
"text": [
"methotrimeprazine"
],
"offsets": [
[
29,
46
]
],
"normalized": []
},
{
"id": "79821",
"type": "Intervention_Pharmacological",
"text": [
"Methotrimeprazine"
],
"offsets": [
[
642,
659
]
],
"normalized": []
},
{
"id": "79822",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
16,
24
]
],
"normalized": []
},
{
"id": "79823",
"type": "Outcome_Physical",
"text": [
"analgesia , respiration and sedation"
],
"offsets": [
[
80,
116
]
],
"normalized": []
},
{
"id": "79824",
"type": "Outcome_Physical",
"text": [
"analgesia or antinociceptive activity"
],
"offsets": [
[
221,
258
]
],
"normalized": []
},
{
"id": "79825",
"type": "Outcome_Physical",
"text": [
"respiratory effects"
],
"offsets": [
[
261,
280
]
],
"normalized": []
},
{
"id": "79826",
"type": "Outcome_Physical",
"text": [
"sedation"
],
"offsets": [
[
108,
116
]
],
"normalized": []
},
{
"id": "79827",
"type": "Outcome_Physical",
"text": [
"antinociceptive activity"
],
"offsets": [
[
234,
258
]
],
"normalized": []
},
{
"id": "79828",
"type": "Outcome_Physical",
"text": [
"marked sedation"
],
"offsets": [
[
463,
478
]
],
"normalized": []
},
{
"id": "79829",
"type": "Outcome_Pain",
"text": [
"analgesic action of morphine"
],
"offsets": [
[
553,
581
]
],
"normalized": []
},
{
"id": "79830",
"type": "Outcome_Physical",
"text": [
"significant sedation"
],
"offsets": [
[
680,
700
]
],
"normalized": []
},
{
"id": "79831",
"type": "Outcome_Pain",
"text": [
"pain threshold"
],
"offsets": [
[
753,
767
]
],
"normalized": []
},
{
"id": "79832",
"type": "Outcome_Physical",
"text": [
"ventilatory response"
],
"offsets": [
[
771,
791
]
],
"normalized": []
},
{
"id": "79833",
"type": "Participant_Sex",
"text": [
"man"
],
"offsets": [
[
60,
63
]
],
"normalized": []
},
{
"id": "79834",
"type": "Participant_Sex",
"text": [
"man"
],
"offsets": [
[
60,
63
]
],
"normalized": []
},
{
"id": "79835",
"type": "Participant_Sample-size",
"text": [
"10 volunteers"
],
"offsets": [
[
357,
370
]
],
"normalized": []
}
] | [] | [] | [] |
79836 | 6849742 | [
{
"id": "79837",
"type": "document",
"text": [
"Changes in heart rate and forearm blood flow following intravenous boluses of isoprenaline in the presence of practolol and propranolol . 1 Increases in heart rate and forearm blood flow following graded intravenous bolus injections of isoprenaline sulphate , were measured in a double-blind randomised study of six subjects who received either placebo , practolol 50 mg , practolol 200 mg , propranolol 10 mg or propranolol 40 mg. 2 Dose related increases in forearm blood flow were produced by the graded boluses of isoprenaline sulphate . 3 Practolol 50 mg attenuated the heart rate response to isoprenaline but did not significantly affect the changes in forearm blood flow . Practolol 200 mg further attenuated the heart rate responses but also decreased the forearm blood flow responses . 4 Propranolol 10 mg and propranolol 40 mg significantly attenuated both the heart rate and forearm blood flow responses . The effect on forearm blood flow tended to be greater than the effect on heart rate . 5 Practolol 200 mg had the same effect on heart rate responses as propranolol 10 mg but a significantly smaller effect on the forearm blood flow responses . 6 The measurement of forearm blood flow following intravenous bolus injections of isoprenaline provides useful information about the beta 2-adrenoceptor antagonism of propranolol and practolol . However , application of the technique may be limited by the magnitude of the heart rate response and by the short-lived nature of the increase in forearm blood flow ."
],
"offsets": [
[
0,
1522
]
]
}
] | [
{
"id": "79838",
"type": "Intervention_Pharmacological",
"text": [
"isoprenaline"
],
"offsets": [
[
78,
90
]
],
"normalized": []
},
{
"id": "79839",
"type": "Intervention_Pharmacological",
"text": [
"isoprenaline sulphate"
],
"offsets": [
[
236,
257
]
],
"normalized": []
},
{
"id": "79840",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
345,
352
]
],
"normalized": []
},
{
"id": "79841",
"type": "Intervention_Pharmacological",
"text": [
"practolol"
],
"offsets": [
[
110,
119
]
],
"normalized": []
},
{
"id": "79842",
"type": "Intervention_Pharmacological",
"text": [
"practolol"
],
"offsets": [
[
110,
119
]
],
"normalized": []
},
{
"id": "79843",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
124,
135
]
],
"normalized": []
},
{
"id": "79844",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
124,
135
]
],
"normalized": []
},
{
"id": "79845",
"type": "Intervention_Pharmacological",
"text": [
"isoprenaline sulphate"
],
"offsets": [
[
236,
257
]
],
"normalized": []
},
{
"id": "79846",
"type": "Intervention_Pharmacological",
"text": [
"Practolol"
],
"offsets": [
[
544,
553
]
],
"normalized": []
},
{
"id": "79847",
"type": "Intervention_Pharmacological",
"text": [
"Practolol"
],
"offsets": [
[
544,
553
]
],
"normalized": []
},
{
"id": "79848",
"type": "Intervention_Pharmacological",
"text": [
"Propranolol"
],
"offsets": [
[
797,
808
]
],
"normalized": []
},
{
"id": "79849",
"type": "Intervention_Pharmacological",
"text": [
"Practolol"
],
"offsets": [
[
544,
553
]
],
"normalized": []
},
{
"id": "79850",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
124,
135
]
],
"normalized": []
},
{
"id": "79851",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
124,
135
]
],
"normalized": []
},
{
"id": "79852",
"type": "Intervention_Pharmacological",
"text": [
"practolol"
],
"offsets": [
[
110,
119
]
],
"normalized": []
},
{
"id": "79853",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
11,
21
]
],
"normalized": []
},
{
"id": "79854",
"type": "Outcome_Physical",
"text": [
"forearm blood flow"
],
"offsets": [
[
26,
44
]
],
"normalized": []
},
{
"id": "79855",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
11,
21
]
],
"normalized": []
},
{
"id": "79856",
"type": "Outcome_Physical",
"text": [
"forearm blood flow"
],
"offsets": [
[
26,
44
]
],
"normalized": []
},
{
"id": "79857",
"type": "Outcome_Physical",
"text": [
"forearm blood flow"
],
"offsets": [
[
26,
44
]
],
"normalized": []
},
{
"id": "79858",
"type": "Outcome_Physical",
"text": [
"heart rate response"
],
"offsets": [
[
575,
594
]
],
"normalized": []
},
{
"id": "79859",
"type": "Outcome_Physical",
"text": [
"forearm blood flow"
],
"offsets": [
[
26,
44
]
],
"normalized": []
},
{
"id": "79860",
"type": "Outcome_Physical",
"text": [
"heart rate responses"
],
"offsets": [
[
720,
740
]
],
"normalized": []
},
{
"id": "79861",
"type": "Outcome_Physical",
"text": [
"forearm blood flow responses"
],
"offsets": [
[
764,
792
]
],
"normalized": []
},
{
"id": "79862",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
11,
21
]
],
"normalized": []
},
{
"id": "79863",
"type": "Outcome_Mental",
"text": [
"and"
],
"offsets": [
[
22,
25
]
],
"normalized": []
},
{
"id": "79864",
"type": "Outcome_Physical",
"text": [
"forearm blood flow responses"
],
"offsets": [
[
764,
792
]
],
"normalized": []
},
{
"id": "79865",
"type": "Outcome_Physical",
"text": [
"forearm blood flow"
],
"offsets": [
[
26,
44
]
],
"normalized": []
},
{
"id": "79866",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
11,
21
]
],
"normalized": []
},
{
"id": "79867",
"type": "Outcome_Physical",
"text": [
"heart rate responses"
],
"offsets": [
[
720,
740
]
],
"normalized": []
},
{
"id": "79868",
"type": "Outcome_Physical",
"text": [
"forearm blood flow responses"
],
"offsets": [
[
764,
792
]
],
"normalized": []
},
{
"id": "79869",
"type": "Outcome_Physical",
"text": [
"forearm blood flow"
],
"offsets": [
[
26,
44
]
],
"normalized": []
},
{
"id": "79870",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
11,
21
]
],
"normalized": []
},
{
"id": "79871",
"type": "Outcome_Physical",
"text": [
"forearm blood flow"
],
"offsets": [
[
26,
44
]
],
"normalized": []
},
{
"id": "79872",
"type": "Participant_Sample-size",
"text": [
"six"
],
"offsets": [
[
312,
315
]
],
"normalized": []
}
] | [] | [] | [] |
79873 | 6850464 | [
{
"id": "79874",
"type": "document",
"text": [
"Nonspecific and selective stimulation of the immune system in the treatment of carcinoma in humans . The experience of the Toronto General Hospital in the use of nonspecific stimulation of the immune system with bacille Calmette-Guérin ( BCG ) for the treatment of cancer of the gastrointestinal tract , malignant melanoma and breast cancer is described . The results are presented in terms of survival curves . The use of BCG administered intraperitoneally in a randomized study of patients with gastric , pancreatic and colorectal cancer proved of no benefit . On the other hand , when BCG was given orally in a randomized study of patients with resectable cancer of the colon and in nonrandomized consecutive studies of patients with malignant melanoma and stage IV carcinoma of the breast survival was increased . In a group of patients with advanced gastrointestinal cancer selective stimulation of the immune system with NED 137 produced a significant increase in survival when compared with the survival of historical controls ( the patients given BCG intraperitoneally along with 5-fluorouracil for gastrointestinal cancer ) . The results of these studies suggest the need for a more rational approach in manipulating the immune response that would combine chemotherapy with selective stimulation of the immune system ."
],
"offsets": [
[
0,
1327
]
]
}
] | [] | [] | [] | [] |
79875 | 6859471 | [
{
"id": "79876",
"type": "document",
"text": [
"Postoperative dreaming . A comparison of the incidence following pentazocine and morphine premedication . The incidence of postoperative dreaming following the use of morphine and pentazocine as premedicants in an otherwise standard anaesthetic sequence is compared in healthy volunteers . No statistically significant difference was demonstrated between the two drugs . The causes of psychotomimetic problems in the postoperative period and the difficulty of precise definition of hallucinations are discussed ."
],
"offsets": [
[
0,
512
]
]
}
] | [
{
"id": "79877",
"type": "Intervention_Pharmacological",
"text": [
"pentazocine"
],
"offsets": [
[
65,
76
]
],
"normalized": []
},
{
"id": "79878",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
81,
89
]
],
"normalized": []
},
{
"id": "79879",
"type": "Intervention_Pharmacological",
"text": [
"morphine"
],
"offsets": [
[
81,
89
]
],
"normalized": []
},
{
"id": "79880",
"type": "Intervention_Pharmacological",
"text": [
"pentazocine"
],
"offsets": [
[
65,
76
]
],
"normalized": []
}
] | [] | [] | [] |
79881 | 6871470 | [
{
"id": "79882",
"type": "document",
"text": [
"Delayed alloimmunization using random single donor platelet transfusions : a prospective study in thrombocytopenic patients with acute leukemia . A randomized study was performed in 54 thrombocytopenic patients with acute leukemia . Alloimmunization of recipients of random multiple-donor platelet concentrates ( MD group ) was compared to that of patients receiving random single-donor platelets ( SD group ) . In the SD patients , formation of alloantibodies ( mostly anti-HLA ) occurred less frequently ( p less than 0.002 ) , after a longer time period ( p less than 0.002 ) , and after a higher number of transfusions ( p less than 0.005 ) as compared to MD patients . SD patients also became refractory to random platelets less frequently ( p less than 0.005 ) , after a longer time period , and after a higher number of transfusions ( p less than 0.02 ) . In SD patients , the increments after the first and the last transfusion were in the same range , whereas in MD patients , the 1-hr ( p less than 0.001 ) and the 24-hr ( p less than 0.025 ) increments decreased from the first to the last transfusion . Thus , the use of random SD platelet transfusions postponed alloimmunization ."
],
"offsets": [
[
0,
1193
]
]
}
] | [
{
"id": "79883",
"type": "Intervention_Physical",
"text": [
"random single donor platelet transfusions"
],
"offsets": [
[
31,
72
]
],
"normalized": []
},
{
"id": "79884",
"type": "Intervention_Pharmacological",
"text": [
"multiple-donor platelet concentrates"
],
"offsets": [
[
274,
310
]
],
"normalized": []
},
{
"id": "79885",
"type": "Intervention_Physical",
"text": [
"random single-donor platelets"
],
"offsets": [
[
367,
396
]
],
"normalized": []
},
{
"id": "79886",
"type": "Intervention_Physical",
"text": [
"random SD platelet transfusions"
],
"offsets": [
[
1133,
1164
]
],
"normalized": []
},
{
"id": "79887",
"type": "Outcome_Physical",
"text": [
"Delayed alloimmunization"
],
"offsets": [
[
0,
24
]
],
"normalized": []
},
{
"id": "79888",
"type": "Outcome_Physical",
"text": [
"formation of alloantibodies ( mostly anti-HLA )"
],
"offsets": [
[
433,
480
]
],
"normalized": []
},
{
"id": "79889",
"type": "Outcome_Other",
"text": [
"higher number of transfusions"
],
"offsets": [
[
593,
622
]
],
"normalized": []
},
{
"id": "79890",
"type": "Outcome_Physical",
"text": [
"first and the last transfusion"
],
"offsets": [
[
905,
935
]
],
"normalized": []
},
{
"id": "79891",
"type": "Participant_Condition",
"text": [
"thrombocytopenic"
],
"offsets": [
[
98,
114
]
],
"normalized": []
},
{
"id": "79892",
"type": "Participant_Condition",
"text": [
"acute leukemia"
],
"offsets": [
[
129,
143
]
],
"normalized": []
},
{
"id": "79893",
"type": "Participant_Sample-size",
"text": [
"54"
],
"offsets": [
[
182,
184
]
],
"normalized": []
},
{
"id": "79894",
"type": "Participant_Condition",
"text": [
"thrombocytopenic"
],
"offsets": [
[
98,
114
]
],
"normalized": []
},
{
"id": "79895",
"type": "Participant_Condition",
"text": [
"acute leukemia"
],
"offsets": [
[
129,
143
]
],
"normalized": []
}
] | [] | [] | [] |
79896 | 688257 | [
{
"id": "79897",
"type": "document",
"text": [
"Adriamycin and chlorambucil versus adriamycin and thiabendazole in the treatment of extensive , non-small cell carcinoma of the lung : a Southwest Oncology Group pilot study ."
],
"offsets": [
[
0,
175
]
]
}
] | [
{
"id": "79898",
"type": "Intervention_Pharmacological",
"text": [
"Adriamycin and chlorambucil"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "79899",
"type": "Intervention_Pharmacological",
"text": [
"adriamycin and thiabendazole"
],
"offsets": [
[
35,
63
]
],
"normalized": []
},
{
"id": "79900",
"type": "Outcome_Physical",
"text": [
"extensive , non-small cell carcinoma of the lung :"
],
"offsets": [
[
84,
134
]
],
"normalized": []
}
] | [] | [] | [] |
79901 | 6882809 | [
{
"id": "79902",
"type": "document",
"text": [
"Handwarming and relaxation in temperature feedback : positive placebo effects . Sixteen males and females were randomly assigned to either temperature feedback groups warm-relax ( WR ) or cool-relax ( CR ) to determine how successful hand-warming and -cooling alters the subjective report of relaxation . After eight 1/2-hour sessions the WR and CR demonstrated a significant difference in temperature change , but there were no significant main effects in reported subjective relaxation . The reported feelings of relaxation were negatively correlated to the directionality of temperature change and were primarily attributed to nonspecific expectancies ."
],
"offsets": [
[
0,
656
]
]
}
] | [
{
"id": "79903",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
62,
69
]
],
"normalized": []
},
{
"id": "79904",
"type": "Intervention_Physical",
"text": [
"temperature feedback groups warm-relax ( WR ) or cool-relax ( CR )"
],
"offsets": [
[
139,
205
]
],
"normalized": []
},
{
"id": "79905",
"type": "Outcome_Other",
"text": [
"temperature change"
],
"offsets": [
[
390,
408
]
],
"normalized": []
},
{
"id": "79906",
"type": "Outcome_Mental",
"text": [
"subjective relaxation"
],
"offsets": [
[
466,
487
]
],
"normalized": []
},
{
"id": "79907",
"type": "Outcome_Mental",
"text": [
"relaxation"
],
"offsets": [
[
16,
26
]
],
"normalized": []
},
{
"id": "79908",
"type": "Participant_Condition",
"text": [
"Sixteen males and females"
],
"offsets": [
[
80,
105
]
],
"normalized": []
}
] | [] | [] | [] |
79909 | 6885201 | [
{
"id": "79910",
"type": "document",
"text": [
"Pharmacokinetics of naproxen after oral administration of two tablet formulations in healthy volunteers . The pharmacokinetics of two naproxen tablet formulations were compared after oral administration . The 250-mg naproxen tablets , tablet I from AFI , Oslo , Norway , and tablet II Naprosyn , Astra-Syntex , were taken by 12 healthy volunteers in a randomized two-period crossover study . Plasma levels of naproxen were measured by a sensitive and specific HPLC method . The data were analyzed by means of two-way analysis of variance to test for significant differences between tablet formulation and differences between the first and second trial periods . Rapid absorption , with most Cmax values from 50-60 micrograms/ml reached within 1.5-3 h , was found for both tablet formulations . No significant difference was found in the rate and extent of absorption between the two formulations : the relative bioavailability of tablet I compared to tablet II was 1.05 +/- 0.21 ( mean +/- SD ) . The naproxen concentration 2 h after ingestion and the Cmax were higher on the second occasion , regardless of preparation , suggesting that the subjects were clinically different on the two occasions ."
],
"offsets": [
[
0,
1199
]
]
}
] | [
{
"id": "79911",
"type": "Intervention_Pharmacological",
"text": [
"naproxen"
],
"offsets": [
[
20,
28
]
],
"normalized": []
},
{
"id": "79912",
"type": "Intervention_Pharmacological",
"text": [
"naproxen"
],
"offsets": [
[
20,
28
]
],
"normalized": []
},
{
"id": "79913",
"type": "Intervention_Pharmacological",
"text": [
"250-mg naproxen tablets"
],
"offsets": [
[
209,
232
]
],
"normalized": []
},
{
"id": "79914",
"type": "Intervention_Pharmacological",
"text": [
"naproxen"
],
"offsets": [
[
20,
28
]
],
"normalized": []
},
{
"id": "79915",
"type": "Intervention_Pharmacological",
"text": [
"naproxen"
],
"offsets": [
[
20,
28
]
],
"normalized": []
},
{
"id": "79916",
"type": "Outcome_Other",
"text": [
"sensitive and specific HPLC method"
],
"offsets": [
[
437,
471
]
],
"normalized": []
},
{
"id": "79917",
"type": "Outcome_Physical",
"text": [
"Rapid absorption"
],
"offsets": [
[
662,
678
]
],
"normalized": []
},
{
"id": "79918",
"type": "Outcome_Physical",
"text": [
"Cmax values"
],
"offsets": [
[
691,
702
]
],
"normalized": []
},
{
"id": "79919",
"type": "Outcome_Physical",
"text": [
"difference"
],
"offsets": [
[
562,
572
]
],
"normalized": []
},
{
"id": "79920",
"type": "Outcome_Other",
"text": [
"rate and extent of absorption"
],
"offsets": [
[
837,
866
]
],
"normalized": []
},
{
"id": "79921",
"type": "Outcome_Other",
"text": [
"bioavailability"
],
"offsets": [
[
911,
926
]
],
"normalized": []
},
{
"id": "79922",
"type": "Outcome_Physical",
"text": [
"naproxen concentration"
],
"offsets": [
[
1001,
1023
]
],
"normalized": []
},
{
"id": "79923",
"type": "Outcome_Other",
"text": [
"clinically different"
],
"offsets": [
[
1156,
1176
]
],
"normalized": []
},
{
"id": "79924",
"type": "Participant_Sample-size",
"text": [
"12"
],
"offsets": [
[
325,
327
]
],
"normalized": []
}
] | [] | [] | [] |
79925 | 6927657 | [
{
"id": "79926",
"type": "document",
"text": [
"Extra prompts versus no extra prompts in self-care training of autistic children and adolescents . A color-coded \" extra prompt \" procedure was compared to a \" no extra prompt \" procedure in teaching autistic children and adolescents how to lace shoes . One randomly assigned group of 10 autistic subjects first learned to lace shoes whose laces and eyelets were color-coded red and white , and then encountered the no extra prompt condition in which color codes could no longer be depended upon to solve the position discriminations required to lace properly . In a counterbalanced fashion , the other group of 10 autistic subjects reached criterion on the non-color-coded , naturalistic shoe before experiencing the extra prompt condition . Analysis of variance and post-hoc analyses suggest that subjects who first learned under the color-coded , extra prompt condition encountered significant difficulty in transferring their newly acquired skill to the naturalistic , non-color-coded condition , whereas subjects who learned initially without the extra prompts had little difficulty with the subsequent color-coded condition . A follow-up procedure requiring all subjects to choose between the color prompt and the position cue revealed that 11 of 20 subjects consistently chose the color cue , even though it resulted in improper lacing . It is recommended that clinicians avoid the use of highly salient , non-criterion-related prompts in teaching certain types of adaptive skills to autistic children ."
],
"offsets": [
[
0,
1510
]
]
}
] | [
{
"id": "79927",
"type": "Intervention_Educational",
"text": [
"Extra prompts"
],
"offsets": [
[
0,
13
]
],
"normalized": []
},
{
"id": "79928",
"type": "Intervention_Educational",
"text": [
"no extra prompts"
],
"offsets": [
[
21,
37
]
],
"normalized": []
},
{
"id": "79929",
"type": "Intervention_Educational",
"text": [
"color-coded \" extra prompt \" procedure"
],
"offsets": [
[
101,
139
]
],
"normalized": []
},
{
"id": "79930",
"type": "Intervention_Educational",
"text": [
"compared to a \" no extra prompt \" procedure"
],
"offsets": [
[
144,
187
]
],
"normalized": []
},
{
"id": "79931",
"type": "Intervention_Educational",
"text": [
"lace shoes"
],
"offsets": [
[
241,
251
]
],
"normalized": []
},
{
"id": "79932",
"type": "Intervention_Educational",
"text": [
"eyelets"
],
"offsets": [
[
350,
357
]
],
"normalized": []
},
{
"id": "79933",
"type": "Intervention_Educational",
"text": [
"no extra prompt condition in which color codes could no longer be depended"
],
"offsets": [
[
416,
490
]
],
"normalized": []
}
] | [] | [] | [] |
79934 | 6938012 | [
{
"id": "79935",
"type": "document",
"text": [
"Cardiovascular complications to treatment of prostate cancer with estramustine phosphate ( Estracyt ) or conventional estrogen . A follow-up of 212 randomized patients . Two hundred and twelve patients treated for prostatic cancer grade I or II were investigated for cardiovascular complications . The patients were part of a multicentre study in the Stockholm area and had been randomized to treatment with either estramustine phosphate ( Estracyt ) or polyestradiol phosphate and ethinyl estradiol . Cardiovascular complications categorized as impaired arterial circulation including ischemic heart disease , venous thromboembolism , cardiac incompensation and cerebral depression were found to be equally frequent following the two different forms of treatment . Among the patients getting cardiovascular complications , these occurred within two months after the start of treatment in 50 % and within one year in 85 % of them . There was a statistically significant correlation between the incidence of cardiovascular complications and a history of previous cardiovascular disease . This criterion was however in retrospect found to predict cardiovascular complications in only 67 of the 126 patients getting one or several of these complications ."
],
"offsets": [
[
0,
1252
]
]
}
] | [
{
"id": "79936",
"type": "Intervention_Pharmacological",
"text": [
"estramustine phosphate ( Estracyt )"
],
"offsets": [
[
66,
101
]
],
"normalized": []
},
{
"id": "79937",
"type": "Intervention_Pharmacological",
"text": [
"conventional estrogen"
],
"offsets": [
[
105,
126
]
],
"normalized": []
},
{
"id": "79938",
"type": "Intervention_Pharmacological",
"text": [
"estramustine phosphate ( Estracyt )"
],
"offsets": [
[
66,
101
]
],
"normalized": []
},
{
"id": "79939",
"type": "Intervention_Pharmacological",
"text": [
"polyestradiol phosphate and ethinyl estradiol"
],
"offsets": [
[
454,
499
]
],
"normalized": []
},
{
"id": "79940",
"type": "Outcome_Physical",
"text": [
"ischemic heart disease"
],
"offsets": [
[
586,
608
]
],
"normalized": []
},
{
"id": "79941",
"type": "Outcome_Physical",
"text": [
"venous thromboembolism"
],
"offsets": [
[
611,
633
]
],
"normalized": []
},
{
"id": "79942",
"type": "Outcome_Physical",
"text": [
"cardiac incompensation"
],
"offsets": [
[
636,
658
]
],
"normalized": []
},
{
"id": "79943",
"type": "Outcome_Physical",
"text": [
"cerebral depression"
],
"offsets": [
[
663,
682
]
],
"normalized": []
},
{
"id": "79944",
"type": "Outcome_Adverse-effects",
"text": [
"incidence of cardiovascular complications"
],
"offsets": [
[
994,
1035
]
],
"normalized": []
},
{
"id": "79945",
"type": "Outcome_Physical",
"text": [
"cardiovascular complications"
],
"offsets": [
[
267,
295
]
],
"normalized": []
},
{
"id": "79946",
"type": "Participant_Condition",
"text": [
"prostate cancer"
],
"offsets": [
[
45,
60
]
],
"normalized": []
},
{
"id": "79947",
"type": "Participant_Condition",
"text": [
"follow-up of 212 randomized patients ."
],
"offsets": [
[
131,
169
]
],
"normalized": []
}
] | [] | [] | [] |
79948 | 6958487 | [
{
"id": "79949",
"type": "document",
"text": [
"Budesonide and beclomethasone dipropionate in hay fever - a single blind comparison . 93 patients with seasonal allergic rhinitis took part in a single blind randomized clinical comparison of budesonide and beclomethasone dipropionate ( Becotide Nasal ) . All patients were sensitive to either birch or grass pollen , their sensitivity being confirmed by a skin prick test . The total daily dose was 400 micrograms for both drugs . Budesonide was administered twice a day and Becotide Nasal four times a day . Symptoms were assessed over a four-week period starting with a run-in period of one week . There was no placebo control group . Daily pollen counts were measured throughout the trial . The patients ' diary cards revealed that both drugs had a beneficial therapeutic effect , and that budesonide was significantly more active than Becotide Nasal . The side effects of both drugs were few and transient ."
],
"offsets": [
[
0,
912
]
]
}
] | [
{
"id": "79950",
"type": "Intervention_Pharmacological",
"text": [
"Budesonide and beclomethasone dipropionate"
],
"offsets": [
[
0,
42
]
],
"normalized": []
},
{
"id": "79951",
"type": "Intervention_Pharmacological",
"text": [
"budesonide and beclomethasone dipropionate ( Becotide Nasal )"
],
"offsets": [
[
192,
253
]
],
"normalized": []
},
{
"id": "79952",
"type": "Intervention_Pharmacological",
"text": [
"Budesonide"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "79953",
"type": "Intervention_Pharmacological",
"text": [
"Becotide Nasal"
],
"offsets": [
[
237,
251
]
],
"normalized": []
},
{
"id": "79954",
"type": "Intervention_Pharmacological",
"text": [
"budesonide"
],
"offsets": [
[
192,
202
]
],
"normalized": []
},
{
"id": "79955",
"type": "Intervention_Pharmacological",
"text": [
"Becotide Nasal ."
],
"offsets": [
[
840,
856
]
],
"normalized": []
},
{
"id": "79956",
"type": "Outcome_Physical",
"text": [
"Daily pollen counts"
],
"offsets": [
[
638,
657
]
],
"normalized": []
},
{
"id": "79957",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
861,
873
]
],
"normalized": []
},
{
"id": "79958",
"type": "Participant_Condition",
"text": [
"hay fever"
],
"offsets": [
[
46,
55
]
],
"normalized": []
},
{
"id": "79959",
"type": "Participant_Sample-size",
"text": [
"93"
],
"offsets": [
[
86,
88
]
],
"normalized": []
},
{
"id": "79960",
"type": "Participant_Condition",
"text": [
"seasonal allergic rhinitis"
],
"offsets": [
[
103,
129
]
],
"normalized": []
}
] | [] | [] | [] |
79961 | 6980168 | [
{
"id": "79962",
"type": "document",
"text": [
"Whole pelvic irradiation in stage I endometrial carcinoma : changes in numbers and reactivities of some blood lymphocyte subpopulations ."
],
"offsets": [
[
0,
137
]
]
}
] | [
{
"id": "79963",
"type": "Intervention_Physical",
"text": [
"irradiation"
],
"offsets": [
[
13,
24
]
],
"normalized": []
},
{
"id": "79964",
"type": "Outcome_Physical",
"text": [
"changes in numbers and reactivities of some blood lymphocyte subpopulations ."
],
"offsets": [
[
60,
137
]
],
"normalized": []
},
{
"id": "79965",
"type": "Participant_Condition",
"text": [
"stage I endometrial carcinoma"
],
"offsets": [
[
28,
57
]
],
"normalized": []
},
{
"id": "79966",
"type": "Participant_Condition",
"text": [
"blood lymphocyte subpopulations"
],
"offsets": [
[
104,
135
]
],
"normalized": []
}
] | [] | [] | [] |
79967 | 6984358 | [
{
"id": "79968",
"type": "document",
"text": [
"Tolfenamic acid and caffeine : a useful combination in migraine . Tolfenamic acid is a potent inhibitor of prostaglandin biosynthesis , which has been proved effective in the treatment of acute migraine attacks . The usefulness of caffeine , metoclopramide and pyridoxine as adjuncts to tolfenamic acid was tested in acute migraine attacks in ten patients . A combination of tolfenamic acid ( 200 mg ) with either caffeine ( 100 mg ) , metoclopramide ( 10 mg ) or pyridoxine ( 300 mg ) was given twice to each patient in random order . Thus 60 attacks were treated . The tolfenamic acid-caffeine combination proved the most effective as judged by duration and intensity of attacks , working ability , vigilance , and overall evaluation of the drugs by the patients . Metoclopramide was somewhat better than pyridoxine as an additive ."
],
"offsets": [
[
0,
834
]
]
}
] | [
{
"id": "79969",
"type": "Intervention_Pharmacological",
"text": [
"Tolfenamic acid and caffeine"
],
"offsets": [
[
0,
28
]
],
"normalized": []
},
{
"id": "79970",
"type": "Intervention_Pharmacological",
"text": [
"Tolfenamic acid"
],
"offsets": [
[
0,
15
]
],
"normalized": []
},
{
"id": "79971",
"type": "Intervention_Pharmacological",
"text": [
"caffeine"
],
"offsets": [
[
20,
28
]
],
"normalized": []
},
{
"id": "79972",
"type": "Intervention_Pharmacological",
"text": [
"metoclopramide"
],
"offsets": [
[
242,
256
]
],
"normalized": []
},
{
"id": "79973",
"type": "Intervention_Pharmacological",
"text": [
"pyridoxine"
],
"offsets": [
[
261,
271
]
],
"normalized": []
},
{
"id": "79974",
"type": "Intervention_Pharmacological",
"text": [
"tolfenamic acid"
],
"offsets": [
[
287,
302
]
],
"normalized": []
},
{
"id": "79975",
"type": "Intervention_Pharmacological",
"text": [
"tolfenamic acid"
],
"offsets": [
[
287,
302
]
],
"normalized": []
},
{
"id": "79976",
"type": "Intervention_Pharmacological",
"text": [
"caffeine"
],
"offsets": [
[
20,
28
]
],
"normalized": []
},
{
"id": "79977",
"type": "Intervention_Pharmacological",
"text": [
"metoclopramide"
],
"offsets": [
[
242,
256
]
],
"normalized": []
},
{
"id": "79978",
"type": "Intervention_Pharmacological",
"text": [
"pyridoxine"
],
"offsets": [
[
261,
271
]
],
"normalized": []
},
{
"id": "79979",
"type": "Intervention_Pharmacological",
"text": [
"tolfenamic acid-caffeine combination"
],
"offsets": [
[
571,
607
]
],
"normalized": []
},
{
"id": "79980",
"type": "Intervention_Pharmacological",
"text": [
"Metoclopramide"
],
"offsets": [
[
767,
781
]
],
"normalized": []
},
{
"id": "79981",
"type": "Intervention_Pharmacological",
"text": [
"pyridoxine"
],
"offsets": [
[
261,
271
]
],
"normalized": []
},
{
"id": "79982",
"type": "Outcome_Physical",
"text": [
"migraine"
],
"offsets": [
[
55,
63
]
],
"normalized": []
},
{
"id": "79983",
"type": "Outcome_Physical",
"text": [
"acute migraine attacks"
],
"offsets": [
[
188,
210
]
],
"normalized": []
},
{
"id": "79984",
"type": "Outcome_Other",
"text": [
"duration and intensity of attacks"
],
"offsets": [
[
647,
680
]
],
"normalized": []
},
{
"id": "79985",
"type": "Outcome_Physical",
"text": [
"working ability , vigilance"
],
"offsets": [
[
683,
710
]
],
"normalized": []
},
{
"id": "79986",
"type": "Outcome_Other",
"text": [
"overall evaluation of the drugs"
],
"offsets": [
[
717,
748
]
],
"normalized": []
},
{
"id": "79987",
"type": "Participant_Condition",
"text": [
"migraine"
],
"offsets": [
[
55,
63
]
],
"normalized": []
},
{
"id": "79988",
"type": "Participant_Condition",
"text": [
"migraine"
],
"offsets": [
[
55,
63
]
],
"normalized": []
}
] | [] | [] | [] |
79989 | 698606 | [
{
"id": "79990",
"type": "document",
"text": [
"Ambulation in labour . In a randomised prospective study of 68 women in spontaneous labour half were allocated to an ambulant group and half to a recumbent group . The duration of labour was significantly shorter , the need for analgesia significantly less , and the incidence of fetal heart abnormalities significantly smaller in the ambulant group than in the recumbent group . Apgar scores at one and five minutes were also significantly greater in the ambulant group . More patients in the recumbent group required augmentations with oxytocic drugs . There was no statistically significant difference in the third stage loss in the two groups . Ambulation in labour should be encouraged : it may bring human benefits while allowing the advantages of hospital supervision ."
],
"offsets": [
[
0,
776
]
]
}
] | [
{
"id": "79991",
"type": "Intervention_Physical",
"text": [
"Ambulation"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "79992",
"type": "Intervention_Physical",
"text": [
"ambulant"
],
"offsets": [
[
117,
125
]
],
"normalized": []
},
{
"id": "79993",
"type": "Intervention_Control",
"text": [
"recumbent"
],
"offsets": [
[
146,
155
]
],
"normalized": []
},
{
"id": "79994",
"type": "Intervention_Physical",
"text": [
"oxytocic"
],
"offsets": [
[
538,
546
]
],
"normalized": []
},
{
"id": "79995",
"type": "Intervention_Physical",
"text": [
"Ambulation"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "79996",
"type": "Outcome_Other",
"text": [
"duration of labour"
],
"offsets": [
[
168,
186
]
],
"normalized": []
},
{
"id": "79997",
"type": "Outcome_Pain",
"text": [
"need for analgesia"
],
"offsets": [
[
219,
237
]
],
"normalized": []
},
{
"id": "79998",
"type": "Outcome_Physical",
"text": [
"incidence of fetal heart abnormalities"
],
"offsets": [
[
267,
305
]
],
"normalized": []
},
{
"id": "79999",
"type": "Outcome_Physical",
"text": [
"Apgar scores"
],
"offsets": [
[
380,
392
]
],
"normalized": []
},
{
"id": "80000",
"type": "Outcome_Other",
"text": [
"augmentations with oxytocic drugs ."
],
"offsets": [
[
519,
554
]
],
"normalized": []
},
{
"id": "80001",
"type": "Outcome_Other",
"text": [
"third stage loss"
],
"offsets": [
[
612,
628
]
],
"normalized": []
},
{
"id": "80002",
"type": "Participant_Condition",
"text": [
"68"
],
"offsets": [
[
60,
62
]
],
"normalized": []
},
{
"id": "80003",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
63,
68
]
],
"normalized": []
},
{
"id": "80004",
"type": "Participant_Condition",
"text": [
"in spontaneous labour"
],
"offsets": [
[
69,
90
]
],
"normalized": []
}
] | [] | [] | [] |
80005 | 6988462 | [
{
"id": "80006",
"type": "document",
"text": [
"A comparative trial of liver biopsy needles . A sheathed needle ( Tru-Cut ) was compared with a suction biopsy needle ( Menghini ) in a randomised prospective trial over 18 months to determine whether the former offered any special advantages in routine percutaneous liver biopsy . Seventy-seven consecutive biopsies were performed by a single operator . Although biopsy fragmentation was commoner with the suction needle , the length and volume of the largest core obtained was similar to results with the sheathed needle . Cytology provided useful additional information with the Menghini technique . The suction needle was repeatedly reusable and considerably cheaper than the sheathed needle , which may be used once only ."
],
"offsets": [
[
0,
727
]
]
}
] | [
{
"id": "80007",
"type": "Intervention_Physical",
"text": [
"sheathed needle"
],
"offsets": [
[
48,
63
]
],
"normalized": []
},
{
"id": "80008",
"type": "Intervention_Physical",
"text": [
"suction biopsy needle ( Menghini )"
],
"offsets": [
[
96,
130
]
],
"normalized": []
},
{
"id": "80009",
"type": "Intervention_Surgical",
"text": [
"routine percutaneous liver biopsy"
],
"offsets": [
[
246,
279
]
],
"normalized": []
},
{
"id": "80010",
"type": "Intervention_Physical",
"text": [
"suction needle"
],
"offsets": [
[
407,
421
]
],
"normalized": []
},
{
"id": "80011",
"type": "Intervention_Physical",
"text": [
"Menghini technique"
],
"offsets": [
[
582,
600
]
],
"normalized": []
},
{
"id": "80012",
"type": "Intervention_Other",
"text": [
"."
],
"offsets": [
[
44,
45
]
],
"normalized": []
},
{
"id": "80013",
"type": "Outcome_Other",
"text": [
"repeatedly reusable and considerably cheaper"
],
"offsets": [
[
626,
670
]
],
"normalized": []
},
{
"id": "80014",
"type": "Participant_Sample-size",
"text": [
"Seventy-seven"
],
"offsets": [
[
282,
295
]
],
"normalized": []
}
] | [] | [] | [] |
80015 | 6992570 | [
{
"id": "80016",
"type": "document",
"text": [
"Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients . A prospective , randomized , double-blind study . The results of therapy with carbenicillin plus trimethoprim-sulfamethoxazole ( C-T/S ) were compared to those obtained with carbenicillin plus gentamicin ( C-G ) in a prospective double-blind study of empiric antibiotic therapy in granulocytopenic patients . Patients were stratified into two groups : favorable-prognosis , group 1 ( carcinoma , lymphoma , multiple myeloma ) , or unfavorable-prognosis , group 2 ( acute leukemia , bone marrow transplantation ) , based on anticipated duration of granulocytopenia . Over-all , empiric antibiotic trials were more often successful ( P = 0.004 ) in group 1 ( 55 of 62 patients or 89 per cent ) than in group 2 ( 42 of 64 patients , 66 per cent ) mwithin group 1 , there was a favorable outcome in 30 of 32 ( 94 per cent ) C-T/S trials and in 25 of 30 ( 83 per cent ) C-G trials ( P = 0.25 ) ; within group 2 , there was a favorable outcome in 23 of 30 ( 77 per cent ) C-T/S trials and in 19 of 34 ( 56 per cent ) C-G trials ( P = 0.14 ) , Combined results in both groups indicated a higher proportion of favorable outcome in C-T/S trials ( 53 of 62 , 85 per cent ) than in C-G trials ( 44 of 64 , 69 per cent ) . Further analysis ( Manetl-Naenszel test ) showed the over-all difference in outcome to be significant ( P = 0.049 ) , but the general applicability of this result may be limited by the rather low incidence of gram-negative bacterial infections in this study . There was no difference between the treatment regimens in antibiotic toxicity , and serious superinfection occurred only in group 2 patients ( 21 per cent of trials ) , equally divided between treatment arms . Initial protocol dosing achieved target plasma levels of trimethoprim ( 3 to 8 micrograms/ml ) or gentamicin ( 4 to 10 micrograms/ml ) in 57 of 68 ( 84 per cent ) C-T/S trials compared to 21 of 60 ( 35 per cent ) C-G trials ."
],
"offsets": [
[
0,
2045
]
]
}
] | [
{
"id": "80017",
"type": "Intervention_Pharmacological",
"text": [
"Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin"
],
"offsets": [
[
0,
75
]
],
"normalized": []
},
{
"id": "80018",
"type": "Intervention_Pharmacological",
"text": [
"carbenicillin plus trimethoprim-sulfamethoxazole ( C-T/S ) were compared to those obtained with carbenicillin plus gentamicin ( C-G )"
],
"offsets": [
[
217,
350
]
],
"normalized": []
},
{
"id": "80019",
"type": "Outcome_Other",
"text": [
"successful"
],
"offsets": [
[
758,
768
]
],
"normalized": []
},
{
"id": "80020",
"type": "Outcome_Other",
"text": [
"favorable outcome"
],
"offsets": [
[
913,
930
]
],
"normalized": []
},
{
"id": "80021",
"type": "Outcome_Other",
"text": [
"favorable outcome"
],
"offsets": [
[
913,
930
]
],
"normalized": []
},
{
"id": "80022",
"type": "Outcome_Physical",
"text": [
"analysis ( Manetl-Naenszel test"
],
"offsets": [
[
1358,
1389
]
],
"normalized": []
},
{
"id": "80023",
"type": "Outcome_Other",
"text": [
"no difference"
],
"offsets": [
[
1620,
1633
]
],
"normalized": []
},
{
"id": "80024",
"type": "Outcome_Physical",
"text": [
"antibiotic toxicity"
],
"offsets": [
[
1668,
1687
]
],
"normalized": []
},
{
"id": "80025",
"type": "Outcome_Physical",
"text": [
"serious superinfection"
],
"offsets": [
[
1694,
1716
]
],
"normalized": []
},
{
"id": "80026",
"type": "Participant_Condition",
"text": [
"granulocytopenic"
],
"offsets": [
[
111,
127
]
],
"normalized": []
},
{
"id": "80027",
"type": "Participant_Condition",
"text": [
"granulocytopenic"
],
"offsets": [
[
111,
127
]
],
"normalized": []
},
{
"id": "80028",
"type": "Participant_Sample-size",
"text": [
"two"
],
"offsets": [
[
478,
481
]
],
"normalized": []
},
{
"id": "80029",
"type": "Participant_Sample-size",
"text": [
"group 1"
],
"offsets": [
[
513,
520
]
],
"normalized": []
},
{
"id": "80030",
"type": "Participant_Condition",
"text": [
"carcinoma"
],
"offsets": [
[
523,
532
]
],
"normalized": []
},
{
"id": "80031",
"type": "Participant_Condition",
"text": [
"lymphoma"
],
"offsets": [
[
535,
543
]
],
"normalized": []
},
{
"id": "80032",
"type": "Participant_Condition",
"text": [
"multiple myeloma"
],
"offsets": [
[
546,
562
]
],
"normalized": []
},
{
"id": "80033",
"type": "Participant_Sample-size",
"text": [
"group 2"
],
"offsets": [
[
594,
601
]
],
"normalized": []
},
{
"id": "80034",
"type": "Participant_Condition",
"text": [
"acute leukemia"
],
"offsets": [
[
604,
618
]
],
"normalized": []
},
{
"id": "80035",
"type": "Participant_Condition",
"text": [
"bone marrow transplantation"
],
"offsets": [
[
621,
648
]
],
"normalized": []
},
{
"id": "80036",
"type": "Participant_Condition",
"text": [
"granulocytopenia"
],
"offsets": [
[
686,
702
]
],
"normalized": []
}
] | [] | [] | [] |
80037 | 7003882 | [
{
"id": "80038",
"type": "document",
"text": [
"[ Median and mediolateral episiotomy ] ."
],
"offsets": [
[
0,
40
]
]
}
] | [
{
"id": "80039",
"type": "Intervention_Surgical",
"text": [
"Median and mediolateral episiotomy"
],
"offsets": [
[
2,
36
]
],
"normalized": []
},
{
"id": "80040",
"type": "Participant_Condition",
"text": [
"[ Median and mediolateral episiotomy ] ."
],
"offsets": [
[
0,
40
]
],
"normalized": []
}
] | [] | [] | [] |
80041 | 7005474 | [
{
"id": "80042",
"type": "document",
"text": [
"Comparison of antihypertensive effects of captopril and propranolol in essential hypertension . The antihypertensive effects of the oral converting enzyme inhibitor captopril and of propranolol were evaluated in a single-blind trial of 12 weeks in 19 ambulatory men with moderated essential hypertension ( supine diastolic blood pressure [ DPB ] , 100 to 120 mm Hg after receiving placebo for two weeks ) whose sodium intake was unrestricted . The captopril group included 12 patients and the propranolol group seven . After the initial dose-finding period of four weeks , supine DBP was significantly reduced in eight patients receiving captopril and in four of the patients receiving propranolol . In these patients DBP decreased throughout the following eight weeks . In the remaining patients from each group , DBP was not reduced by either drug given alone at maximum allowable dosages during dose-finding periods , nor by combined administration in following weeks . No adverse side effects attributable to captopril were noted , except in one patient in whom proteinuria developed after seven weeks . Captopril has potential value in the treatment of moderate essential hypertension ."
],
"offsets": [
[
0,
1191
]
]
}
] | [
{
"id": "80043",
"type": "Intervention_Pharmacological",
"text": [
"captopril"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "80044",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
56,
67
]
],
"normalized": []
},
{
"id": "80045",
"type": "Intervention_Pharmacological",
"text": [
"captopril"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "80046",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
56,
67
]
],
"normalized": []
},
{
"id": "80047",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
381,
388
]
],
"normalized": []
},
{
"id": "80048",
"type": "Intervention_Pharmacological",
"text": [
"captopril"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "80049",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
56,
67
]
],
"normalized": []
},
{
"id": "80050",
"type": "Intervention_Pharmacological",
"text": [
"captopril"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "80051",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
56,
67
]
],
"normalized": []
},
{
"id": "80052",
"type": "Intervention_Pharmacological",
"text": [
"captopril"
],
"offsets": [
[
42,
51
]
],
"normalized": []
},
{
"id": "80053",
"type": "Intervention_Pharmacological",
"text": [
"Captopril"
],
"offsets": [
[
1108,
1117
]
],
"normalized": []
},
{
"id": "80054",
"type": "Outcome_Physical",
"text": [
"antihypertensive effects"
],
"offsets": [
[
14,
38
]
],
"normalized": []
},
{
"id": "80055",
"type": "Outcome_Physical",
"text": [
"( supine diastolic blood pressure [ DPB ]"
],
"offsets": [
[
304,
345
]
],
"normalized": []
},
{
"id": "80056",
"type": "Outcome_Physical",
"text": [
"supine DBP"
],
"offsets": [
[
573,
583
]
],
"normalized": []
},
{
"id": "80057",
"type": "Outcome_Physical",
"text": [
"DBP"
],
"offsets": [
[
580,
583
]
],
"normalized": []
},
{
"id": "80058",
"type": "Outcome_Physical",
"text": [
"DBP"
],
"offsets": [
[
580,
583
]
],
"normalized": []
},
{
"id": "80059",
"type": "Outcome_Adverse-effects",
"text": [
"No adverse side effects"
],
"offsets": [
[
973,
996
]
],
"normalized": []
},
{
"id": "80060",
"type": "Outcome_Adverse-effects",
"text": [
"proteinuria"
],
"offsets": [
[
1066,
1077
]
],
"normalized": []
}
] | [] | [] | [] |
80061 | 7006663 | [
{
"id": "80062",
"type": "document",
"text": [
"Report on the second myelomatosis trial after five years of follow-up . Medical Research Council 's Working Party on Leukaemia in Adults . Three hundred and seventy-two patients were randomized between 3 regimens of chemotherapy : cyclophosphamide , intermittent melphalan , and melphalan with prednisone , and were followed up to death or for at least 5 years . There was no difference in survival between the treatments , either overall or in any subgroup of patients . Therefore , the choice among these 3 treatments should be guided by the patient 's comfort and convenience . The most important prognostic feature at presentation was the quality of renal function . It was possible to define good , intermediate and poor renal-function groups which were highly correlated with prognosis ( X2 for trend = 62.6 ) . The haemoglobin level at presentation was strongly correlated with prognosis among patients in the good renal-function group . Among 107 patients who presented with good renal function and with haemoglobin above 100 g/l , the 5-year survival was 43 % . Other prognostic features were much less important when account was taken of renal function and haemoglobin level ."
],
"offsets": [
[
0,
1186
]
]
}
] | [
{
"id": "80063",
"type": "Intervention_Pharmacological",
"text": [
"3 regimens of chemotherapy : cyclophosphamide , intermittent melphalan , and melphalan with prednisone , and were followed up to death or for at least 5 years"
],
"offsets": [
[
202,
360
]
],
"normalized": []
},
{
"id": "80064",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
390,
398
]
],
"normalized": []
},
{
"id": "80065",
"type": "Outcome_Physical",
"text": [
"renal function"
],
"offsets": [
[
654,
668
]
],
"normalized": []
},
{
"id": "80066",
"type": "Outcome_Physical",
"text": [
"haemoglobin level"
],
"offsets": [
[
822,
839
]
],
"normalized": []
},
{
"id": "80067",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
390,
398
]
],
"normalized": []
},
{
"id": "80068",
"type": "Participant_Condition",
"text": [
"Leukaemia"
],
"offsets": [
[
117,
126
]
],
"normalized": []
},
{
"id": "80069",
"type": "Participant_Age",
"text": [
"Adults"
],
"offsets": [
[
130,
136
]
],
"normalized": []
},
{
"id": "80070",
"type": "Participant_Sample-size",
"text": [
"Three hundred and seventy-two"
],
"offsets": [
[
139,
168
]
],
"normalized": []
},
{
"id": "80071",
"type": "Participant_Condition",
"text": [
"good"
],
"offsets": [
[
697,
701
]
],
"normalized": []
},
{
"id": "80072",
"type": "Participant_Condition",
"text": [
"intermediate"
],
"offsets": [
[
704,
716
]
],
"normalized": []
},
{
"id": "80073",
"type": "Participant_Condition",
"text": [
"poor"
],
"offsets": [
[
721,
725
]
],
"normalized": []
},
{
"id": "80074",
"type": "Participant_Condition",
"text": [
"good renal-function"
],
"offsets": [
[
917,
936
]
],
"normalized": []
},
{
"id": "80075",
"type": "Participant_Sample-size",
"text": [
"107"
],
"offsets": [
[
951,
954
]
],
"normalized": []
},
{
"id": "80076",
"type": "Participant_Condition",
"text": [
"good renal function"
],
"offsets": [
[
983,
1002
]
],
"normalized": []
}
] | [] | [] | [] |
80077 | 7007454 | [
{
"id": "80078",
"type": "document",
"text": [
"Effects of topical and systemic folic acid supplementation on gingivitis in pregnancy . A double-blind study evaluated the effects of systemic and topical folate on gingival inflammation during the fourth and eighth months of pregnancy . Thirty women were randomly divided into three groups . Group A received placebo mouthwash and tablets ; Group B ; placebo mouthwash and 5 mg folate tablets ; Group C : folate mouthwash and placebo tablets . Supplementation lasted for 14 days during months 4 and 8 . Subjects took one tablet daily and rinsed twice daily for 1 min with the mouthwash . At the start and finish of each 14-day period , fasting serum and red cell folate levels were estimated and oral status assessed by a plaque index ( P1I ) , a gingival index ( GI ) , and gingival exudate flow meter ( GEF ) . Subjects completed 1-week diet sheets which were analysed for dietary folate . All groups were similar in each parameter at the start . Correlation was demonstrated between GI and P1I , and between GI and GEF . GI tended to increase throughout pregnancy in all groups except Group C , when in the eighth month there was a highly significant improvement ( 0.001 less than P 0.01 ) despite no significant change in P1I . Although dietary intake of folate was significantly higher during the eighth month in Group C as compared with Groups A and B , ( 0.001 less than P less than 0.01 ) , the folate mouthwash produced highly significantly improvement in gingival health in pregnancy ."
],
"offsets": [
[
0,
1496
]
]
}
] | [
{
"id": "80079",
"type": "Intervention_Pharmacological",
"text": [
"topical and systemic folic acid"
],
"offsets": [
[
11,
42
]
],
"normalized": []
},
{
"id": "80080",
"type": "Intervention_Educational",
"text": [
"systemic and topical folate"
],
"offsets": [
[
134,
161
]
],
"normalized": []
},
{
"id": "80081",
"type": "Intervention_Control",
"text": [
"placebo mouthwash and tablets"
],
"offsets": [
[
310,
339
]
],
"normalized": []
},
{
"id": "80082",
"type": "Intervention_Pharmacological",
"text": [
";"
],
"offsets": [
[
340,
341
]
],
"normalized": []
},
{
"id": "80083",
"type": "Intervention_Pharmacological",
"text": [
"placebo mouthwash and 5 mg folate tablets ;"
],
"offsets": [
[
352,
395
]
],
"normalized": []
},
{
"id": "80084",
"type": "Intervention_Pharmacological",
"text": [
"folate mouthwash and placebo tablets ."
],
"offsets": [
[
406,
444
]
],
"normalized": []
},
{
"id": "80085",
"type": "Outcome_Physical",
"text": [
"gingivitis in pregnancy ."
],
"offsets": [
[
62,
87
]
],
"normalized": []
},
{
"id": "80086",
"type": "Outcome_Physical",
"text": [
"gingival inflammation during the fourth and eighth months of pregnancy ."
],
"offsets": [
[
165,
237
]
],
"normalized": []
},
{
"id": "80087",
"type": "Outcome_Physical",
"text": [
"fasting serum and red cell folate levels"
],
"offsets": [
[
637,
677
]
],
"normalized": []
},
{
"id": "80088",
"type": "Outcome_Physical",
"text": [
"plaque index ( P1I ) , a gingival index ( GI ) , and gingival exudate flow meter ( GEF )"
],
"offsets": [
[
723,
811
]
],
"normalized": []
},
{
"id": "80089",
"type": "Outcome_Physical",
"text": [
"dietary folate"
],
"offsets": [
[
876,
890
]
],
"normalized": []
},
{
"id": "80090",
"type": "Outcome_Physical",
"text": [
"GI and P1I"
],
"offsets": [
[
987,
997
]
],
"normalized": []
},
{
"id": "80091",
"type": "Outcome_Physical",
"text": [
"GI and GEF"
],
"offsets": [
[
1012,
1022
]
],
"normalized": []
},
{
"id": "80092",
"type": "Outcome_Physical",
"text": [
"GI"
],
"offsets": [
[
765,
767
]
],
"normalized": []
},
{
"id": "80093",
"type": "Outcome_Physical",
"text": [
"gingival health"
],
"offsets": [
[
1466,
1481
]
],
"normalized": []
},
{
"id": "80094",
"type": "Participant_Condition",
"text": [
"gingival inflammation during the fourth and eighth months of pregnancy ."
],
"offsets": [
[
165,
237
]
],
"normalized": []
}
] | [] | [] | [] |
80095 | 7010528 | [
{
"id": "80096",
"type": "document",
"text": [
"The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer . A double-blind controlled trial . Patients with benign gastric ulcer were treated for four weeks with carbenoxolone sodium as Biogastrone tablets 100 mg three times a day , and if the ulcers were not healed at 4 weeks treatment was continued for a further 4 weeks . Fifty two patients entered the trial , and 12 were withdrawn . In 17 patients who were randomly allotted double-blind additional dummy tablets 16 of their ulcer healed completely endoscopically , whereas of the 23 patients given additional amiloride 5 mg three times a day only 14 ulcers healed , a significant reduction in ulcer healing . The clinical ( weight gain and oedema ) and metabolic ( hypertension , hypokalaemia and hypernatraemia ) side-effects were reduced by the active amiloride therapy , but serum carbenoxolone levels were not affected . Thus the potassium-retaining diuretic amiloride , like the aldosterone antagonist spironolactone , markedly reduces both the ulcer-healing and the metabolic side-effects of carbenoxolone sodium , and should not be used together with it in the treatment of peptic ulcer ."
],
"offsets": [
[
0,
1210
]
]
}
] | [
{
"id": "80097",
"type": "Intervention_Pharmacological",
"text": [
"amiloride"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "80098",
"type": "Intervention_Pharmacological",
"text": [
"carbenoxolone"
],
"offsets": [
[
71,
84
]
],
"normalized": []
},
{
"id": "80099",
"type": "Intervention_Pharmacological",
"text": [
"carbenoxolone sodium as Biogastrone tablets 100 mg three times a day"
],
"offsets": [
[
220,
288
]
],
"normalized": []
},
{
"id": "80100",
"type": "Intervention_Control",
"text": [
"dummy tablets"
],
"offsets": [
[
513,
526
]
],
"normalized": []
},
{
"id": "80101",
"type": "Intervention_Pharmacological",
"text": [
"amiloride"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "80102",
"type": "Intervention_Pharmacological",
"text": [
"amiloride"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "80103",
"type": "Intervention_Pharmacological",
"text": [
"carbenoxolone"
],
"offsets": [
[
71,
84
]
],
"normalized": []
},
{
"id": "80104",
"type": "Intervention_Pharmacological",
"text": [
"amiloride"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "80105",
"type": "Intervention_Pharmacological",
"text": [
"spironolactone"
],
"offsets": [
[
1022,
1036
]
],
"normalized": []
},
{
"id": "80106",
"type": "Outcome_Physical",
"text": [
"weight gain"
],
"offsets": [
[
739,
750
]
],
"normalized": []
},
{
"id": "80107",
"type": "Outcome_Physical",
"text": [
"oedema"
],
"offsets": [
[
755,
761
]
],
"normalized": []
},
{
"id": "80108",
"type": "Outcome_Physical",
"text": [
"hypertension , hypokalaemia and hypernatraemia"
],
"offsets": [
[
780,
826
]
],
"normalized": []
},
{
"id": "80109",
"type": "Outcome_Physical",
"text": [
"serum carbenoxolone levels"
],
"offsets": [
[
893,
919
]
],
"normalized": []
},
{
"id": "80110",
"type": "Outcome_Physical",
"text": [
"ulcer-healing"
],
"offsets": [
[
1065,
1078
]
],
"normalized": []
},
{
"id": "80111",
"type": "Outcome_Adverse-effects",
"text": [
"metabolic side-effects"
],
"offsets": [
[
1087,
1109
]
],
"normalized": []
},
{
"id": "80112",
"type": "Participant_Condition",
"text": [
"patients with gastric ulcer ."
],
"offsets": [
[
88,
117
]
],
"normalized": []
},
{
"id": "80113",
"type": "Participant_Condition",
"text": [
"Patients with benign gastric ulcer"
],
"offsets": [
[
152,
186
]
],
"normalized": []
},
{
"id": "80114",
"type": "Participant_Condition",
"text": [
"Fifty two patients entered the trial , and 12 were withdrawn ."
],
"offsets": [
[
384,
446
]
],
"normalized": []
},
{
"id": "80115",
"type": "Participant_Condition",
"text": [
"peptic ulcer ."
],
"offsets": [
[
1196,
1210
]
],
"normalized": []
}
] | [] | [] | [] |
80116 | 7010662 | [
{
"id": "80117",
"type": "document",
"text": [
"[ Biological and clinical effects of oral magnesium and associated magnesium-vitamin B6 administration on certain disorders observed in infantile autism ( author 's transl ) ] ."
],
"offsets": [
[
0,
177
]
]
}
] | [
{
"id": "80118",
"type": "Intervention_Pharmacological",
"text": [
"oral magnesium"
],
"offsets": [
[
37,
51
]
],
"normalized": []
},
{
"id": "80119",
"type": "Intervention_Pharmacological",
"text": [
"associated magnesium-vitamin B6 administration"
],
"offsets": [
[
56,
102
]
],
"normalized": []
},
{
"id": "80120",
"type": "Participant_Condition",
"text": [
"certain disorders observed in infantile autism"
],
"offsets": [
[
106,
152
]
],
"normalized": []
}
] | [] | [] | [] |
80121 | 7010854 | [
{
"id": "80122",
"type": "document",
"text": [
"Clinical evaluation of the antihypertensive effect of metoprolol in combination with hydrochlorothiazide and hydralazine in an unselected hypertensive population . One hundred nineteen patients with essential hypertension ( 96 completing six months and 92 a one year study period ) were randomized into four parallel groups and treated with one of four programs : 200 mg of metoprolol plus placebo ; 200 mg of metoprolol plus 25 mg of hydrochlorothiazide ; 200 mg of metoprolol plus 50 mg hydrochlorothiazide , or ; 200 mg metoprolol plus 50 mg of hydralazine . Blood pressure reduction was significant in these all groups and no differences were observed in blood pressure reduction among the groups . During the one year therapy the levels of serum bilirubin , uric acid and triglycerides were significantly increased in all groups but the group treated with metoprolol and hydralazine . Serum cholesterol level did not increase in any group during the one year therapy . The results indicate that the combination therapy in mild to moderate hypertension should not be initiated before individual response to single drug therapy is evaluated . Antihypertensive drug treatment may cause some biochemical changes and those changes seem to be smallest patients treated with combination of beta-blocker and hydralazine ."
],
"offsets": [
[
0,
1318
]
]
}
] | [
{
"id": "80123",
"type": "Intervention_Pharmacological",
"text": [
"metoprolol"
],
"offsets": [
[
54,
64
]
],
"normalized": []
},
{
"id": "80124",
"type": "Intervention_Pharmacological",
"text": [
"hydrochlorothiazide"
],
"offsets": [
[
85,
104
]
],
"normalized": []
},
{
"id": "80125",
"type": "Intervention_Pharmacological",
"text": [
"hydralazine"
],
"offsets": [
[
109,
120
]
],
"normalized": []
},
{
"id": "80126",
"type": "Intervention_Pharmacological",
"text": [
"200 mg of metoprolol plus placebo"
],
"offsets": [
[
364,
397
]
],
"normalized": []
},
{
"id": "80127",
"type": "Intervention_Pharmacological",
"text": [
"200 mg of metoprolol"
],
"offsets": [
[
364,
384
]
],
"normalized": []
},
{
"id": "80128",
"type": "Intervention_Pharmacological",
"text": [
"25 mg of hydrochlorothiazide"
],
"offsets": [
[
426,
454
]
],
"normalized": []
},
{
"id": "80129",
"type": "Intervention_Pharmacological",
"text": [
"200 mg of metoprolol"
],
"offsets": [
[
364,
384
]
],
"normalized": []
},
{
"id": "80130",
"type": "Intervention_Pharmacological",
"text": [
"50 mg hydrochlorothiazide"
],
"offsets": [
[
483,
508
]
],
"normalized": []
},
{
"id": "80131",
"type": "Intervention_Pharmacological",
"text": [
"200 mg metoprolol"
],
"offsets": [
[
516,
533
]
],
"normalized": []
},
{
"id": "80132",
"type": "Intervention_Pharmacological",
"text": [
"50 mg of hydralazine"
],
"offsets": [
[
539,
559
]
],
"normalized": []
},
{
"id": "80133",
"type": "Intervention_Pharmacological",
"text": [
"metoprolol"
],
"offsets": [
[
54,
64
]
],
"normalized": []
},
{
"id": "80134",
"type": "Intervention_Pharmacological",
"text": [
"hydralazine"
],
"offsets": [
[
109,
120
]
],
"normalized": []
},
{
"id": "80135",
"type": "Intervention_Physical",
"text": [
"beta-blocker"
],
"offsets": [
[
1288,
1300
]
],
"normalized": []
},
{
"id": "80136",
"type": "Intervention_Pharmacological",
"text": [
"hydralazine"
],
"offsets": [
[
109,
120
]
],
"normalized": []
},
{
"id": "80137",
"type": "Outcome_Physical",
"text": [
"Blood pressure reduction"
],
"offsets": [
[
562,
586
]
],
"normalized": []
},
{
"id": "80138",
"type": "Outcome_Physical",
"text": [
"levels of serum bilirubin"
],
"offsets": [
[
735,
760
]
],
"normalized": []
},
{
"id": "80139",
"type": "Outcome_Physical",
"text": [
"uric acid"
],
"offsets": [
[
763,
772
]
],
"normalized": []
},
{
"id": "80140",
"type": "Outcome_Physical",
"text": [
"triglycerides"
],
"offsets": [
[
777,
790
]
],
"normalized": []
},
{
"id": "80141",
"type": "Outcome_Physical",
"text": [
"Serum cholesterol level"
],
"offsets": [
[
890,
913
]
],
"normalized": []
},
{
"id": "80142",
"type": "Outcome_Physical",
"text": [
"mild to moderate hypertension"
],
"offsets": [
[
1027,
1056
]
],
"normalized": []
},
{
"id": "80143",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
31,
43
]
],
"normalized": []
},
{
"id": "80144",
"type": "Participant_Sample-size",
"text": [
"One hundred nineteen"
],
"offsets": [
[
164,
184
]
],
"normalized": []
},
{
"id": "80145",
"type": "Participant_Condition",
"text": [
"essential hypertension"
],
"offsets": [
[
199,
221
]
],
"normalized": []
},
{
"id": "80146",
"type": "Participant_Sample-size",
"text": [
"96"
],
"offsets": [
[
224,
226
]
],
"normalized": []
},
{
"id": "80147",
"type": "Participant_Sample-size",
"text": [
"92"
],
"offsets": [
[
253,
255
]
],
"normalized": []
}
] | [] | [] | [] |
80148 | 7011331 | [
{
"id": "80149",
"type": "document",
"text": [
"Preventive treatment of serotonin-migraine with 1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo ( b , f ) pyrazino- ( 1,2 -- d ) - ( 1,4 ) -oxazepine hydrogen maleate ( Org GC 94 ) . A double-blind study . 1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo ( b , f ) pyrazino- ( 1,2-d ) - ( 1,4 ) -oxazepine hydrogen maleate ( Org GC 94 ) is an oral \" antamine \" preparation with anti-serotoninergic and anti-histaminic effects . Its lack of unpleasant side-effects permits protracted use for the preventive treatment of serotonin-migraine . Its chemical structure -- tetracyclic ring , C-beta , C-alpha , amine in a secondary position -- allows block of the receptors for serotonin and histamine . Preventive treatment with 3 x 5 mg/day of Org GC 94 for a period of 3 months can almost completely eliminate migraine attacks . 21 out of 30 patients ( 70 % ) profited from such a treatment , showing a drop from 5 -- 30 attacks to 0 -- 1 attack per month and normalization of high urinary serotonin , 5-HIAA or histamine levels . However , 30 patients receiving 3 x 0.5 mg or placebo daily reacted only rarely . The typical side-effects of anti-serotonin drugs , especially sedation or dizziness and hyperorexia were hardly observed . Randomization of the serotonin-migraine cases and double-blind methodology were applied throughout the trial ."
],
"offsets": [
[
0,
1335
]
]
}
] | [
{
"id": "80150",
"type": "Intervention_Pharmacological",
"text": [
"1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo ( b , f ) pyrazino- ( 1,2 -- d ) - ( 1,4 ) -oxazepine hydrogen maleate ( Org GC 94 ) ."
],
"offsets": [
[
48,
179
]
],
"normalized": []
},
{
"id": "80151",
"type": "Intervention_Pharmacological",
"text": [
"1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo ( b , f ) pyrazino- ( 1,2-d ) - ( 1,4 ) -oxazepine hydrogen maleate ( Org GC 94 )"
],
"offsets": [
[
203,
329
]
],
"normalized": []
},
{
"id": "80152",
"type": "Intervention_Pharmacological",
"text": [
"Org GC 94"
],
"offsets": [
[
166,
175
]
],
"normalized": []
},
{
"id": "80153",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
1066,
1073
]
],
"normalized": []
},
{
"id": "80154",
"type": "Outcome_Physical",
"text": [
"migraine"
],
"offsets": [
[
34,
42
]
],
"normalized": []
},
{
"id": "80155",
"type": "Outcome_Other",
"text": [
"attack per month"
],
"offsets": [
[
928,
944
]
],
"normalized": []
},
{
"id": "80156",
"type": "Outcome_Physical",
"text": [
"and normalization of high urinary serotonin"
],
"offsets": [
[
945,
988
]
],
"normalized": []
},
{
"id": "80157",
"type": "Outcome_Physical",
"text": [
"5-HIAA or histamine levels"
],
"offsets": [
[
991,
1017
]
],
"normalized": []
},
{
"id": "80158",
"type": "Outcome_Adverse-effects",
"text": [
"sedation"
],
"offsets": [
[
1164,
1172
]
],
"normalized": []
},
{
"id": "80159",
"type": "Outcome_Adverse-effects",
"text": [
"dizziness"
],
"offsets": [
[
1176,
1185
]
],
"normalized": []
},
{
"id": "80160",
"type": "Outcome_Adverse-effects",
"text": [
"hyperorexia"
],
"offsets": [
[
1190,
1201
]
],
"normalized": []
},
{
"id": "80161",
"type": "Participant_Condition",
"text": [
"serotonin-migraine"
],
"offsets": [
[
24,
42
]
],
"normalized": []
},
{
"id": "80162",
"type": "Participant_Sample-size",
"text": [
"30"
],
"offsets": [
[
828,
830
]
],
"normalized": []
},
{
"id": "80163",
"type": "Participant_Sample-size",
"text": [
"30 patients"
],
"offsets": [
[
828,
839
]
],
"normalized": []
}
] | [] | [] | [] |
80164 | 7015093 | [
{
"id": "80165",
"type": "document",
"text": [
"[ Prevention of stress ulcers with synthetic depot secretin ] . The pathogenesis of stress ulcers is still far from being understood . It is reported about a synthetic secretin ( Hoe 069 + depot component ) given prophylactically to 100 patients postoperatively . It eliminated or ameliorated stress ulcers . The result , confirmed by gastroscopy , demonstrates the treatment with secretin plus depot component as a highly recommendable prophylaxis in the postsurgical intensive care treatment ."
],
"offsets": [
[
0,
495
]
]
}
] | [
{
"id": "80166",
"type": "Intervention_Pharmacological",
"text": [
"synthetic depot secretin ]"
],
"offsets": [
[
35,
61
]
],
"normalized": []
},
{
"id": "80167",
"type": "Intervention_Pharmacological",
"text": [
"synthetic secretin ( Hoe 069 + depot component )"
],
"offsets": [
[
158,
206
]
],
"normalized": []
},
{
"id": "80168",
"type": "Intervention_Pharmacological",
"text": [
"treatment with secretin plus depot component"
],
"offsets": [
[
366,
410
]
],
"normalized": []
},
{
"id": "80169",
"type": "Outcome_Physical",
"text": [
"eliminated or ameliorated stress ulcers"
],
"offsets": [
[
267,
306
]
],
"normalized": []
},
{
"id": "80170",
"type": "Participant_Condition",
"text": [
"stress ulcers"
],
"offsets": [
[
16,
29
]
],
"normalized": []
},
{
"id": "80171",
"type": "Participant_Condition",
"text": [
"stress ulcers"
],
"offsets": [
[
16,
29
]
],
"normalized": []
}
] | [] | [] | [] |
80172 | 701664 | [
{
"id": "80173",
"type": "document",
"text": [
"Poylmerized whole ragweed : an improved method of immunotherapy . A single-blind study compared the effectiveness of glutaraldehyde-treated polymerized ragweed with nonpolymerized monomeric ragweed . These studies are an extension of those previously reported for polymerized AgE using a readily available ragweed preparation containing all ragweed antigens . Nineteen ragweed-sensitive patients were randomized into 2 groups ; 10 received the polymerized form and 9 received the monomeric form . Four parameters were followed : serum-specific IgE against antigen E , total blocking antibody against antigen E , local and systemic reactions to injection therapy , and symptom score indices . Pretreatment levels of antigen E -- specific IgE and blocking antibody activity were similar in both groups . After a total of 15,000 protein nitrogen units ( PNU ) had been given , blocking antibody activity in the monomer group rose from a mean of 170 ng AgE bound per ml to a mean of 2,813 . The rise in blocking antibody activity in the polymer group was from a mean of 181 ng AgE bound per ml to 1,574 . At 15,000 PNU , blocking antibody activity levels were not statistically different in the 2 groups . After 1 year of treatment , no consistent decrease in postseasonal specific IgE rise could be shown in either group . Forty times less erythema and 15 times less induration were found with polymerized ragweed . There were 7 systemic reactions with the monomer and none with the polymer . Both groups experienced symptomatic improvement with treatment ."
],
"offsets": [
[
0,
1554
]
]
}
] | [
{
"id": "80174",
"type": "Intervention_Pharmacological",
"text": [
"Poylmerized whole ragweed"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "80175",
"type": "Intervention_Pharmacological",
"text": [
"glutaraldehyde-treated polymerized ragweed"
],
"offsets": [
[
117,
159
]
],
"normalized": []
},
{
"id": "80176",
"type": "Intervention_Pharmacological",
"text": [
"nonpolymerized monomeric ragweed ."
],
"offsets": [
[
165,
199
]
],
"normalized": []
},
{
"id": "80177",
"type": "Intervention_Pharmacological",
"text": [
"ragweed"
],
"offsets": [
[
18,
25
]
],
"normalized": []
},
{
"id": "80178",
"type": "Intervention_Pharmacological",
"text": [
"polymerized form"
],
"offsets": [
[
444,
460
]
],
"normalized": []
},
{
"id": "80179",
"type": "Intervention_Pharmacological",
"text": [
"monomeric form"
],
"offsets": [
[
480,
494
]
],
"normalized": []
},
{
"id": "80180",
"type": "Intervention_Pharmacological",
"text": [
"polymerized ragweed"
],
"offsets": [
[
140,
159
]
],
"normalized": []
},
{
"id": "80181",
"type": "Outcome_Physical",
"text": [
"blocking antibody activity"
],
"offsets": [
[
745,
771
]
],
"normalized": []
},
{
"id": "80182",
"type": "Outcome_Physical",
"text": [
"rise in blocking antibody activity"
],
"offsets": [
[
991,
1025
]
],
"normalized": []
},
{
"id": "80183",
"type": "Outcome_Physical",
"text": [
"blocking antibody activity levels"
],
"offsets": [
[
1117,
1150
]
],
"normalized": []
},
{
"id": "80184",
"type": "Outcome_Physical",
"text": [
"postseasonal specific IgE rise"
],
"offsets": [
[
1256,
1286
]
],
"normalized": []
},
{
"id": "80185",
"type": "Outcome_Physical",
"text": [
"erythema"
],
"offsets": [
[
1337,
1345
]
],
"normalized": []
},
{
"id": "80186",
"type": "Outcome_Physical",
"text": [
"induration"
],
"offsets": [
[
1364,
1374
]
],
"normalized": []
},
{
"id": "80187",
"type": "Outcome_Adverse-effects",
"text": [
"systemic reactions"
],
"offsets": [
[
622,
640
]
],
"normalized": []
},
{
"id": "80188",
"type": "Outcome_Other",
"text": [
"symptomatic improvement"
],
"offsets": [
[
1514,
1537
]
],
"normalized": []
},
{
"id": "80189",
"type": "Participant_Sample-size",
"text": [
"Nineteen"
],
"offsets": [
[
360,
368
]
],
"normalized": []
},
{
"id": "80190",
"type": "Participant_Condition",
"text": [
"ragweed-sensitive"
],
"offsets": [
[
369,
386
]
],
"normalized": []
},
{
"id": "80191",
"type": "Participant_Condition",
"text": [
"were randomized into 2 groups ;"
],
"offsets": [
[
396,
427
]
],
"normalized": []
},
{
"id": "80192",
"type": "Participant_Sample-size",
"text": [
"10"
],
"offsets": [
[
428,
430
]
],
"normalized": []
},
{
"id": "80193",
"type": "Participant_Condition",
"text": [
"and"
],
"offsets": [
[
402,
405
]
],
"normalized": []
},
{
"id": "80194",
"type": "Participant_Sample-size",
"text": [
"9"
],
"offsets": [
[
465,
466
]
],
"normalized": []
},
{
"id": "80195",
"type": "Participant_Condition",
"text": [
"."
],
"offsets": [
[
64,
65
]
],
"normalized": []
}
] | [] | [] | [] |
80196 | 7017139 | [
{
"id": "80197",
"type": "document",
"text": [
"Value of an anal dilator after anal stretch for haemorrhoids . A prospective randomized trial compared anal stretch with or without continued dilatation for three months in 89 consecutive patients with haemorrhoids . Complications of therapy occurred in only 4 patients , 3 of whom had transient incontinence of flatus . When patients were reviewed four months after treatment , only 4 of 44 patients ( 9 % ) who used a dilator had not been improved and required additional therapy , compared with 15 of 42 patients ( 36 % ) who had anal stretch alone ( P less than 0.02 ) . It is concluded that the use of an anal dilator improves the results of anal stretch ."
],
"offsets": [
[
0,
661
]
]
}
] | [
{
"id": "80198",
"type": "Intervention_Physical",
"text": [
"anal dilator"
],
"offsets": [
[
12,
24
]
],
"normalized": []
},
{
"id": "80199",
"type": "Intervention_Control",
"text": [
"anal stretch"
],
"offsets": [
[
31,
43
]
],
"normalized": []
},
{
"id": "80200",
"type": "Intervention_Physical",
"text": [
"continued dilatation"
],
"offsets": [
[
132,
152
]
],
"normalized": []
},
{
"id": "80201",
"type": "Intervention_Control",
"text": [
"anal stretch"
],
"offsets": [
[
31,
43
]
],
"normalized": []
},
{
"id": "80202",
"type": "Intervention_Control",
"text": [
"anal stretch"
],
"offsets": [
[
31,
43
]
],
"normalized": []
},
{
"id": "80203",
"type": "Outcome_Physical",
"text": [
"haemorrhoids ."
],
"offsets": [
[
48,
62
]
],
"normalized": []
},
{
"id": "80204",
"type": "Outcome_Adverse-effects",
"text": [
"Complications of therapy"
],
"offsets": [
[
217,
241
]
],
"normalized": []
},
{
"id": "80205",
"type": "Outcome_Physical",
"text": [
"incontinence"
],
"offsets": [
[
296,
308
]
],
"normalized": []
},
{
"id": "80206",
"type": "Outcome_Physical",
"text": [
"anal stretch ."
],
"offsets": [
[
647,
661
]
],
"normalized": []
},
{
"id": "80207",
"type": "Participant_Condition",
"text": [
"haemorrhoids"
],
"offsets": [
[
48,
60
]
],
"normalized": []
},
{
"id": "80208",
"type": "Participant_Sample-size",
"text": [
"89"
],
"offsets": [
[
173,
175
]
],
"normalized": []
},
{
"id": "80209",
"type": "Participant_Condition",
"text": [
"haemorrhoids"
],
"offsets": [
[
48,
60
]
],
"normalized": []
}
] | [] | [] | [] |
80210 | 7028532 | [
{
"id": "80211",
"type": "document",
"text": [
"A controlled trial with diclofensine , a new psychoactive drug , in the treatment of depression . Diclofensine inhibits the uptake of serotonin , noradrenaline and dopamine . In a controlled study , out-patients suffering from moderate to severe depression were treated with the objective of assessing the new drug 's therapeutically effective dose range . Maprotiline was used as a reference drug : fourteen patients were assigned to receive diclofensine and thirteen to receive maprotiline in a double-blind design . Depending on tolerance and efficacy , they were treated for periods ranging from 5 to 150 days . Doses were titrated to the optimum . Findings suggest that a 50 mg daily dose of diclofensine would be sufficient for the majority of the patients . The dosage can be safely increased up to 150 mg daily but this offers few therapeutic advantages . While the efficacy index of the two drugs was similar ( approximately 60 % ) , they differed greatly in their profile of side-effects . No signs of abrupt dissipation of the achieved clinical effects were observed during continued treatment , and no withdrawal reactions were observed when the treatment was stopped . The new drug may be more effective in treating patients in whom a psycho-energizing and mood alleviating effect is desired ."
],
"offsets": [
[
0,
1306
]
]
}
] | [
{
"id": "80212",
"type": "Intervention_Pharmacological",
"text": [
"diclofensine"
],
"offsets": [
[
24,
36
]
],
"normalized": []
},
{
"id": "80213",
"type": "Intervention_Pharmacological",
"text": [
"Diclofensine"
],
"offsets": [
[
98,
110
]
],
"normalized": []
},
{
"id": "80214",
"type": "Intervention_Pharmacological",
"text": [
"Maprotiline"
],
"offsets": [
[
357,
368
]
],
"normalized": []
},
{
"id": "80215",
"type": "Intervention_Pharmacological",
"text": [
"diclofensine"
],
"offsets": [
[
24,
36
]
],
"normalized": []
},
{
"id": "80216",
"type": "Intervention_Pharmacological",
"text": [
"maprotiline"
],
"offsets": [
[
480,
491
]
],
"normalized": []
},
{
"id": "80217",
"type": "Intervention_Pharmacological",
"text": [
"diclofensine"
],
"offsets": [
[
24,
36
]
],
"normalized": []
},
{
"id": "80218",
"type": "Outcome_Physical",
"text": [
"efficacy index"
],
"offsets": [
[
874,
888
]
],
"normalized": []
},
{
"id": "80219",
"type": "Outcome_Adverse-effects",
"text": [
"profile of side-effects"
],
"offsets": [
[
974,
997
]
],
"normalized": []
},
{
"id": "80220",
"type": "Outcome_Other",
"text": [
"No signs of abrupt dissipation of the achieved clinical effects"
],
"offsets": [
[
1000,
1063
]
],
"normalized": []
},
{
"id": "80221",
"type": "Outcome_Physical",
"text": [
"no withdrawal reactions"
],
"offsets": [
[
1111,
1134
]
],
"normalized": []
},
{
"id": "80222",
"type": "Outcome_Adverse-effects",
"text": [
"effective"
],
"offsets": [
[
334,
343
]
],
"normalized": []
},
{
"id": "80223",
"type": "Participant_Condition",
"text": [
"out-patients suffering from moderate to severe depression"
],
"offsets": [
[
199,
256
]
],
"normalized": []
},
{
"id": "80224",
"type": "Participant_Sample-size",
"text": [
"fourteen"
],
"offsets": [
[
400,
408
]
],
"normalized": []
},
{
"id": "80225",
"type": "Participant_Sample-size",
"text": [
"thirteen"
],
"offsets": [
[
460,
468
]
],
"normalized": []
}
] | [] | [] | [] |
80226 | 7029293 | [
{
"id": "80227",
"type": "document",
"text": [
"Multimodal therapy for the management of primary , nonmetastatic Ewing 's sarcoma of bone : an Intergroup Study . A randomized study of 264 children and adults with previously untreated localized Ewing 's sarcoma of bone was undertaken between 1973 and 1978 by 83 institutions of three national study groups : Children 's Cancer Study Group , Southwest Oncology Group , and Cancer and Leukemia Group B . The Intergroup Study was designed to determine if the addition of adriamycin ( ADR ) or bilateral pulmonary radiotherapy ( RT ) to vincristine , dactinomycin , and cyclophosphamide ( VAC therapy ) would improve survival and reduce local recurrences and metastases . All patients received RT to the primary lesion , and the survival rate after 3 years was 65 % . The most effective treatment regimen was VAC plus ADR ; 74 % of the patients were free of disease at 2 years . The lengths of disease-free status and survival of patients treated with VAC plus ADR or VAC plus RT did not differ . However , both regimens were significantly superior to treatment with VAC alone . The addition of ADR or bilateral pulmonary RT to VAC was highly advantageous to patients with nonpelvic primaries . Bone and lung were the major sites of distant relapse , but the addition of bilateral pulmonary RT showed no advantage over that of ADR in reducing the occurrence of lung metastases . These recent results should eliminate some of the pessimism that has accompanied a diagnosis of Ewing 's sarcoma , although distant metastases continued to be a major reason for failure in the control of this tumor . Survival of these patients can be improved through well-controlled clinical trials designed to determine optimal adjuvant chemotherapy and treatment of the primary lesion ."
],
"offsets": [
[
0,
1766
]
]
}
] | [
{
"id": "80228",
"type": "Intervention_Pharmacological",
"text": [
"addition of adriamycin ( ADR )"
],
"offsets": [
[
458,
488
]
],
"normalized": []
},
{
"id": "80229",
"type": "Intervention_Control",
"text": [
"or"
],
"offsets": [
[
20,
22
]
],
"normalized": []
},
{
"id": "80230",
"type": "Intervention_Physical",
"text": [
"bilateral pulmonary radiotherapy ( RT )"
],
"offsets": [
[
492,
531
]
],
"normalized": []
},
{
"id": "80231",
"type": "Intervention_Control",
"text": [
"to"
],
"offsets": [
[
438,
440
]
],
"normalized": []
},
{
"id": "80232",
"type": "Intervention_Pharmacological",
"text": [
"vincristine , dactinomycin , and cyclophosphamide ( VAC therapy )"
],
"offsets": [
[
535,
600
]
],
"normalized": []
},
{
"id": "80233",
"type": "Outcome_Mortality",
"text": [
"improve survival"
],
"offsets": [
[
607,
623
]
],
"normalized": []
},
{
"id": "80234",
"type": "Outcome_Physical",
"text": [
"and reduce local recurrences and metastases"
],
"offsets": [
[
624,
667
]
],
"normalized": []
},
{
"id": "80235",
"type": "Outcome_Mortality",
"text": [
"survival rate"
],
"offsets": [
[
727,
740
]
],
"normalized": []
},
{
"id": "80236",
"type": "Outcome_Physical",
"text": [
"lengths of disease-free status and survival of patients"
],
"offsets": [
[
881,
936
]
],
"normalized": []
},
{
"id": "80237",
"type": "Outcome_Other",
"text": [
"highly advantageous"
],
"offsets": [
[
1134,
1153
]
],
"normalized": []
},
{
"id": "80238",
"type": "Outcome_Other",
"text": [
"no advantage"
],
"offsets": [
[
1299,
1311
]
],
"normalized": []
},
{
"id": "80239",
"type": "Outcome_Physical",
"text": [
"occurrence of lung metastases ."
],
"offsets": [
[
1345,
1376
]
],
"normalized": []
}
] | [] | [] | [] |
80240 | 7032533 | [
{
"id": "80241",
"type": "document",
"text": [
"Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia . The effects of a new drug , N-2- ( p-chlorophenoxy ) -isobutyryl-N'-morpholinomethylurea ( plafibride , ITA 104 ) , were studied in a double blind study lasting four months on a group of 30 patients with a type IV hyperlipoproteinemia . In the patients treated with the active drug significant reductions in blood triglycerides were obtained , with a trend to normal . Reduction in blood cholesterol was inconsistent and not significant . As for the lipoproteinogram , a tendency towards a decrease in the pre-beta-lipoprotein fraction was observed and so was a non-significant tendency towards an increase in the alpha- and beta-lipoprotein fractions . Studies on the platelet functioning showed an obvious decrease in platelet aggregation in those patients treated with the active drug . This was very evident for the ADP and adrenaline inductors and rather less significant for collagen . Neither platelet adhesiveness nor aggregation rate changed . Tolerance of the drug was generally excellent . In one patient a decrease in some palpebral xanthelasmas was observed after two months of treatment with the active drug . In only one case there was heartburn and this was corrected with alkalines . In one other case an urticarial rash appeared , but disappeared spontaneously when the drug was temporarily stopped and did not reappear when it was administered again . During the trial no evidence of renal , hepatic or hematological malfunctions were observed . However , a slight tendency towards an increase in the GOT , GPT and LDH was observed , which was not statistically significant . The drug tested may be very useful in the treatment of type IV hyperlipoproteinemia , especially in those forms in which an increase in thromboembolic risk is suspected , either associated with , or secondary to , the actual atherosclerotic disease ."
],
"offsets": [
[
0,
1945
]
]
}
] | [
{
"id": "80242",
"type": "Intervention_Pharmacological",
"text": [
"plafibride"
],
"offsets": [
[
38,
48
]
],
"normalized": []
},
{
"id": "80243",
"type": "Intervention_Pharmacological",
"text": [
"N-2- ( p-chlorophenoxy ) -isobutyryl-N'-morpholinomethylurea ( plafibride , ITA 104 )"
],
"offsets": [
[
128,
213
]
],
"normalized": []
},
{
"id": "80244",
"type": "Outcome_Physical",
"text": [
"blood triglycerides"
],
"offsets": [
[
408,
427
]
],
"normalized": []
},
{
"id": "80245",
"type": "Outcome_Physical",
"text": [
"blood cholesterol"
],
"offsets": [
[
482,
499
]
],
"normalized": []
},
{
"id": "80246",
"type": "Outcome_Physical",
"text": [
"pre-beta-lipoprotein fraction"
],
"offsets": [
[
606,
635
]
],
"normalized": []
},
{
"id": "80247",
"type": "Outcome_Physical",
"text": [
"platelet aggregation"
],
"offsets": [
[
820,
840
]
],
"normalized": []
},
{
"id": "80248",
"type": "Outcome_Physical",
"text": [
"platelet adhesiveness"
],
"offsets": [
[
1000,
1021
]
],
"normalized": []
},
{
"id": "80249",
"type": "Outcome_Physical",
"text": [
"aggregation rate"
],
"offsets": [
[
1026,
1042
]
],
"normalized": []
},
{
"id": "80250",
"type": "Outcome_Other",
"text": [
"Tolerance"
],
"offsets": [
[
1053,
1062
]
],
"normalized": []
},
{
"id": "80251",
"type": "Outcome_Adverse-effects",
"text": [
"palpebral xanthelasmas"
],
"offsets": [
[
1135,
1157
]
],
"normalized": []
},
{
"id": "80252",
"type": "Outcome_Adverse-effects",
"text": [
"heartburn"
],
"offsets": [
[
1251,
1260
]
],
"normalized": []
},
{
"id": "80253",
"type": "Outcome_Adverse-effects",
"text": [
"urticarial rash"
],
"offsets": [
[
1322,
1337
]
],
"normalized": []
},
{
"id": "80254",
"type": "Outcome_Physical",
"text": [
"renal , hepatic or hematological malfunctions"
],
"offsets": [
[
1503,
1548
]
],
"normalized": []
},
{
"id": "80255",
"type": "Outcome_Physical",
"text": [
"thromboembolic risk"
],
"offsets": [
[
1831,
1850
]
],
"normalized": []
}
] | [] | [] | [] |
80256 | 7032811 | [
{
"id": "80257",
"type": "document",
"text": [
"Effects of a low-salt diet and of acute salt loading on blood pressure and intralymphocytic sodium concentration in young subjects with borderline hypertension . 1 . Three groups of young patients with borderline hypertension were studied for a 12 months period . The first was on a free sodium diet while the second was on a low-salt diet . The third group of patients underwent acute salt loading . 2 . After 12 months the group on free diet showed a significant increase of intralymphocytic sodium but no change in blood pressure was noted . Five patients who were re-checked after 24 months also had a significant increase in blood pressure . 3 . Patients treated with a low-salt diet showed a significant decrease of both intralymphocytic sodium concentration and blood pressure . 4 . After acute salt loading , borderline subjects with high intralymphocytic sodium showed a significant greater natriuresis whereas intralymphocytic sodium increased only in those subjects in whom it was initially normal ."
],
"offsets": [
[
0,
1010
]
]
}
] | [
{
"id": "80258",
"type": "Intervention_Pharmacological",
"text": [
"low-salt diet"
],
"offsets": [
[
13,
26
]
],
"normalized": []
},
{
"id": "80259",
"type": "Intervention_Pharmacological",
"text": [
"acute salt loading"
],
"offsets": [
[
34,
52
]
],
"normalized": []
},
{
"id": "80260",
"type": "Intervention_Pharmacological",
"text": [
"free sodium diet"
],
"offsets": [
[
283,
299
]
],
"normalized": []
},
{
"id": "80261",
"type": "Intervention_Pharmacological",
"text": [
"low-salt diet ."
],
"offsets": [
[
326,
341
]
],
"normalized": []
},
{
"id": "80262",
"type": "Intervention_Pharmacological",
"text": [
"acute salt loading ."
],
"offsets": [
[
380,
400
]
],
"normalized": []
},
{
"id": "80263",
"type": "Intervention_Physical",
"text": [
"free diet"
],
"offsets": [
[
434,
443
]
],
"normalized": []
},
{
"id": "80264",
"type": "Intervention_Physical",
"text": [
"low-salt diet"
],
"offsets": [
[
13,
26
]
],
"normalized": []
},
{
"id": "80265",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
56,
70
]
],
"normalized": []
},
{
"id": "80266",
"type": "Outcome_Physical",
"text": [
"intralymphocytic sodium concentration"
],
"offsets": [
[
75,
112
]
],
"normalized": []
},
{
"id": "80267",
"type": "Outcome_Physical",
"text": [
"intralymphocytic sodium"
],
"offsets": [
[
75,
98
]
],
"normalized": []
},
{
"id": "80268",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
56,
70
]
],
"normalized": []
},
{
"id": "80269",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
56,
70
]
],
"normalized": []
},
{
"id": "80270",
"type": "Outcome_Physical",
"text": [
"intralymphocytic sodium concentration"
],
"offsets": [
[
75,
112
]
],
"normalized": []
},
{
"id": "80271",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
56,
70
]
],
"normalized": []
},
{
"id": "80272",
"type": "Outcome_Physical",
"text": [
"natriuresis"
],
"offsets": [
[
900,
911
]
],
"normalized": []
},
{
"id": "80273",
"type": "Outcome_Physical",
"text": [
"intralymphocytic sodium"
],
"offsets": [
[
75,
98
]
],
"normalized": []
},
{
"id": "80274",
"type": "Participant_Age",
"text": [
"young subjects"
],
"offsets": [
[
116,
130
]
],
"normalized": []
},
{
"id": "80275",
"type": "Participant_Condition",
"text": [
"with borderline hypertension ."
],
"offsets": [
[
131,
161
]
],
"normalized": []
},
{
"id": "80276",
"type": "Participant_Age",
"text": [
"young patients"
],
"offsets": [
[
182,
196
]
],
"normalized": []
},
{
"id": "80277",
"type": "Participant_Condition",
"text": [
"borderline hypertension"
],
"offsets": [
[
136,
159
]
],
"normalized": []
}
] | [] | [] | [] |
80278 | 7035637 | [
{
"id": "80279",
"type": "document",
"text": [
"Age-related response to two Haemophilus influenzae type b vaccines . Two types of Hib vaccines were compared for efficacy and safety in 71 normal children in three age groups : 36 to 72 months , 15 to 18 months , and 6 to 8 months . One vaccine contained the Hib-specific capsular polysaccharide , PRP ; the second vaccine contained PRP combined with pertussis vaccine , PRP-P. A third vaccine , DTP , was administered to a control group for each age . Anti-PRP antibody levels were greater after vaccination with PRP-P than after PRP in all three age groups . Immunoresponsiveness to both vaccines increased with age . A lower incidence of side effects was seen with both PRP ( 15 % ) and PRP-P ( 20 % ) than with DTP ( 56 % ) . The results suggest that PRP-P is both well tolerated clinically and has greater immunogenicity than PRP ."
],
"offsets": [
[
0,
836
]
]
}
] | [
{
"id": "80280",
"type": "Intervention_Pharmacological",
"text": [
"Haemophilus influenzae type b vaccines ."
],
"offsets": [
[
28,
68
]
],
"normalized": []
},
{
"id": "80281",
"type": "Intervention_Pharmacological",
"text": [
"Hib vaccines"
],
"offsets": [
[
82,
94
]
],
"normalized": []
},
{
"id": "80282",
"type": "Intervention_Pharmacological",
"text": [
"Hib-specific capsular polysaccharide , PRP ;"
],
"offsets": [
[
259,
303
]
],
"normalized": []
},
{
"id": "80283",
"type": "Intervention_Pharmacological",
"text": [
"PRP"
],
"offsets": [
[
298,
301
]
],
"normalized": []
},
{
"id": "80284",
"type": "Intervention_Pharmacological",
"text": [
"pertussis vaccine , PRP-P."
],
"offsets": [
[
351,
377
]
],
"normalized": []
},
{
"id": "80285",
"type": "Intervention_Pharmacological",
"text": [
"DTP"
],
"offsets": [
[
396,
399
]
],
"normalized": []
},
{
"id": "80286",
"type": "Intervention_Control",
"text": [
"control"
],
"offsets": [
[
424,
431
]
],
"normalized": []
},
{
"id": "80287",
"type": "Intervention_Pharmacological",
"text": [
"PRP"
],
"offsets": [
[
298,
301
]
],
"normalized": []
},
{
"id": "80288",
"type": "Intervention_Pharmacological",
"text": [
"PRP-P"
],
"offsets": [
[
371,
376
]
],
"normalized": []
},
{
"id": "80289",
"type": "Intervention_Pharmacological",
"text": [
"PRP-P"
],
"offsets": [
[
371,
376
]
],
"normalized": []
},
{
"id": "80290",
"type": "Outcome_Physical",
"text": [
"Age-related response"
],
"offsets": [
[
0,
20
]
],
"normalized": []
},
{
"id": "80291",
"type": "Outcome_Other",
"text": [
"efficacy and safety"
],
"offsets": [
[
113,
132
]
],
"normalized": []
},
{
"id": "80292",
"type": "Outcome_Physical",
"text": [
"Anti-PRP antibody levels"
],
"offsets": [
[
453,
477
]
],
"normalized": []
},
{
"id": "80293",
"type": "Outcome_Physical",
"text": [
"Immunoresponsiveness"
],
"offsets": [
[
561,
581
]
],
"normalized": []
},
{
"id": "80294",
"type": "Outcome_Adverse-effects",
"text": [
"lower incidence of side effects"
],
"offsets": [
[
622,
653
]
],
"normalized": []
},
{
"id": "80295",
"type": "Outcome_Other",
"text": [
"well tolerated clinically and has greater immunogenicity"
],
"offsets": [
[
769,
825
]
],
"normalized": []
},
{
"id": "80296",
"type": "Participant_Sample-size",
"text": [
"71"
],
"offsets": [
[
136,
138
]
],
"normalized": []
},
{
"id": "80297",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
146,
154
]
],
"normalized": []
},
{
"id": "80298",
"type": "Participant_Age",
"text": [
"36 to 72 months , 15 to 18 months"
],
"offsets": [
[
177,
210
]
],
"normalized": []
},
{
"id": "80299",
"type": "Participant_Age",
"text": [
"6 to 8 months"
],
"offsets": [
[
217,
230
]
],
"normalized": []
}
] | [] | [] | [] |
80300 | 7036084 | [
{
"id": "80301",
"type": "document",
"text": [
"[ Credé 's prevention method has lost its justification today ] ."
],
"offsets": [
[
0,
65
]
]
}
] | [
{
"id": "80302",
"type": "Intervention_Educational",
"text": [
"Credé 's prevention method"
],
"offsets": [
[
2,
28
]
],
"normalized": []
},
{
"id": "80303",
"type": "Participant_Condition",
"text": [
"[ Credé 's prevention method"
],
"offsets": [
[
0,
28
]
],
"normalized": []
}
] | [] | [] | [] |
80304 | 7036799 | [
{
"id": "80305",
"type": "document",
"text": [
"Lidocaine and bupivacaine mixtures for epidural blockade . In a prospective double-blind clinical study , single-dose lumbar epidural blockade was instituted in 60 healthy patients undergoing lower abdominal surgery . Patients were randomly assigned to one of five groups . Each group received treatment with a different local anesthetic solution containing 1:200,000 epinephrine . Local anesthetic solutions used were 0.5 per cent bupivacaine HCl , 2 per cent lidocaine HCl , and lidocaine-bupivacaine mixtures in the ratios of 1:3 , 1:1 or 3:1 by volume . Onset and complete spread of sensory blockade were similar in all five groups . Time to regression to two segments of partial and complete sensory blockade was positively correlated ( P less than 0.05 ) with increasing dose of bupivacaine in the solutions and ranged from 84 min ( partial ) and 70 min ( complete ) for lidocaine , to 128 min ( partial ) and 101 min ( complete ) for bupivacaine . Using skin temperature as a criterion of sympathetic blockade , all three mixtures demonstrated a duration of action intermediate between the two single drugs , lidocaine ( 124 +/- 13 min ) and bupivacaine ( 286 +/- 32 min ) . Onset of complete motor blockade was fastest and the degree of motor blockade was most profound with the mixture containing equal proportions of lidocaine and bupivacaine . Pharmacokinetics of individual drugs were unaltered in any of the mixtures ."
],
"offsets": [
[
0,
1431
]
]
}
] | [
{
"id": "80306",
"type": "Intervention_Pharmacological",
"text": [
"Lidocaine"
],
"offsets": [
[
0,
9
]
],
"normalized": []
},
{
"id": "80307",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
14,
25
]
],
"normalized": []
},
{
"id": "80308",
"type": "Intervention_Pharmacological",
"text": [
"epinephrine ."
],
"offsets": [
[
368,
381
]
],
"normalized": []
},
{
"id": "80309",
"type": "Intervention_Pharmacological",
"text": [
"0.5 per cent bupivacaine HCl , 2 per cent lidocaine HCl , and lidocaine-bupivacaine mixtures"
],
"offsets": [
[
419,
511
]
],
"normalized": []
},
{
"id": "80310",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
14,
25
]
],
"normalized": []
},
{
"id": "80311",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
461,
470
]
],
"normalized": []
},
{
"id": "80312",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
14,
25
]
],
"normalized": []
},
{
"id": "80313",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
14,
25
]
],
"normalized": []
},
{
"id": "80314",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
461,
470
]
],
"normalized": []
},
{
"id": "80315",
"type": "Intervention_Pharmacological",
"text": [
"bupivacaine"
],
"offsets": [
[
14,
25
]
],
"normalized": []
},
{
"id": "80316",
"type": "Outcome_Mental",
"text": [
"Onset and complete spread of"
],
"offsets": [
[
558,
586
]
],
"normalized": []
},
{
"id": "80317",
"type": "Outcome_Physical",
"text": [
"sensory blockade"
],
"offsets": [
[
587,
603
]
],
"normalized": []
},
{
"id": "80318",
"type": "Outcome_Other",
"text": [
"duration of action"
],
"offsets": [
[
1053,
1071
]
],
"normalized": []
},
{
"id": "80319",
"type": "Outcome_Physical",
"text": [
"Onset of complete motor blockade"
],
"offsets": [
[
1182,
1214
]
],
"normalized": []
},
{
"id": "80320",
"type": "Outcome_Physical",
"text": [
"degree of motor blockade"
],
"offsets": [
[
1235,
1259
]
],
"normalized": []
},
{
"id": "80321",
"type": "Participant_Sample-size",
"text": [
"60"
],
"offsets": [
[
161,
163
]
],
"normalized": []
},
{
"id": "80322",
"type": "Participant_Condition",
"text": [
"healthy patients undergoing lower abdominal surgery"
],
"offsets": [
[
164,
215
]
],
"normalized": []
}
] | [] | [] | [] |
80323 | 7037697 | [
{
"id": "80324",
"type": "document",
"text": [
"Preliminary report of the M.D . Anderson Hospital randomized trial of neutron and photon irradiation for locally advanced carcinoma of the uterine cervix ."
],
"offsets": [
[
0,
155
]
]
}
] | [
{
"id": "80325",
"type": "Intervention_Physical",
"text": [
"neutron and photon irradiation"
],
"offsets": [
[
70,
100
]
],
"normalized": []
},
{
"id": "80326",
"type": "Outcome_Physical",
"text": [
"locally advanced carcinoma of the uterine cervix"
],
"offsets": [
[
105,
153
]
],
"normalized": []
},
{
"id": "80327",
"type": "Participant_Condition",
"text": [
"advanced carcinoma"
],
"offsets": [
[
113,
131
]
],
"normalized": []
},
{
"id": "80328",
"type": "Participant_Condition",
"text": [
"uterine cervix ."
],
"offsets": [
[
139,
155
]
],
"normalized": []
}
] | [] | [] | [] |
80329 | 7044324 | [
{
"id": "80330",
"type": "document",
"text": [
"Treatment of human tungiasis with niridazole ( Ambilhar ) a double-blind placebo-controlled trial ."
],
"offsets": [
[
0,
99
]
]
}
] | [
{
"id": "80331",
"type": "Intervention_Pharmacological",
"text": [
"niridazole ( Ambilhar )"
],
"offsets": [
[
34,
57
]
],
"normalized": []
},
{
"id": "80332",
"type": "Participant_Condition",
"text": [
"human tungiasis"
],
"offsets": [
[
13,
28
]
],
"normalized": []
}
] | [] | [] | [] |
80333 | 7047002 | [
{
"id": "80334",
"type": "document",
"text": [
"Corticosteroid-induced osteopenia and vitamin D metabolism . Effect of vitamin D2 , calcium phosphate and sodium fluoride administration . Thirty-one patients scheduled for long-term ( 24 weeks ) treatment with prednisone in comparatively high doses were randomly allocated to two further treatment groups . Group A received prednisone plus 'triple-treatment ' ( vitamin D2 45000 iu twice weekly , sodium fluoride 50 mg and calcium phosphate 4.5 g daily ) , group B received only prednisone . The study was undertaken in order to evaluate the effect of prednisone- and triple-treatment upon bone mineral content ( BMC ) and vitamin D metabolism . The groups were comparable with regard to age , sex and prednisone dose . BMC fell rapidly and similarly in both groups , demonstrating that the triple-treatment has no preventive effect on corticosteroid induced osteopenia . Serum concentrations of 25OHD2 , 25OHD3 and 1,25 ( OH ) 2D were unchanged in group B ( without triple-treatment ) , whereas in group A 25OHD2 increased enormously , 25OHD3 was suppressed possibly by substrate competition for hydroxylation in the liver and 1,25 ( OH ) 2D was halved . The suppression of 1,25 ( OH ) 2D may be an effect of raised 25OHD2 alone , or in combination with corticosteroid excess ."
],
"offsets": [
[
0,
1279
]
]
}
] | [
{
"id": "80335",
"type": "Intervention_Pharmacological",
"text": [
"vitamin D2 , calcium phosphate"
],
"offsets": [
[
71,
101
]
],
"normalized": []
},
{
"id": "80336",
"type": "Intervention_Pharmacological",
"text": [
"sodium fluoride"
],
"offsets": [
[
106,
121
]
],
"normalized": []
},
{
"id": "80337",
"type": "Intervention_Pharmacological",
"text": [
"prednisone"
],
"offsets": [
[
211,
221
]
],
"normalized": []
},
{
"id": "80338",
"type": "Intervention_Pharmacological",
"text": [
"Group A received prednisone plus 'triple-treatment ' ( vitamin D2 45000 iu twice weekly , sodium fluoride 50 mg and calcium phosphate 4.5 g daily ) , group B received only prednisone"
],
"offsets": [
[
308,
490
]
],
"normalized": []
},
{
"id": "80339",
"type": "Intervention_Pharmacological",
"text": [
"prednisone-"
],
"offsets": [
[
553,
564
]
],
"normalized": []
},
{
"id": "80340",
"type": "Intervention_Pharmacological",
"text": [
"triple-treatment"
],
"offsets": [
[
342,
358
]
],
"normalized": []
},
{
"id": "80341",
"type": "Outcome_Physical",
"text": [
"osteopenia"
],
"offsets": [
[
23,
33
]
],
"normalized": []
},
{
"id": "80342",
"type": "Outcome_Physical",
"text": [
"vitamin D metabolism"
],
"offsets": [
[
38,
58
]
],
"normalized": []
},
{
"id": "80343",
"type": "Outcome_Physical",
"text": [
"bone mineral content ( BMC )"
],
"offsets": [
[
591,
619
]
],
"normalized": []
},
{
"id": "80344",
"type": "Outcome_Physical",
"text": [
"vitamin D metabolism"
],
"offsets": [
[
38,
58
]
],
"normalized": []
},
{
"id": "80345",
"type": "Outcome_Physical",
"text": [
"BMC"
],
"offsets": [
[
614,
617
]
],
"normalized": []
},
{
"id": "80346",
"type": "Outcome_Physical",
"text": [
"Serum concentrations of 25OHD2 , 25OHD3 and 1,25 ( OH ) 2D"
],
"offsets": [
[
873,
931
]
],
"normalized": []
},
{
"id": "80347",
"type": "Outcome_Physical",
"text": [
"25OHD2"
],
"offsets": [
[
897,
903
]
],
"normalized": []
},
{
"id": "80348",
"type": "Outcome_Physical",
"text": [
"25OHD3"
],
"offsets": [
[
906,
912
]
],
"normalized": []
},
{
"id": "80349",
"type": "Outcome_Physical",
"text": [
"1,25 ( OH ) 2D"
],
"offsets": [
[
917,
931
]
],
"normalized": []
},
{
"id": "80350",
"type": "Outcome_Physical",
"text": [
"1,25 ( OH ) 2D"
],
"offsets": [
[
917,
931
]
],
"normalized": []
},
{
"id": "80351",
"type": "Participant_Sample-size",
"text": [
"Thirty-one"
],
"offsets": [
[
139,
149
]
],
"normalized": []
}
] | [] | [] | [] |
80352 | 7048172 | [
{
"id": "80353",
"type": "document",
"text": [
"Non-Hodgkin 's malignant lymphomas : treatment of localized relapses with chemo + radio + BCG-therapy . 16 patients with relapsing non-Hodgkin 's malignant lymphomas considered as clinical stage I or II were treated by an association of chemo + radiotherapy and thereafter by maintenance BCG therapy . 5 of them were included in a randomized trial and have a significantly different disease-free survival from patients receiving the same treatment but without BCG . 11 were systematically treated by BCG and they also have a fairly good disease-free survival . Such a treatment appears to be of value in treating these patients and even probably of curing some of them ."
],
"offsets": [
[
0,
670
]
]
}
] | [
{
"id": "80354",
"type": "Intervention_Physical",
"text": [
"chemo + radio + BCG-therapy"
],
"offsets": [
[
74,
101
]
],
"normalized": []
},
{
"id": "80355",
"type": "Intervention_Pharmacological",
"text": [
"chemo + radiotherapy and thereafter by maintenance BCG therapy"
],
"offsets": [
[
237,
299
]
],
"normalized": []
},
{
"id": "80356",
"type": "Intervention_Physical",
"text": [
"BCG"
],
"offsets": [
[
90,
93
]
],
"normalized": []
},
{
"id": "80357",
"type": "Intervention_Physical",
"text": [
"BCG"
],
"offsets": [
[
90,
93
]
],
"normalized": []
},
{
"id": "80358",
"type": "Outcome_Mortality",
"text": [
"disease-free survival"
],
"offsets": [
[
383,
404
]
],
"normalized": []
},
{
"id": "80359",
"type": "Outcome_Mortality",
"text": [
"disease-free survival"
],
"offsets": [
[
383,
404
]
],
"normalized": []
},
{
"id": "80360",
"type": "Participant_Sample-size",
"text": [
"16"
],
"offsets": [
[
104,
106
]
],
"normalized": []
},
{
"id": "80361",
"type": "Participant_Condition",
"text": [
"relapsing non-Hodgkin 's malignant lymphomas"
],
"offsets": [
[
121,
165
]
],
"normalized": []
},
{
"id": "80362",
"type": "Participant_Sample-size",
"text": [
"5"
],
"offsets": [
[
302,
303
]
],
"normalized": []
},
{
"id": "80363",
"type": "Participant_Sample-size",
"text": [
"11"
],
"offsets": [
[
466,
468
]
],
"normalized": []
}
] | [] | [] | [] |
80364 | 7053590 | [
{
"id": "80365",
"type": "document",
"text": [
"Laser conization versus cold knife conization . This prospective , randomized study compares , for the first time , measured blood loss at conization and within 24 hours after using either the cold knife technique or the carbon dioxide laser scalpel . One hundred and ten consecutive patients were evaluated . The median blood loss in the laser group of 55 patients was 4.6 milliliters at , and within , 24 hours after operation compared with 30.1 milliliters in the cold knife group of 55 patients . More important , however , is that the corresponding figures for the range of bleeding were 0.4 to 155.4 milliliters and 5.6 to 1,570.9 milliliters , respectively . The incidence rate for bleeding complications requiring surgical intervention was 1.8 per cet for the laser group and 14.6 per cent for the cold knife group . This difference was statistically significant , p less than 0.015 -- Fischer 's exact test . Conization for treatment of premalignant changes of the cervix uteri will probably remain the treatment of choice for some time to come . It is our opinion that , in the future , laser conization will replace cold knife conization ."
],
"offsets": [
[
0,
1150
]
]
}
] | [
{
"id": "80366",
"type": "Intervention_Physical",
"text": [
"Laser conization"
],
"offsets": [
[
0,
16
]
],
"normalized": []
},
{
"id": "80367",
"type": "Intervention_Physical",
"text": [
"cold knife conization"
],
"offsets": [
[
24,
45
]
],
"normalized": []
},
{
"id": "80368",
"type": "Intervention_Physical",
"text": [
"cold knife technique"
],
"offsets": [
[
193,
213
]
],
"normalized": []
},
{
"id": "80369",
"type": "Intervention_Physical",
"text": [
"carbon dioxide laser scalpel"
],
"offsets": [
[
221,
249
]
],
"normalized": []
},
{
"id": "80370",
"type": "Intervention_Physical",
"text": [
"cold knife"
],
"offsets": [
[
24,
34
]
],
"normalized": []
},
{
"id": "80371",
"type": "Intervention_Physical",
"text": [
"cold knife"
],
"offsets": [
[
24,
34
]
],
"normalized": []
},
{
"id": "80372",
"type": "Intervention_Physical",
"text": [
"laser"
],
"offsets": [
[
236,
241
]
],
"normalized": []
},
{
"id": "80373",
"type": "Intervention_Physical",
"text": [
"cold knife"
],
"offsets": [
[
24,
34
]
],
"normalized": []
},
{
"id": "80374",
"type": "Outcome_Physical",
"text": [
"median blood loss"
],
"offsets": [
[
314,
331
]
],
"normalized": []
},
{
"id": "80375",
"type": "Outcome_Physical",
"text": [
"range of bleeding"
],
"offsets": [
[
570,
587
]
],
"normalized": []
},
{
"id": "80376",
"type": "Outcome_Adverse-effects",
"text": [
"incidence rate for bleeding complications requiring surgical intervention"
],
"offsets": [
[
670,
743
]
],
"normalized": []
},
{
"id": "80377",
"type": "Participant_Sample-size",
"text": [
"One hundred and ten"
],
"offsets": [
[
252,
271
]
],
"normalized": []
}
] | [] | [] | [] |
80378 | 7056921 | [
{
"id": "80379",
"type": "document",
"text": [
"Effects of vicarious reinforcement in normal and severely disturbed children ."
],
"offsets": [
[
0,
78
]
]
}
] | [
{
"id": "80380",
"type": "Intervention_Educational",
"text": [
"vicarious reinforcement"
],
"offsets": [
[
11,
34
]
],
"normalized": []
},
{
"id": "80381",
"type": "Participant_Condition",
"text": [
"normal and severely disturbed"
],
"offsets": [
[
38,
67
]
],
"normalized": []
},
{
"id": "80382",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
68,
76
]
],
"normalized": []
}
] | [] | [] | [] |
80383 | 7069027 | [
{
"id": "80384",
"type": "document",
"text": [
"Perception of social interactions in depressed psychiatric patients ."
],
"offsets": [
[
0,
69
]
]
}
] | [
{
"id": "80385",
"type": "Intervention_Educational",
"text": [
"social interactions"
],
"offsets": [
[
14,
33
]
],
"normalized": []
},
{
"id": "80386",
"type": "Outcome_Mental",
"text": [
"social interactions"
],
"offsets": [
[
14,
33
]
],
"normalized": []
},
{
"id": "80387",
"type": "Participant_Condition",
"text": [
"depressed psychiatric"
],
"offsets": [
[
37,
58
]
],
"normalized": []
}
] | [] | [] | [] |
80388 | 7072873 | [
{
"id": "80389",
"type": "document",
"text": [
"Memory aids in longitudinal health surveys : results from a field experiment . The use of memory aids to improve respondent recall is becoming increasingly popular in health surveys . In a one-year field experiment involving over 1,200 respondents , people assigned memory aids reported over 50 per cent more symptom episodes than those not assigned memory aids . Differences in reporting levels were particularly striking during the first six to 12 weeks of the survey , for symptoms related to acute , transitory illness , and among minorities and the lower socioeconomic groups . Respondents assigned memory aids were also more likely to report a doctor contact -- especially during the fall/winter months . Among respondent who used their memory aids at least once ( N = 252 ) , nearly 35 per cent said they were influenced by the information recorded in their memory aids , and most of those who were influenced said that they became more aware of their health . Ten of these people said that they became more worried or depressed because of the information recorded in their memory aids . This constitutes about a four per cent risk among those people who reported using their memory aids at least once . There was no evidence to suggest that the memory aids influenced perceptions of health status ."
],
"offsets": [
[
0,
1306
]
]
}
] | [
{
"id": "80390",
"type": "Intervention_Other",
"text": [
"Memory aids"
],
"offsets": [
[
0,
11
]
],
"normalized": []
},
{
"id": "80391",
"type": "Intervention_Other",
"text": [
"memory aids"
],
"offsets": [
[
90,
101
]
],
"normalized": []
},
{
"id": "80392",
"type": "Intervention_Educational",
"text": [
"memory aids"
],
"offsets": [
[
90,
101
]
],
"normalized": []
},
{
"id": "80393",
"type": "Intervention_Other",
"text": [
"memory aids"
],
"offsets": [
[
90,
101
]
],
"normalized": []
},
{
"id": "80394",
"type": "Intervention_Other",
"text": [
"memory aids"
],
"offsets": [
[
90,
101
]
],
"normalized": []
},
{
"id": "80395",
"type": "Intervention_Other",
"text": [
"memory aids"
],
"offsets": [
[
90,
101
]
],
"normalized": []
},
{
"id": "80396",
"type": "Outcome_Mental",
"text": [
"influenced by the information recorded in their memory aids"
],
"offsets": [
[
817,
876
]
],
"normalized": []
},
{
"id": "80397",
"type": "Outcome_Mental",
"text": [
"became more aware of their health"
],
"offsets": [
[
932,
965
]
],
"normalized": []
},
{
"id": "80398",
"type": "Outcome_Mental",
"text": [
"more worried or depressed"
],
"offsets": [
[
1010,
1035
]
],
"normalized": []
},
{
"id": "80399",
"type": "Outcome_Mental",
"text": [
"perceptions of health status"
],
"offsets": [
[
1276,
1304
]
],
"normalized": []
},
{
"id": "80400",
"type": "Participant_Condition",
"text": [
"over 1,200 respondents , people assigned memory aids reported over 50 per cent more symptom episodes than those not assigned memory aids ."
],
"offsets": [
[
225,
363
]
],
"normalized": []
}
] | [] | [] | [] |
80401 | 7075499 | [
{
"id": "80402",
"type": "document",
"text": [
"[ Dose-effect relationship of isosorbide dinitrate in the treatment of angina pectoris ( author 's transl ) ] . Fifteen males with angiographic evidence of coronary heart disease and stable , exercise-induced angina pectoris were given placebo or isosorbide dinitrate ( ISDN ) in a dialy dose of 30 mg , 120 mg , 240 mg and 480 mg in a randomized single-blind trial . The daily doses were given as a single oral dose of 5 mg , 20 mg , 40 mg and 80 mg tablets . Each dose and placebo was given for seven days . On the seventh day an exercise ECG of standardized level and duration of exercise was recorded . The ischaemia response in the ECG revealed a dose-dependent reduction by 28 % ( 5 mg ISDN ) , 43 % ( 20 mg ) , 60 % ( 40 mg ) and 73 % ( 80 mg ) . The number of anginal attacks similarly fell parallel to dose . Plasma level of ISDN and the mononitrates , measured one and four hours after drug intake , rose almost linearly in relation to dose . Oral ISDN thus has a dose-dependent effect on the frequency of angina and ischaemia parameters during ergometric exercise . The protracted anti-anginal effect of ISDN is largely due to its metabolites . At high doses there is presumably an added effect of the high blood level of the basic substance.U"
],
"offsets": [
[
0,
1254
]
]
}
] | [
{
"id": "80403",
"type": "Intervention_Pharmacological",
"text": [
"isosorbide dinitrate"
],
"offsets": [
[
30,
50
]
],
"normalized": []
},
{
"id": "80404",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
236,
243
]
],
"normalized": []
},
{
"id": "80405",
"type": "Intervention_Pharmacological",
"text": [
"isosorbide dinitrate ( ISDN )"
],
"offsets": [
[
247,
276
]
],
"normalized": []
},
{
"id": "80406",
"type": "Outcome_Physical",
"text": [
"exercise ECG"
],
"offsets": [
[
532,
544
]
],
"normalized": []
},
{
"id": "80407",
"type": "Outcome_Other",
"text": [
"duration of exercise"
],
"offsets": [
[
571,
591
]
],
"normalized": []
},
{
"id": "80408",
"type": "Outcome_Physical",
"text": [
"ischaemia"
],
"offsets": [
[
611,
620
]
],
"normalized": []
},
{
"id": "80409",
"type": "Outcome_Other",
"text": [
"reduction"
],
"offsets": [
[
667,
676
]
],
"normalized": []
},
{
"id": "80410",
"type": "Outcome_Physical",
"text": [
"number of anginal attacks"
],
"offsets": [
[
758,
783
]
],
"normalized": []
},
{
"id": "80411",
"type": "Outcome_Physical",
"text": [
"Plasma level of ISDN and the mononitrates"
],
"offsets": [
[
818,
859
]
],
"normalized": []
},
{
"id": "80412",
"type": "Outcome_Physical",
"text": [
"frequency of angina and ischaemia parameters"
],
"offsets": [
[
1003,
1047
]
],
"normalized": []
},
{
"id": "80413",
"type": "Outcome_Physical",
"text": [
"anti-anginal effect"
],
"offsets": [
[
1092,
1111
]
],
"normalized": []
}
] | [] | [] | [] |
80414 | 7080985 | [
{
"id": "80415",
"type": "document",
"text": [
"[ Comparative study of cinoxacin ( Cinobac ) , nitrofurantoin ( Furadantine MC ) and oxolinic acid ( Uritrate ) in urinary tract infections . Results of a random study of three groups of 30 patients with uncomplicated urinary infections ] ."
],
"offsets": [
[
0,
240
]
]
}
] | [
{
"id": "80416",
"type": "Intervention_Pharmacological",
"text": [
"cinoxacin ( Cinobac ) , nitrofurantoin ( Furadantine MC ) and oxolinic acid ( Uritrate )"
],
"offsets": [
[
23,
111
]
],
"normalized": []
},
{
"id": "80417",
"type": "Participant_Sample-size",
"text": [
"30"
],
"offsets": [
[
187,
189
]
],
"normalized": []
},
{
"id": "80418",
"type": "Participant_Condition",
"text": [
"urinary infections"
],
"offsets": [
[
218,
236
]
],
"normalized": []
}
] | [] | [] | [] |
80419 | 7092002 | [
{
"id": "80420",
"type": "document",
"text": [
"Antibiotic therapy of acute exacerbations of chronic bronchitis . A controlled study using tetracycline . We conducted a double-blind , randomized , placebo-controlled trial in 40 patients to evaluate the need for antibiotics in acute exacerbations of chronic bronchitis . All patients were sufficiently ill to require hospitalization although none needed ventilatory support ; the presence of pneumonia was excluded . Treatment consisted of bronchodilators , corticosteroids , and either tetracycline , 500 mg , or placebo by mouth every 6 hours for 1 week . Arterial blood gases , spirometric tests , bacteriologic evaluation of sputum , and patient and physician evaluation of the severity of illness were assessed at the beginning and end of the study . All patients improved both symptomatically and by objective measures of lung function . At the end of the study period there were no differences between those patients receiving tetracycline and those receiving placebo . We conclude that antibiotic therapy is not needed in moderately ill patients with exacerbations of chronic bronchitis ."
],
"offsets": [
[
0,
1098
]
]
}
] | [
{
"id": "80421",
"type": "Intervention_Pharmacological",
"text": [
"tetracycline"
],
"offsets": [
[
91,
103
]
],
"normalized": []
},
{
"id": "80422",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
149,
167
]
],
"normalized": []
},
{
"id": "80423",
"type": "Intervention_Pharmacological",
"text": [
"bronchodilators"
],
"offsets": [
[
442,
457
]
],
"normalized": []
},
{
"id": "80424",
"type": "Intervention_Pharmacological",
"text": [
"corticosteroids"
],
"offsets": [
[
460,
475
]
],
"normalized": []
},
{
"id": "80425",
"type": "Intervention_Pharmacological",
"text": [
"tetracycline"
],
"offsets": [
[
91,
103
]
],
"normalized": []
},
{
"id": "80426",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
149,
156
]
],
"normalized": []
},
{
"id": "80427",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
149,
156
]
],
"normalized": []
},
{
"id": "80428",
"type": "Outcome_Physical",
"text": [
"Arterial blood gases"
],
"offsets": [
[
560,
580
]
],
"normalized": []
},
{
"id": "80429",
"type": "Outcome_Other",
"text": [
"spirometric tests"
],
"offsets": [
[
583,
600
]
],
"normalized": []
},
{
"id": "80430",
"type": "Outcome_Physical",
"text": [
"bacteriologic evaluation of sputum"
],
"offsets": [
[
603,
637
]
],
"normalized": []
},
{
"id": "80431",
"type": "Outcome_Other",
"text": [
"patient and physician evaluation of the"
],
"offsets": [
[
644,
683
]
],
"normalized": []
},
{
"id": "80432",
"type": "Outcome_Physical",
"text": [
"severity of illness"
],
"offsets": [
[
684,
703
]
],
"normalized": []
},
{
"id": "80433",
"type": "Participant_Condition",
"text": [
"40 patients to evaluate the need for antibiotics in acute exacerbations of chronic bronchitis ."
],
"offsets": [
[
177,
272
]
],
"normalized": []
}
] | [] | [] | [] |
80434 | 709549 | [
{
"id": "80435",
"type": "document",
"text": [
"Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix ."
],
"offsets": [
[
0,
187
]
]
}
] | [
{
"id": "80436",
"type": "Intervention_Pharmacological",
"text": [
"adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide"
],
"offsets": [
[
41,
132
]
],
"normalized": []
},
{
"id": "80437",
"type": "Participant_Condition",
"text": [
"advanced carcinoma of the cervix ."
],
"offsets": [
[
153,
187
]
],
"normalized": []
}
] | [] | [] | [] |
80438 | 7104637 | [
{
"id": "80439",
"type": "document",
"text": [
"Intraoperative microscopy of bile -- is it useful ? Direct microscopy of the bile was performed during cholecystectomy in 111 patients in an attempt to identify those with a high risk of wound infection . Bacteria were identified in 23 patients , 11 of 83 undergoing cholecystectomy alone and 12 of 28 undergoing exploration of the common bile duct ( P less than 0.01 ) . These 23 patients were randomly allocated to an antibiotic group or a control group ; there was one wound infection in the antibiotic group and two in the control group . A total of 14 patients developed wound sepsis . Infection was more likely if the common bile duct was explored ( 6 of 28 ) rather than cholecystectomy alone ( 8 of 83 ) . There was a poor correlation between microscopy and culture of the bile for bacteria and there was no increase in sepsis when bacteria were observed on microscopy . We were not able to identify a high risk group of patients by intraoperative microscopy of bile ."
],
"offsets": [
[
0,
976
]
]
}
] | [
{
"id": "80440",
"type": "Intervention_Other",
"text": [
"Intraoperative microscopy"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "80441",
"type": "Intervention_Physical",
"text": [
"Direct microscopy of the bile"
],
"offsets": [
[
52,
81
]
],
"normalized": []
},
{
"id": "80442",
"type": "Intervention_Surgical",
"text": [
"cholecystectomy"
],
"offsets": [
[
103,
118
]
],
"normalized": []
},
{
"id": "80443",
"type": "Intervention_Surgical",
"text": [
"cholecystectomy"
],
"offsets": [
[
103,
118
]
],
"normalized": []
},
{
"id": "80444",
"type": "Intervention_Pharmacological",
"text": [
"antibiotic group"
],
"offsets": [
[
420,
436
]
],
"normalized": []
},
{
"id": "80445",
"type": "Intervention_Pharmacological",
"text": [
"antibiotic group"
],
"offsets": [
[
420,
436
]
],
"normalized": []
},
{
"id": "80446",
"type": "Intervention_Control",
"text": [
"control group"
],
"offsets": [
[
442,
455
]
],
"normalized": []
},
{
"id": "80447",
"type": "Intervention_Surgical",
"text": [
"cholecystectomy"
],
"offsets": [
[
103,
118
]
],
"normalized": []
},
{
"id": "80448",
"type": "Outcome_Physical",
"text": [
"wound sepsis ."
],
"offsets": [
[
576,
590
]
],
"normalized": []
},
{
"id": "80449",
"type": "Outcome_Adverse-effects",
"text": [
"Infection"
],
"offsets": [
[
591,
600
]
],
"normalized": []
},
{
"id": "80450",
"type": "Outcome_Adverse-effects",
"text": [
"bacteria"
],
"offsets": [
[
790,
798
]
],
"normalized": []
},
{
"id": "80451",
"type": "Outcome_Physical",
"text": [
"sepsis"
],
"offsets": [
[
582,
588
]
],
"normalized": []
},
{
"id": "80452",
"type": "Participant_Condition",
"text": [
"cholecystectomy"
],
"offsets": [
[
103,
118
]
],
"normalized": []
},
{
"id": "80453",
"type": "Participant_Sample-size",
"text": [
"111"
],
"offsets": [
[
122,
125
]
],
"normalized": []
},
{
"id": "80454",
"type": "Participant_Sample-size",
"text": [
"23"
],
"offsets": [
[
233,
235
]
],
"normalized": []
},
{
"id": "80455",
"type": "Participant_Sample-size",
"text": [
"11"
],
"offsets": [
[
122,
124
]
],
"normalized": []
},
{
"id": "80456",
"type": "Participant_Sample-size",
"text": [
"83"
],
"offsets": [
[
253,
255
]
],
"normalized": []
},
{
"id": "80457",
"type": "Participant_Condition",
"text": [
"cholecystectomy"
],
"offsets": [
[
103,
118
]
],
"normalized": []
},
{
"id": "80458",
"type": "Participant_Sample-size",
"text": [
"12"
],
"offsets": [
[
293,
295
]
],
"normalized": []
},
{
"id": "80459",
"type": "Participant_Sample-size",
"text": [
"28"
],
"offsets": [
[
299,
301
]
],
"normalized": []
},
{
"id": "80460",
"type": "Participant_Condition",
"text": [
"exploration of the common bile duct"
],
"offsets": [
[
313,
348
]
],
"normalized": []
},
{
"id": "80461",
"type": "Participant_Sample-size",
"text": [
"23"
],
"offsets": [
[
233,
235
]
],
"normalized": []
},
{
"id": "80462",
"type": "Participant_Sample-size",
"text": [
"14"
],
"offsets": [
[
554,
556
]
],
"normalized": []
}
] | [] | [] | [] |
80463 | 7118776 | [
{
"id": "80464",
"type": "document",
"text": [
"The pharmacokinetics of metronidazole and tinidazole in patients with mixed aerobic -- anaerobic infections ."
],
"offsets": [
[
0,
109
]
]
}
] | [
{
"id": "80465",
"type": "Intervention_Pharmacological",
"text": [
"metronidazole and tinidazole"
],
"offsets": [
[
24,
52
]
],
"normalized": []
},
{
"id": "80466",
"type": "Outcome_Physical",
"text": [
"pharmacokinetics"
],
"offsets": [
[
4,
20
]
],
"normalized": []
},
{
"id": "80467",
"type": "Participant_Condition",
"text": [
"patients with mixed aerobic -- anaerobic infections"
],
"offsets": [
[
56,
107
]
],
"normalized": []
}
] | [] | [] | [] |
80468 | 7134226 | [
{
"id": "80469",
"type": "document",
"text": [
"Inhibition of spontaneous platelet aggregation and adhesion by indobufen ( K 3920 ) . A randomized , double-blind crossover study on platelet , coagulation and fibrinolysis function tests . In a randomized double-blind crossover study in 12 patients with atherosclerotic disease , the effect of 2 dosages ( 100 and 200 mg twice daily ) of indobufen , a new synthetic inhibition of platelet aggregation , on some platelet functions , coagulation and fibrinolysis tests was investigated . Regardless of the dosage used , indobufen was shown to induce a prompt normalization of the enhanced platelet aggregation of these patients . The effect lasted for the entire period of drug administration and in 50 % of patients a normal platelet aggregation was maintained until the fourth day after discontinuation of the drug . Indobufen was also able to reduce platelet adhesiveness and to lengthen bleeding time , especially when the higher dosage was used ."
],
"offsets": [
[
0,
950
]
]
}
] | [
{
"id": "80470",
"type": "Intervention_Pharmacological",
"text": [
"indobufen ( K 3920 ) ."
],
"offsets": [
[
63,
85
]
],
"normalized": []
},
{
"id": "80471",
"type": "Intervention_Pharmacological",
"text": [
"indobufen"
],
"offsets": [
[
63,
72
]
],
"normalized": []
},
{
"id": "80472",
"type": "Intervention_Pharmacological",
"text": [
"indobufen"
],
"offsets": [
[
63,
72
]
],
"normalized": []
},
{
"id": "80473",
"type": "Intervention_Pharmacological",
"text": [
"Indobufen"
],
"offsets": [
[
818,
827
]
],
"normalized": []
},
{
"id": "80474",
"type": "Outcome_Physical",
"text": [
"platelet aggregation and adhesion"
],
"offsets": [
[
26,
59
]
],
"normalized": []
},
{
"id": "80475",
"type": "Outcome_Physical",
"text": [
"platelet functions , coagulation and fibrinolysis tests"
],
"offsets": [
[
412,
467
]
],
"normalized": []
},
{
"id": "80476",
"type": "Outcome_Physical",
"text": [
"enhanced platelet aggregation"
],
"offsets": [
[
579,
608
]
],
"normalized": []
},
{
"id": "80477",
"type": "Outcome_Physical",
"text": [
"platelet adhesiveness"
],
"offsets": [
[
852,
873
]
],
"normalized": []
},
{
"id": "80478",
"type": "Outcome_Physical",
"text": [
"bleeding time"
],
"offsets": [
[
890,
903
]
],
"normalized": []
},
{
"id": "80479",
"type": "Participant_Sample-size",
"text": [
"12"
],
"offsets": [
[
238,
240
]
],
"normalized": []
},
{
"id": "80480",
"type": "Participant_Condition",
"text": [
"atherosclerotic disease"
],
"offsets": [
[
255,
278
]
],
"normalized": []
}
] | [] | [] | [] |
80481 | 7148967 | [
{
"id": "80482",
"type": "document",
"text": [
"A comparison of dorsal and volar resting hand splints in the reduction of hypertonus . Ten adults with hypertonic wrist flexors volunteered as subjects in an experiment comparing the effectiveness of dorsal and volar resting hand splints in the reduction of abnormal muscle tone . Subjects were randomly assigned to two groups of five each . Individuals in one group were fitted with dorsal splints , and individuals in a second group with volar splints . Measurements by spring-weighted scales were taken to assess the efficiency of each splint design in the reduction of hypertonus . Results demonstrated no significant differences between the volar and dorsal splints in reducing hypertonus . However , the age of the subjects was found to be an intervening variable : The older subjects of both groups demonstrated a gradual but not significant decline in hypertonus , whereas the younger adults demonstrated a significant decline in hypertonus over a 6-week period ."
],
"offsets": [
[
0,
971
]
]
}
] | [
{
"id": "80483",
"type": "Intervention_Physical",
"text": [
"dorsal and volar resting hand splints"
],
"offsets": [
[
16,
53
]
],
"normalized": []
},
{
"id": "80484",
"type": "Intervention_Physical",
"text": [
"dorsal and volar resting hand splints"
],
"offsets": [
[
16,
53
]
],
"normalized": []
},
{
"id": "80485",
"type": "Intervention_Physical",
"text": [
"dorsal splints"
],
"offsets": [
[
384,
398
]
],
"normalized": []
},
{
"id": "80486",
"type": "Intervention_Physical",
"text": [
"volar splints"
],
"offsets": [
[
440,
453
]
],
"normalized": []
},
{
"id": "80487",
"type": "Intervention_Physical",
"text": [
"volar and dorsal splints"
],
"offsets": [
[
646,
670
]
],
"normalized": []
},
{
"id": "80488",
"type": "Outcome_Physical",
"text": [
"abnormal muscle tone ."
],
"offsets": [
[
258,
280
]
],
"normalized": []
},
{
"id": "80489",
"type": "Outcome_Physical",
"text": [
"hypertonus ."
],
"offsets": [
[
74,
86
]
],
"normalized": []
},
{
"id": "80490",
"type": "Outcome_Other",
"text": [
"no significant differences"
],
"offsets": [
[
607,
633
]
],
"normalized": []
},
{
"id": "80491",
"type": "Outcome_Physical",
"text": [
"hypertonus"
],
"offsets": [
[
74,
84
]
],
"normalized": []
},
{
"id": "80492",
"type": "Participant_Condition",
"text": [
"hypertonus ."
],
"offsets": [
[
74,
86
]
],
"normalized": []
},
{
"id": "80493",
"type": "Participant_Sample-size",
"text": [
"Ten"
],
"offsets": [
[
87,
90
]
],
"normalized": []
},
{
"id": "80494",
"type": "Participant_Age",
"text": [
"adults"
],
"offsets": [
[
91,
97
]
],
"normalized": []
},
{
"id": "80495",
"type": "Participant_Condition",
"text": [
"hypertonic"
],
"offsets": [
[
103,
113
]
],
"normalized": []
},
{
"id": "80496",
"type": "Participant_Condition",
"text": [
"hypertonus ."
],
"offsets": [
[
74,
86
]
],
"normalized": []
},
{
"id": "80497",
"type": "Participant_Age",
"text": [
"older"
],
"offsets": [
[
776,
781
]
],
"normalized": []
},
{
"id": "80498",
"type": "Participant_Age",
"text": [
"younger adults"
],
"offsets": [
[
885,
899
]
],
"normalized": []
}
] | [] | [] | [] |
80499 | 7159500 | [
{
"id": "80500",
"type": "document",
"text": [
"Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar . The effect of guar ( 15.6 g/day ) , a dietary fibre , and simultaneous administration of bezafibrate ( 600 mg/day ) during dietetic treatment on the plasma lipoproteins and apolipoproteins was investigated in 12 patients with familial hypercholesterolemia ( corresponding to the HLP type IIa pattern ) . Either bezafibrate alone or bezafibrate in combination with guar was administered in a cross-over study for 3 months . Guar led to an additional lowering of the total cholesterol in the plasma by 7 % ( P less than or equal to 0.05 ) associated with a fall of the low density lipoprotein cholesterol ( LDL-cholesterol ( LDL-cholesterol ) by 13 % ( P less than or equal to 0.01 ) without any changes in the very low density lipoprotein ( VLDL ) and high density lipoprotein ( HDL ) cholesterols . In parallel with the decrease in LDL-cholesterol , the apoprotein B also was diminished by 20 % ( P less than or equal to 0.05 ) . The plasma triglyceride level and the triglyceride distribution within the individual lipoprotein fractions were not altered in any consistent manner by the addition of guar . Neither the fasting plasma glucose level nor the body weight were affected . The side-effects due to guar treatment consisted of slight nausea , meteorism and constipation , but this did not in any of the cases lead to early termination of the study . These results demonstrate that guar exerts its cholesterol-lowering effect in addition to that of bezafibrate ."
],
"offsets": [
[
0,
1557
]
]
}
] | [
{
"id": "80501",
"type": "Intervention_Pharmacological",
"text": [
"combination of bezafibrate and guar"
],
"offsets": [
[
50,
85
]
],
"normalized": []
},
{
"id": "80502",
"type": "Intervention_Pharmacological",
"text": [
"guar"
],
"offsets": [
[
81,
85
]
],
"normalized": []
},
{
"id": "80503",
"type": "Intervention_Pharmacological",
"text": [
"a dietary fibre"
],
"offsets": [
[
124,
139
]
],
"normalized": []
},
{
"id": "80504",
"type": "Intervention_Pharmacological",
"text": [
"bezafibrate"
],
"offsets": [
[
65,
76
]
],
"normalized": []
},
{
"id": "80505",
"type": "Intervention_Pharmacological",
"text": [
"Either bezafibrate alone or bezafibrate in combination with guar was administered in a cross-over study for 3 months"
],
"offsets": [
[
392,
508
]
],
"normalized": []
},
{
"id": "80506",
"type": "Intervention_Pharmacological",
"text": [
"Guar"
],
"offsets": [
[
511,
515
]
],
"normalized": []
},
{
"id": "80507",
"type": "Intervention_Pharmacological",
"text": [
"guar ."
],
"offsets": [
[
81,
87
]
],
"normalized": []
},
{
"id": "80508",
"type": "Intervention_Pharmacological",
"text": [
"guar treatment"
],
"offsets": [
[
1295,
1309
]
],
"normalized": []
},
{
"id": "80509",
"type": "Intervention_Pharmacological",
"text": [
"guar"
],
"offsets": [
[
81,
85
]
],
"normalized": []
},
{
"id": "80510",
"type": "Intervention_Pharmacological",
"text": [
"bezafibrate ."
],
"offsets": [
[
1544,
1557
]
],
"normalized": []
},
{
"id": "80511",
"type": "Outcome_Physical",
"text": [
"effect"
],
"offsets": [
[
92,
98
]
],
"normalized": []
},
{
"id": "80512",
"type": "Outcome_Physical",
"text": [
"total cholesterol"
],
"offsets": [
[
553,
570
]
],
"normalized": []
},
{
"id": "80513",
"type": "Outcome_Physical",
"text": [
"low density lipoprotein cholesterol ( LDL-cholesterol"
],
"offsets": [
[
655,
708
]
],
"normalized": []
},
{
"id": "80514",
"type": "Outcome_Physical",
"text": [
"LDL-cholesterol"
],
"offsets": [
[
693,
708
]
],
"normalized": []
},
{
"id": "80515",
"type": "Outcome_Physical",
"text": [
"apoprotein B"
],
"offsets": [
[
942,
954
]
],
"normalized": []
},
{
"id": "80516",
"type": "Outcome_Physical",
"text": [
"plasma triglyceride level and the triglyceride distribution"
],
"offsets": [
[
1022,
1081
]
],
"normalized": []
},
{
"id": "80517",
"type": "Outcome_Physical",
"text": [
"fasting plasma glucose level nor the body weight"
],
"offsets": [
[
1206,
1254
]
],
"normalized": []
},
{
"id": "80518",
"type": "Outcome_Adverse-effects",
"text": [
"slight nausea , meteorism and constipation"
],
"offsets": [
[
1323,
1365
]
],
"normalized": []
},
{
"id": "80519",
"type": "Participant_Condition",
"text": [
"12 patients with familial hypercholesterolemia ( corresponding to the HLP type IIa pattern ) ."
],
"offsets": [
[
297,
391
]
],
"normalized": []
}
] | [] | [] | [] |
80520 | 7174605 | [
{
"id": "80521",
"type": "document",
"text": [
"The effects of haloperidol on learning and behavior in autistic children . The effects of haloperidol on behavioral symptoms and learning were critically assessed in autistic children in an ongoing double-blind placebo-controlled clinical trial . Children were randomly assigned to haloperidol-placebo-haloperidol or placebo-haloperidol-placebo treatment sequences . Statistically , haloperidol was significantly superior to placebo in reducing behavioral symptoms . In discrimination learning paradigm , children receiving haloperidol learned the discrimination while those on placebo did not . Discrimination attained on haloperidol was retained when the children were switched to placebo ."
],
"offsets": [
[
0,
692
]
]
}
] | [
{
"id": "80522",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
15,
26
]
],
"normalized": []
},
{
"id": "80523",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
15,
26
]
],
"normalized": []
},
{
"id": "80524",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
211,
229
]
],
"normalized": []
},
{
"id": "80525",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol-placebo-haloperidol"
],
"offsets": [
[
282,
313
]
],
"normalized": []
},
{
"id": "80526",
"type": "Intervention_Pharmacological",
"text": [
"placebo-haloperidol-placebo"
],
"offsets": [
[
317,
344
]
],
"normalized": []
},
{
"id": "80527",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
15,
26
]
],
"normalized": []
},
{
"id": "80528",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
211,
218
]
],
"normalized": []
},
{
"id": "80529",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
15,
26
]
],
"normalized": []
},
{
"id": "80530",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
211,
218
]
],
"normalized": []
},
{
"id": "80531",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
15,
26
]
],
"normalized": []
},
{
"id": "80532",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
211,
218
]
],
"normalized": []
},
{
"id": "80533",
"type": "Outcome_Mental",
"text": [
"learning and behavior"
],
"offsets": [
[
30,
51
]
],
"normalized": []
},
{
"id": "80534",
"type": "Outcome_Mental",
"text": [
"behavioral symptoms and learning"
],
"offsets": [
[
105,
137
]
],
"normalized": []
},
{
"id": "80535",
"type": "Outcome_Mental",
"text": [
"behavioral symptoms"
],
"offsets": [
[
105,
124
]
],
"normalized": []
},
{
"id": "80536",
"type": "Outcome_Mental",
"text": [
"learned the discrimination"
],
"offsets": [
[
536,
562
]
],
"normalized": []
},
{
"id": "80537",
"type": "Participant_Condition",
"text": [
"autistic children ."
],
"offsets": [
[
55,
74
]
],
"normalized": []
}
] | [] | [] | [] |
80538 | 7196452 | [
{
"id": "80539",
"type": "document",
"text": [
"Menstrual cycle symptoms in infertile and control subjects : a re-evaluation of the evidence for psychological changes ."
],
"offsets": [
[
0,
120
]
]
}
] | [
{
"id": "80540",
"type": "Intervention_Other",
"text": [
"re-evaluation of the evidence"
],
"offsets": [
[
63,
92
]
],
"normalized": []
},
{
"id": "80541",
"type": "Outcome_Physical",
"text": [
"Menstrual cycle symptoms"
],
"offsets": [
[
0,
24
]
],
"normalized": []
},
{
"id": "80542",
"type": "Outcome_Mental",
"text": [
"psychological changes"
],
"offsets": [
[
97,
118
]
],
"normalized": []
},
{
"id": "80543",
"type": "Participant_Condition",
"text": [
"infertile"
],
"offsets": [
[
28,
37
]
],
"normalized": []
},
{
"id": "80544",
"type": "Participant_Condition",
"text": [
"control"
],
"offsets": [
[
42,
49
]
],
"normalized": []
}
] | [] | [] | [] |
80545 | 7200736 | [
{
"id": "80546",
"type": "document",
"text": [
"Prostaglandin E1 as a hypotensive drug during general anaesthesia . Hypotension induced by prostaglandin E1 ( PGE1 ) infusion ( 100-150 ng/kg/minute ) during halothane anaesthesia to reduce operative blood loss during mastectomy was investigated . PGE1 decreased systolic arterial pressure approximately 34 % from pre-administration values . The duration of induced hypotension was about 75 minutes . When the infusion was stopped , blood pressure returned to within 15 % of the control with 15 minutes . Heart rate did not change significantly during PGE1 infusion ; the pre-ejection period and left ventricular ejection period were shortened . Renal function during the hypotensive period was well maintained . Blood loss during surgery was significantly decreased . These findings suggest that PGE1 can be used safely to control arterial pressure during surgery ."
],
"offsets": [
[
0,
866
]
]
}
] | [
{
"id": "80547",
"type": "Intervention_Pharmacological",
"text": [
"prostaglandin E1 ( PGE1 ) infusion"
],
"offsets": [
[
91,
125
]
],
"normalized": []
},
{
"id": "80548",
"type": "Intervention_Pharmacological",
"text": [
"halothane anaesthesia"
],
"offsets": [
[
158,
179
]
],
"normalized": []
},
{
"id": "80549",
"type": "Outcome_Physical",
"text": [
"Hypotension"
],
"offsets": [
[
68,
79
]
],
"normalized": []
},
{
"id": "80550",
"type": "Outcome_Physical",
"text": [
"systolic arterial pressure"
],
"offsets": [
[
263,
289
]
],
"normalized": []
},
{
"id": "80551",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
433,
447
]
],
"normalized": []
},
{
"id": "80552",
"type": "Outcome_Physical",
"text": [
"Heart rate"
],
"offsets": [
[
505,
515
]
],
"normalized": []
},
{
"id": "80553",
"type": "Outcome_Other",
"text": [
"pre-ejection period"
],
"offsets": [
[
572,
591
]
],
"normalized": []
},
{
"id": "80554",
"type": "Outcome_Physical",
"text": [
"left ventricular ejection"
],
"offsets": [
[
596,
621
]
],
"normalized": []
},
{
"id": "80555",
"type": "Outcome_Physical",
"text": [
"Renal function"
],
"offsets": [
[
646,
660
]
],
"normalized": []
},
{
"id": "80556",
"type": "Outcome_Physical",
"text": [
"Blood loss"
],
"offsets": [
[
713,
723
]
],
"normalized": []
},
{
"id": "80557",
"type": "Outcome_Physical",
"text": [
"arterial pressure"
],
"offsets": [
[
272,
289
]
],
"normalized": []
},
{
"id": "80558",
"type": "Participant_Condition",
"text": [
"Prostaglandin E1 as a hypotensive drug during general anaesthesia ."
],
"offsets": [
[
0,
67
]
],
"normalized": []
},
{
"id": "80559",
"type": "Participant_Condition",
"text": [
"mastectomy"
],
"offsets": [
[
218,
228
]
],
"normalized": []
}
] | [] | [] | [] |
80560 | 7205145 | [
{
"id": "80561",
"type": "document",
"text": [
"An evaluation method providing confidence intervals applied to radioimmunoassay . A method for evaluation of radioimmunoassay results is described . The order of the single tubes in each assay run is randomized . A polynomial is fitted to untransformed data ( y = counts per minute ; x = concentration of curve.A confidence interval is calculated for each sample , taking into account the variance of the standard curve and that of the actual duplicate assay jointly ."
],
"offsets": [
[
0,
468
]
]
}
] | [
{
"id": "80562",
"type": "Intervention_Physical",
"text": [
"radioimmunoassay"
],
"offsets": [
[
63,
79
]
],
"normalized": []
},
{
"id": "80563",
"type": "Intervention_Physical",
"text": [
"evaluation of radioimmunoassay"
],
"offsets": [
[
95,
125
]
],
"normalized": []
},
{
"id": "80564",
"type": "Intervention_Physical",
"text": [
"single tubes"
],
"offsets": [
[
166,
178
]
],
"normalized": []
}
] | [] | [] | [] |
80565 | 7208897 | [
{
"id": "80566",
"type": "document",
"text": [
"Breast cancer screening in Sweden . The single modality approach . Four population-based breast cancer screening projects are in progress in Sweden , three of which are randomized studies . Mammography is the only screening method . 51 % of all carcinomas detected at the first screening were either in situ or invasive with a diameter of 10 mm or less . Axillary metastases were found in 16 % of the patients . Sensitivity was over 90 % in all projects . The ultimate aim of the randomized projects is to demonstrate the effect of screening on breast cancer mortality . It is estimated that mortality statistics will reach significant levels in 1983. ,"
],
"offsets": [
[
0,
653
]
]
}
] | [
{
"id": "80567",
"type": "Intervention_Physical",
"text": [
"screening"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "80568",
"type": "Intervention_Physical",
"text": [
"Mammography"
],
"offsets": [
[
190,
201
]
],
"normalized": []
},
{
"id": "80569",
"type": "Intervention_Physical",
"text": [
"screening"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "80570",
"type": "Outcome_Physical",
"text": [
"Axillary metastases"
],
"offsets": [
[
355,
374
]
],
"normalized": []
},
{
"id": "80571",
"type": "Outcome_Physical",
"text": [
"Sensitivity"
],
"offsets": [
[
412,
423
]
],
"normalized": []
},
{
"id": "80572",
"type": "Outcome_Mortality",
"text": [
"effect of screening on breast cancer mortality"
],
"offsets": [
[
522,
568
]
],
"normalized": []
},
{
"id": "80573",
"type": "Outcome_Mortality",
"text": [
"mortality statistics"
],
"offsets": [
[
592,
612
]
],
"normalized": []
},
{
"id": "80574",
"type": "Participant_Condition",
"text": [
"Breast cancer screening"
],
"offsets": [
[
0,
23
]
],
"normalized": []
},
{
"id": "80575",
"type": "Participant_Condition",
"text": [
"Sweden ."
],
"offsets": [
[
27,
35
]
],
"normalized": []
}
] | [] | [] | [] |
80576 | 7211918 | [
{
"id": "80577",
"type": "document",
"text": [
"Heparin therapy in venous thromboembolism . Patients with pulmonary embolism or deep venous thrombosis were randomly assigned to receive either intermittent or continuous intravenous heparin therapy . In patients with an enhanced risk of bleeding , major bleeding was significantly more common during the intermittent use of heparin ; in patients without these risk factors , hemorrhage occurred with equal frequency during intermittent and continuous heparin therapy . Recurrent thromboembolism was seen significantly more often in patients receiving continuous heparin therapy . Controlling the dose of heparin with coagulation tests resulted in the administration of significantly larger daily doses of heparin with intermittent injections than with continuous infusion . Therefore , the bleeding complications of intermittent heparin therapy could have been due to the higher dose , and the recurrences associated with continuous heparin therapy may have resulted from lower doses rather than from differences in the method of administration . In a small trial , arbitrary lower doses of heparin given intermittently similar to the doses of heparin given continuously resulted in fewer bleeding complications and more recurrences . In patients without risk factors for bleeding , the intermittent administration of heparin in the higher dose is preferable because of fewer recurrences and no increase in hemorrhagic complications . In patients with a high risk of bleeding , conventional doses of heparin given continuously can reduce the rate of hemorrhagic complications but will result in more recurrences ."
],
"offsets": [
[
0,
1614
]
]
}
] | [
{
"id": "80578",
"type": "Intervention_Pharmacological",
"text": [
"Heparin"
],
"offsets": [
[
0,
7
]
],
"normalized": []
},
{
"id": "80579",
"type": "Intervention_Pharmacological",
"text": [
"intermittent or continuous intravenous heparin therapy"
],
"offsets": [
[
144,
198
]
],
"normalized": []
},
{
"id": "80580",
"type": "Intervention_Pharmacological",
"text": [
"continuous heparin therapy"
],
"offsets": [
[
441,
467
]
],
"normalized": []
},
{
"id": "80581",
"type": "Intervention_Pharmacological",
"text": [
"heparin"
],
"offsets": [
[
183,
190
]
],
"normalized": []
},
{
"id": "80582",
"type": "Intervention_Pharmacological",
"text": [
"heparin"
],
"offsets": [
[
183,
190
]
],
"normalized": []
},
{
"id": "80583",
"type": "Outcome_Physical",
"text": [
"bleeding"
],
"offsets": [
[
238,
246
]
],
"normalized": []
},
{
"id": "80584",
"type": "Outcome_Physical",
"text": [
"hemorrhage"
],
"offsets": [
[
376,
386
]
],
"normalized": []
},
{
"id": "80585",
"type": "Outcome_Physical",
"text": [
"Recurrent thromboembolism"
],
"offsets": [
[
470,
495
]
],
"normalized": []
},
{
"id": "80586",
"type": "Outcome_Physical",
"text": [
"bleeding complications"
],
"offsets": [
[
791,
813
]
],
"normalized": []
},
{
"id": "80587",
"type": "Outcome_Physical",
"text": [
"recurrences ."
],
"offsets": [
[
1222,
1235
]
],
"normalized": []
},
{
"id": "80588",
"type": "Outcome_Physical",
"text": [
"hemorrhagic complications ."
],
"offsets": [
[
1408,
1435
]
],
"normalized": []
},
{
"id": "80589",
"type": "Outcome_Physical",
"text": [
"rate of hemorrhagic complications"
],
"offsets": [
[
1543,
1576
]
],
"normalized": []
}
] | [] | [] | [] |
80590 | 7218018 | [
{
"id": "80591",
"type": "document",
"text": [
"Are oral cathartics of value in optimizing the gallium scan ? Concise communication . The normal intestinal secretion of 9-15 % of an administered dose of gallium-67 may prevent early detection of intra-abdominal disease . We randomized 50 patients to receive either no bowel preparation or 30 cc of milk of magnesia plus 5 cc of cascara . No significant difference was found between the two groups in frequency with which gallium interfered with readings or time to complete the study ."
],
"offsets": [
[
0,
487
]
]
}
] | [
{
"id": "80592",
"type": "Intervention_Pharmacological",
"text": [
"gallium-67"
],
"offsets": [
[
155,
165
]
],
"normalized": []
},
{
"id": "80593",
"type": "Intervention_Pharmacological",
"text": [
"30 cc of milk of magnesia"
],
"offsets": [
[
291,
316
]
],
"normalized": []
},
{
"id": "80594",
"type": "Intervention_Pharmacological",
"text": [
"5 cc of cascara"
],
"offsets": [
[
322,
337
]
],
"normalized": []
},
{
"id": "80595",
"type": "Outcome_Physical",
"text": [
"frequency with which gallium interfered with readings or time to complete the study ."
],
"offsets": [
[
402,
487
]
],
"normalized": []
},
{
"id": "80596",
"type": "Participant_Condition",
"text": [
"randomized"
],
"offsets": [
[
226,
236
]
],
"normalized": []
},
{
"id": "80597",
"type": "Participant_Sample-size",
"text": [
"50"
],
"offsets": [
[
237,
239
]
],
"normalized": []
}
] | [] | [] | [] |
80598 | 7219904 | [
{
"id": "80599",
"type": "document",
"text": [
"The effects of prophylactic management and therapeutics on hypertensive disease in pregnancy : preliminary studies . A controlled prospective evaluation of pregnancy complicated by chronic hypertension is proposed and preliminary data on population selection and pregnancy outcome are presented . Sixty-three women with evidence of underlying hypertensive disease were followed prospectively throughout pregnancy . Twenty-three patients were followed in a protocol of intensified prenatal care and randomized assignment of antihypertensive agents : placebo , hydralazine , or methyldopa . Forty patients were followed in the high-risk pregnancy clinics at Duke University . The incidence of preeclampsia in the randomized prophylactic antihypertensive group was statistically lower than that in the nonrandomized group ( 8.7 versus 32.5 % ; P less than .01 ) . There were no other statistically significant differences between the groups . The 63 hypertensive women had a high incidence of diabetes mellitus diagnosed during pregnancy ( 49.2 % ) as compared to the authors ' general obstetric population ( 8.1 % ) ."
],
"offsets": [
[
0,
1115
]
]
}
] | [
{
"id": "80600",
"type": "Intervention_Psychological",
"text": [
"prophylactic management and therapeutics"
],
"offsets": [
[
15,
55
]
],
"normalized": []
},
{
"id": "80601",
"type": "Intervention_Pharmacological",
"text": [
"antihypertensive agents : placebo , hydralazine , or methyldopa"
],
"offsets": [
[
523,
586
]
],
"normalized": []
},
{
"id": "80602",
"type": "Outcome_Adverse-effects",
"text": [
"effects"
],
"offsets": [
[
4,
11
]
],
"normalized": []
},
{
"id": "80603",
"type": "Outcome_Physical",
"text": [
"hypertensive disease"
],
"offsets": [
[
59,
79
]
],
"normalized": []
},
{
"id": "80604",
"type": "Outcome_Other",
"text": [
"population selection"
],
"offsets": [
[
238,
258
]
],
"normalized": []
},
{
"id": "80605",
"type": "Outcome_Physical",
"text": [
"incidence of preeclampsia"
],
"offsets": [
[
678,
703
]
],
"normalized": []
},
{
"id": "80606",
"type": "Outcome_Physical",
"text": [
"diabetes mellitus"
],
"offsets": [
[
990,
1007
]
],
"normalized": []
},
{
"id": "80607",
"type": "Participant_Condition",
"text": [
"hypertensive disease"
],
"offsets": [
[
59,
79
]
],
"normalized": []
},
{
"id": "80608",
"type": "Participant_Sample-size",
"text": [
"Sixty-three"
],
"offsets": [
[
297,
308
]
],
"normalized": []
},
{
"id": "80609",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
309,
314
]
],
"normalized": []
},
{
"id": "80610",
"type": "Participant_Condition",
"text": [
"hypertensive disease"
],
"offsets": [
[
59,
79
]
],
"normalized": []
},
{
"id": "80611",
"type": "Participant_Sample-size",
"text": [
"Forty"
],
"offsets": [
[
589,
594
]
],
"normalized": []
},
{
"id": "80612",
"type": "Participant_Sample-size",
"text": [
"63"
],
"offsets": [
[
944,
946
]
],
"normalized": []
},
{
"id": "80613",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
59,
71
]
],
"normalized": []
}
] | [] | [] | [] |
80614 | 7235205 | [
{
"id": "80615",
"type": "document",
"text": [
"Theophylline concentrations in serum and saliva after oral microcrystalline and sustained-release preparations in asthmatics . Theophylline concentrations in saliva have been compared with those in serum in 13 asthmatic patients after single and multiple oral dosage of a microcrystalline theophylline tablet ( Nuelin ) and a sustained-release preparation ( Nuelin Retard ) . There was wide individual variation in the ratio of serum to saliva concentrations indicating that , even when individual serum to saliva ratios have been established , the use of saliva theophylline measurements alone is unreliable for the routine monitoring of theophylline therapy . Both preparations produced mean serum theophylline concentrations within the 10 -- 20 mcg/ml range , the sustained-release tablet giving higher monitoring through values and smaller through to peak variation . The preparations were equally and highly bioavailable . Side effects were reported by three patients , which were the patients with the highest AUC . The Nuelin Retard preparation appears to provide smooth , sustained serum theophylline concentrations within the therapeutic range and the simple , twice-daily dosage should result in improved patient compliance ."
],
"offsets": [
[
0,
1235
]
]
}
] | [
{
"id": "80616",
"type": "Intervention_Pharmacological",
"text": [
"Theophylline"
],
"offsets": [
[
0,
12
]
],
"normalized": []
},
{
"id": "80617",
"type": "Intervention_Pharmacological",
"text": [
"microcrystalline"
],
"offsets": [
[
59,
75
]
],
"normalized": []
},
{
"id": "80618",
"type": "Intervention_Pharmacological",
"text": [
"sustained-release preparations"
],
"offsets": [
[
80,
110
]
],
"normalized": []
},
{
"id": "80619",
"type": "Intervention_Pharmacological",
"text": [
"Theophylline"
],
"offsets": [
[
0,
12
]
],
"normalized": []
},
{
"id": "80620",
"type": "Intervention_Pharmacological",
"text": [
"microcrystalline theophylline tablet"
],
"offsets": [
[
272,
308
]
],
"normalized": []
},
{
"id": "80621",
"type": "Intervention_Pharmacological",
"text": [
"sustained-release preparation"
],
"offsets": [
[
80,
109
]
],
"normalized": []
},
{
"id": "80622",
"type": "Intervention_Pharmacological",
"text": [
"theophylline"
],
"offsets": [
[
289,
301
]
],
"normalized": []
},
{
"id": "80623",
"type": "Intervention_Pharmacological",
"text": [
"theophylline"
],
"offsets": [
[
289,
301
]
],
"normalized": []
},
{
"id": "80624",
"type": "Intervention_Pharmacological",
"text": [
"Nuelin Retard"
],
"offsets": [
[
358,
371
]
],
"normalized": []
},
{
"id": "80625",
"type": "Outcome_Physical",
"text": [
"Theophylline concentrations"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "80626",
"type": "Outcome_Physical",
"text": [
"Theophylline concentrations"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "80627",
"type": "Outcome_Physical",
"text": [
"ratio of serum to saliva concentrations"
],
"offsets": [
[
419,
458
]
],
"normalized": []
},
{
"id": "80628",
"type": "Outcome_Physical",
"text": [
"mean serum theophylline concentrations"
],
"offsets": [
[
689,
727
]
],
"normalized": []
},
{
"id": "80629",
"type": "Outcome_Adverse-effects",
"text": [
"Side effects"
],
"offsets": [
[
928,
940
]
],
"normalized": []
},
{
"id": "80630",
"type": "Outcome_Physical",
"text": [
"serum theophylline concentrations"
],
"offsets": [
[
694,
727
]
],
"normalized": []
},
{
"id": "80631",
"type": "Participant_Condition",
"text": [
"asthmatics"
],
"offsets": [
[
114,
124
]
],
"normalized": []
},
{
"id": "80632",
"type": "Participant_Sample-size",
"text": [
"13"
],
"offsets": [
[
207,
209
]
],
"normalized": []
},
{
"id": "80633",
"type": "Participant_Condition",
"text": [
"asthmatic"
],
"offsets": [
[
114,
123
]
],
"normalized": []
}
] | [] | [] | [] |
80634 | 7259216 | [
{
"id": "80635",
"type": "document",
"text": [
"Topical treatment of alopecia areata . It has been shown previously that alopecia areata can be treated with dinitrochlorobenzene ( DNCB ) and other contact allergens . Whether these agents work by inducing immunologic stimulation or simply a nonspecific inflammatory reaction has not been definitively demonstrated . To test the relative importance of these two mechanisms , we have randomly studied 22 patients with alopecia areata to whom either DNCB or croton oil was applied topically . Sixty-three percent of patients without spontaneous regrowth of hair regrew hair after DNCB application . None of those treated with croton oil regrew hair when treated later with DNCB . Therefore , a proved contact allergen was shown to be required for therapeutic success . Patient acceptance of the induced contact dermatitis was excellent . In light of recent data on the mutagenicity of DNCB to bacteria , other contact allergens for topical immunotherapy are being sought ."
],
"offsets": [
[
0,
971
]
]
}
] | [
{
"id": "80636",
"type": "Intervention_Pharmacological",
"text": [
"Topical treatment"
],
"offsets": [
[
0,
17
]
],
"normalized": []
},
{
"id": "80637",
"type": "Intervention_Pharmacological",
"text": [
"dinitrochlorobenzene ( DNCB )"
],
"offsets": [
[
109,
138
]
],
"normalized": []
},
{
"id": "80638",
"type": "Intervention_Pharmacological",
"text": [
"contact allergens"
],
"offsets": [
[
149,
166
]
],
"normalized": []
},
{
"id": "80639",
"type": "Intervention_Pharmacological",
"text": [
"DNCB"
],
"offsets": [
[
132,
136
]
],
"normalized": []
},
{
"id": "80640",
"type": "Intervention_Pharmacological",
"text": [
"croton oil"
],
"offsets": [
[
457,
467
]
],
"normalized": []
},
{
"id": "80641",
"type": "Intervention_Pharmacological",
"text": [
"croton oil"
],
"offsets": [
[
457,
467
]
],
"normalized": []
},
{
"id": "80642",
"type": "Intervention_Pharmacological",
"text": [
"DNCB"
],
"offsets": [
[
132,
136
]
],
"normalized": []
},
{
"id": "80643",
"type": "Intervention_Pharmacological",
"text": [
"DNCB"
],
"offsets": [
[
132,
136
]
],
"normalized": []
},
{
"id": "80644",
"type": "Outcome_Physical",
"text": [
"regrowth of hair regrew hair"
],
"offsets": [
[
544,
572
]
],
"normalized": []
},
{
"id": "80645",
"type": "Outcome_Physical",
"text": [
"None"
],
"offsets": [
[
598,
602
]
],
"normalized": []
},
{
"id": "80646",
"type": "Outcome_Physical",
"text": [
"regrew hair"
],
"offsets": [
[
561,
572
]
],
"normalized": []
},
{
"id": "80647",
"type": "Outcome_Mental",
"text": [
"Patient acceptance"
],
"offsets": [
[
768,
786
]
],
"normalized": []
},
{
"id": "80648",
"type": "Participant_Condition",
"text": [
"22 patients with alopecia areata to whom either DNCB or croton oil was applied topically ."
],
"offsets": [
[
401,
491
]
],
"normalized": []
}
] | [] | [] | [] |
80649 | 7272152 | [
{
"id": "80650",
"type": "document",
"text": [
"Single and combined effects of atropine and metoclopramide on the lower oesophageal sphincter pressure . The effects of atropine and metoclopramide on the lower oesophageal sphincter pressure ( LOSP ) were studied in 12 healthy volunteers using oesophageal pressure transducers . Atropine decreased LOSP significantly at 5 min after i.v . injection ( P less than 0.005 ) and this change was sustained for 60 min . Metoclopramide increased LOSP significantly at 3 min after administration i.v . ( P less than 0.05 ) and this change was sustained for 40 min . Following consecutive administration of the drugs the effects of atropine predominated ."
],
"offsets": [
[
0,
646
]
]
}
] | [
{
"id": "80651",
"type": "Intervention_Pharmacological",
"text": [
"atropine"
],
"offsets": [
[
31,
39
]
],
"normalized": []
},
{
"id": "80652",
"type": "Intervention_Pharmacological",
"text": [
"metoclopramide"
],
"offsets": [
[
44,
58
]
],
"normalized": []
},
{
"id": "80653",
"type": "Intervention_Pharmacological",
"text": [
"atropine"
],
"offsets": [
[
31,
39
]
],
"normalized": []
},
{
"id": "80654",
"type": "Intervention_Pharmacological",
"text": [
"metoclopramide"
],
"offsets": [
[
44,
58
]
],
"normalized": []
},
{
"id": "80655",
"type": "Intervention_Pharmacological",
"text": [
"Atropine"
],
"offsets": [
[
280,
288
]
],
"normalized": []
},
{
"id": "80656",
"type": "Intervention_Pharmacological",
"text": [
"Metoclopramide"
],
"offsets": [
[
414,
428
]
],
"normalized": []
},
{
"id": "80657",
"type": "Intervention_Pharmacological",
"text": [
"atropine"
],
"offsets": [
[
31,
39
]
],
"normalized": []
},
{
"id": "80658",
"type": "Outcome_Physical",
"text": [
"lower oesophageal sphincter pressure ( LOSP )"
],
"offsets": [
[
155,
200
]
],
"normalized": []
},
{
"id": "80659",
"type": "Outcome_Physical",
"text": [
"LOSP"
],
"offsets": [
[
194,
198
]
],
"normalized": []
},
{
"id": "80660",
"type": "Outcome_Physical",
"text": [
"LOSP"
],
"offsets": [
[
194,
198
]
],
"normalized": []
},
{
"id": "80661",
"type": "Participant_Sample-size",
"text": [
"12"
],
"offsets": [
[
217,
219
]
],
"normalized": []
},
{
"id": "80662",
"type": "Participant_Condition",
"text": [
"healthy volunteers using oesophageal pressure transducers ."
],
"offsets": [
[
220,
279
]
],
"normalized": []
}
] | [] | [] | [] |
80663 | 7285032 | [
{
"id": "80664",
"type": "document",
"text": [
"[ Changes in renal arterial flow during the treatment of essential arterial hypertension ; prazosin in comparison with propranolol ] ."
],
"offsets": [
[
0,
134
]
]
}
] | [
{
"id": "80665",
"type": "Intervention_Pharmacological",
"text": [
"prazosin"
],
"offsets": [
[
91,
99
]
],
"normalized": []
},
{
"id": "80666",
"type": "Intervention_Pharmacological",
"text": [
"propranolol"
],
"offsets": [
[
119,
130
]
],
"normalized": []
},
{
"id": "80667",
"type": "Outcome_Physical",
"text": [
"renal arterial flow"
],
"offsets": [
[
13,
32
]
],
"normalized": []
},
{
"id": "80668",
"type": "Participant_Condition",
"text": [
"essential arterial hypertension ; prazosin in comparison with propranolol"
],
"offsets": [
[
57,
130
]
],
"normalized": []
}
] | [] | [] | [] |
80669 | 7298122 | [
{
"id": "80670",
"type": "document",
"text": [
"Changing sodium intake in children . The Minneapolis Children 's Blood Pressure Study . To assess the effects of modifying dietary sodium intake , 80 school children with blood pressures above the 95th percentile for age and sex but below 130/90 mm Hg at school screening were randomized to a family intervention program or a control group . Twenty children aged 6 to 9 years and their families began a program to modify the family diet toward a goal of 70 mEq sodium per person per day . Adherence was assessed by 3-day food records and urine collections in children and adults . The sodium intakes and blood pressures of the intervention and control group were compared 1 year after randomization . Sodium intake was significantly lower in the intervention group only in the active participants as compared to dropouts and controls ( 87 vs 130 and 133 mmoles/24 hr ) . There were no significant differences between the groups in height , weight , or blood pressure ."
],
"offsets": [
[
0,
968
]
]
}
] | [
{
"id": "80671",
"type": "Intervention_Educational",
"text": [
"family intervention program"
],
"offsets": [
[
293,
320
]
],
"normalized": []
},
{
"id": "80672",
"type": "Intervention_Control",
"text": [
"control group"
],
"offsets": [
[
326,
339
]
],
"normalized": []
},
{
"id": "80673",
"type": "Outcome_Mental",
"text": [
"Adherence"
],
"offsets": [
[
489,
498
]
],
"normalized": []
},
{
"id": "80674",
"type": "Outcome_Other",
"text": [
"3-day food records and urine collections in children and adults"
],
"offsets": [
[
515,
578
]
],
"normalized": []
},
{
"id": "80675",
"type": "Outcome_Mental",
"text": [
"sodium intakes"
],
"offsets": [
[
585,
599
]
],
"normalized": []
},
{
"id": "80676",
"type": "Outcome_Physical",
"text": [
"blood pressures"
],
"offsets": [
[
171,
186
]
],
"normalized": []
},
{
"id": "80677",
"type": "Outcome_Mental",
"text": [
"Sodium intake"
],
"offsets": [
[
701,
714
]
],
"normalized": []
},
{
"id": "80678",
"type": "Outcome_Physical",
"text": [
"height"
],
"offsets": [
[
931,
937
]
],
"normalized": []
},
{
"id": "80679",
"type": "Outcome_Physical",
"text": [
"weight"
],
"offsets": [
[
940,
946
]
],
"normalized": []
},
{
"id": "80680",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
171,
185
]
],
"normalized": []
},
{
"id": "80681",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
26,
34
]
],
"normalized": []
},
{
"id": "80682",
"type": "Participant_Sample-size",
"text": [
"80"
],
"offsets": [
[
147,
149
]
],
"normalized": []
},
{
"id": "80683",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
26,
34
]
],
"normalized": []
},
{
"id": "80684",
"type": "Participant_Condition",
"text": [
"blood pressures above the 95th percentile for age and sex but below 130/90 mm Hg"
],
"offsets": [
[
171,
251
]
],
"normalized": []
},
{
"id": "80685",
"type": "Participant_Sample-size",
"text": [
"Twenty"
],
"offsets": [
[
342,
348
]
],
"normalized": []
},
{
"id": "80686",
"type": "Participant_Age",
"text": [
"children aged 6 to 9 years"
],
"offsets": [
[
349,
375
]
],
"normalized": []
}
] | [] | [] | [] |
80687 | 7326194 | [
{
"id": "80688",
"type": "document",
"text": [
"Lower relapse rates after neighbourhood injection of Corynebacterium parvum in operable cervix carcinoma . The effect of adjuvant immunotherapy with a single neighbourhood injection of 2 mg C. parvum ( CP ) was investigated in a randomized study involving 43 patients with carcinoma of the cervix uteri , all of whom were treated by radical surgery . All patients had carcinoma confined to the cervix , the upper part of the vagina or the parametrial region . When the malignancy had spread to the parametrial region , additional postoperative radiotherapy was given . 22 patients received immunotherapy 10 days before surgery , whereas the remaining 21 control patients received no immune stimulation . Only minor side effects of CP were encountered . Follow-up shows a relapse rate of 5 % in the CP treated group and of 29 % in the controls ( P less than 0.05 ) . A further 15 patients with more advanced malignancies were added to our studies . In these , CP stimulation had no effect on relapse rates , but the relapse-free intervals were longer after immune stimulation : control 3.5 months ( mean ) +/- 1.5 ( s.d . ) , CP 13.0 months +/- 7.0 ( P less than 0.05 ) . The number of peripheral T cells and the ability to become sensitized to DNCB were increased after CP stimulation . A decrease was found in the number of blood monocytes and the number of monocytes capable of transforming into active macrophages , indicating a possible sequestration of these cells in the tissues ."
],
"offsets": [
[
0,
1486
]
]
}
] | [
{
"id": "80689",
"type": "Intervention_Pharmacological",
"text": [
"Corynebacterium parvum"
],
"offsets": [
[
53,
75
]
],
"normalized": []
},
{
"id": "80690",
"type": "Intervention_Pharmacological",
"text": [
"parvum ( CP )"
],
"offsets": [
[
193,
206
]
],
"normalized": []
},
{
"id": "80691",
"type": "Intervention_Surgical",
"text": [
"radical surgery"
],
"offsets": [
[
333,
348
]
],
"normalized": []
},
{
"id": "80692",
"type": "Intervention_Physical",
"text": [
"postoperative radiotherapy"
],
"offsets": [
[
530,
556
]
],
"normalized": []
},
{
"id": "80693",
"type": "Intervention_Pharmacological",
"text": [
"immunotherapy"
],
"offsets": [
[
130,
143
]
],
"normalized": []
},
{
"id": "80694",
"type": "Intervention_Control",
"text": [
"no immune stimulation"
],
"offsets": [
[
680,
701
]
],
"normalized": []
},
{
"id": "80695",
"type": "Intervention_Pharmacological",
"text": [
"CP stimulation"
],
"offsets": [
[
959,
973
]
],
"normalized": []
},
{
"id": "80696",
"type": "Intervention_Pharmacological",
"text": [
"immune stimulation"
],
"offsets": [
[
683,
701
]
],
"normalized": []
},
{
"id": "80697",
"type": "Intervention_Pharmacological",
"text": [
"CP stimulation"
],
"offsets": [
[
959,
973
]
],
"normalized": []
},
{
"id": "80698",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
715,
727
]
],
"normalized": []
},
{
"id": "80699",
"type": "Outcome_Physical",
"text": [
"relapse rate"
],
"offsets": [
[
6,
18
]
],
"normalized": []
},
{
"id": "80700",
"type": "Outcome_Physical",
"text": [
"relapse rates"
],
"offsets": [
[
6,
19
]
],
"normalized": []
},
{
"id": "80701",
"type": "Outcome_Physical",
"text": [
"relapse-free intervals"
],
"offsets": [
[
1015,
1037
]
],
"normalized": []
},
{
"id": "80702",
"type": "Outcome_Physical",
"text": [
"number of peripheral T cells and the ability to become sensitized to DNCB"
],
"offsets": [
[
1175,
1248
]
],
"normalized": []
},
{
"id": "80703",
"type": "Outcome_Physical",
"text": [
"number of blood monocytes and the number of monocytes capable of transforming into active macrophages"
],
"offsets": [
[
1315,
1416
]
],
"normalized": []
},
{
"id": "80704",
"type": "Participant_Condition",
"text": [
"43 patients with carcinoma of the cervix uteri , all of whom were treated by radical surgery ."
],
"offsets": [
[
256,
350
]
],
"normalized": []
}
] | [] | [] | [] |
80705 | 7381634 | [
{
"id": "80706",
"type": "document",
"text": [
"Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis ? A controlled study was designed to clarify the indications for antibiotic therapy in children with advanced cystic fibrosis hospitalized with respiratory exacerbations . Twenty-two children with severe CF and signs of acute lower respiratory infection were randomly assigned to receive either cloxacillin or carbenicillin plus gentamicin administered intravenously for ten days . Other aspects of therapy were constant . The groups were comparable in all respects and Pseudomonas aeruginosa was the predominant sputum pathogen in most patients . Clinical improvement , chest radiograph changes , evidence of airway obstruction , and bacteriologic flora of sputum were no different regardless of the regimen used . These results suggest that the use of anti-Pseudomonas medication in these children may not always be necessary . These observations need to be confirmed by blind-controlled studies in larger numbers of patients with mild as well as severe respiratory involvement ."
],
"offsets": [
[
0,
1087
]
]
}
] | [
{
"id": "80707",
"type": "Intervention_Pharmacological",
"text": [
"cloxacillin"
],
"offsets": [
[
401,
412
]
],
"normalized": []
},
{
"id": "80708",
"type": "Intervention_Pharmacological",
"text": [
"carbenicillin plus gentamicin"
],
"offsets": [
[
416,
445
]
],
"normalized": []
},
{
"id": "80709",
"type": "Outcome_Physical",
"text": [
"respiratory exacerbations"
],
"offsets": [
[
47,
72
]
],
"normalized": []
},
{
"id": "80710",
"type": "Outcome_Physical",
"text": [
"Clinical improvement , chest radiograph changes , evidence of airway obstruction , and bacteriologic flora of sputum"
],
"offsets": [
[
654,
770
]
],
"normalized": []
},
{
"id": "80711",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
76,
84
]
],
"normalized": []
},
{
"id": "80712",
"type": "Participant_Condition",
"text": [
"cystic fibrosis"
],
"offsets": [
[
90,
105
]
],
"normalized": []
},
{
"id": "80713",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
76,
84
]
],
"normalized": []
},
{
"id": "80714",
"type": "Participant_Condition",
"text": [
"advanced cystic fibrosis hospitalized"
],
"offsets": [
[
207,
244
]
],
"normalized": []
},
{
"id": "80715",
"type": "Participant_Condition",
"text": [
"respiratory exacerbations"
],
"offsets": [
[
47,
72
]
],
"normalized": []
},
{
"id": "80716",
"type": "Participant_Sample-size",
"text": [
"Twenty-two"
],
"offsets": [
[
278,
288
]
],
"normalized": []
},
{
"id": "80717",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
76,
84
]
],
"normalized": []
},
{
"id": "80718",
"type": "Participant_Condition",
"text": [
"severe CF"
],
"offsets": [
[
303,
312
]
],
"normalized": []
},
{
"id": "80719",
"type": "Participant_Condition",
"text": [
"acute lower respiratory infection"
],
"offsets": [
[
326,
359
]
],
"normalized": []
}
] | [] | [] | [] |
80720 | 7388581 | [
{
"id": "80721",
"type": "document",
"text": [
"Vaginal pH and microflora related to yeast infections and treatment . The relationship between vaginal pH , microflora , and yeast infection was investigated in 93 women randomly treated with either nystatin or miconazole pessaries and cream for two weeks . The vaginal pH was measured in a control group of 48 women . In the study group , 37 patients defaulted , 39 were cured , and 17 required treatment during the six-month follow-up period . In both study and control groups before and after treatment the mean vaginal pH was in the range of 4.3-4.6 . Lactobacilli were plentiful in 78 ( 91 % ) out of 86 patients and shows that lactobacilli and yeasts commonly coexist . The influence of other organisms appeared to be negligible . The trial showed that nystatin and micromazole were equallly effective in the treatment of vaginal yeast infection and that the broad-spectrum activity of micronazole offered no advantage in this condition ."
],
"offsets": [
[
0,
944
]
]
}
] | [
{
"id": "80722",
"type": "Intervention_Pharmacological",
"text": [
"nystatin"
],
"offsets": [
[
199,
207
]
],
"normalized": []
},
{
"id": "80723",
"type": "Intervention_Pharmacological",
"text": [
"miconazole pessaries and cream"
],
"offsets": [
[
211,
241
]
],
"normalized": []
},
{
"id": "80724",
"type": "Intervention_Pharmacological",
"text": [
"micronazole"
],
"offsets": [
[
892,
903
]
],
"normalized": []
},
{
"id": "80725",
"type": "Outcome_Physical",
"text": [
"Vaginal pH and microflora"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "80726",
"type": "Outcome_Physical",
"text": [
"vaginal pH , microflora"
],
"offsets": [
[
95,
118
]
],
"normalized": []
},
{
"id": "80727",
"type": "Outcome_Physical",
"text": [
"vaginal pH"
],
"offsets": [
[
95,
105
]
],
"normalized": []
},
{
"id": "80728",
"type": "Outcome_Physical",
"text": [
"mean vaginal pH"
],
"offsets": [
[
510,
525
]
],
"normalized": []
},
{
"id": "80729",
"type": "Outcome_Physical",
"text": [
"Lactobacilli"
],
"offsets": [
[
556,
568
]
],
"normalized": []
},
{
"id": "80730",
"type": "Outcome_Other",
"text": [
"effective"
],
"offsets": [
[
798,
807
]
],
"normalized": []
},
{
"id": "80731",
"type": "Participant_Condition",
"text": [
"yeast infections"
],
"offsets": [
[
37,
53
]
],
"normalized": []
},
{
"id": "80732",
"type": "Participant_Sample-size",
"text": [
"93"
],
"offsets": [
[
161,
163
]
],
"normalized": []
},
{
"id": "80733",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
164,
169
]
],
"normalized": []
},
{
"id": "80734",
"type": "Participant_Condition",
"text": [
"randomly treated with either nystatin or miconazole pessaries and cream for two weeks"
],
"offsets": [
[
170,
255
]
],
"normalized": []
},
{
"id": "80735",
"type": "Participant_Sample-size",
"text": [
"48"
],
"offsets": [
[
308,
310
]
],
"normalized": []
},
{
"id": "80736",
"type": "Participant_Sex",
"text": [
"women ."
],
"offsets": [
[
311,
318
]
],
"normalized": []
}
] | [] | [] | [] |
80737 | 7390376 | [
{
"id": "80738",
"type": "document",
"text": [
"[ Obstetrical analgesia with tramadol ] . Parenteral analgesia with Tramal was performed in 23 normal deliveries . The results were compared with a group of normal deliveries in which analgesia was achieved with pethidine . Both medicaments excerted an identical analgetic efficiency . No adverse side effects were observed with Tramal concerning the follow-up of labour or the newborn . Tramal can be recommended for obstetrical analgesia since it does not excert inhibitory effects upon the respiratory center ."
],
"offsets": [
[
0,
513
]
]
}
] | [
{
"id": "80739",
"type": "Intervention_Pharmacological",
"text": [
"tramadol"
],
"offsets": [
[
29,
37
]
],
"normalized": []
},
{
"id": "80740",
"type": "Intervention_Pharmacological",
"text": [
"Tramal"
],
"offsets": [
[
68,
74
]
],
"normalized": []
},
{
"id": "80741",
"type": "Intervention_Pharmacological",
"text": [
"pethidine"
],
"offsets": [
[
212,
221
]
],
"normalized": []
},
{
"id": "80742",
"type": "Intervention_Pharmacological",
"text": [
"Tramal"
],
"offsets": [
[
68,
74
]
],
"normalized": []
},
{
"id": "80743",
"type": "Intervention_Pharmacological",
"text": [
"Tramal"
],
"offsets": [
[
68,
74
]
],
"normalized": []
},
{
"id": "80744",
"type": "Outcome_Pain",
"text": [
"analgesia"
],
"offsets": [
[
14,
23
]
],
"normalized": []
},
{
"id": "80745",
"type": "Outcome_Other",
"text": [
"identical"
],
"offsets": [
[
253,
262
]
],
"normalized": []
},
{
"id": "80746",
"type": "Outcome_Pain",
"text": [
"analgetic efficiency"
],
"offsets": [
[
263,
283
]
],
"normalized": []
},
{
"id": "80747",
"type": "Outcome_Adverse-effects",
"text": [
"adverse side effects"
],
"offsets": [
[
289,
309
]
],
"normalized": []
},
{
"id": "80748",
"type": "Outcome_Pain",
"text": [
"obstetrical analgesia"
],
"offsets": [
[
418,
439
]
],
"normalized": []
},
{
"id": "80749",
"type": "Outcome_Physical",
"text": [
"inhibitory effects"
],
"offsets": [
[
465,
483
]
],
"normalized": []
},
{
"id": "80750",
"type": "Participant_Condition",
"text": [
"[ Obstetrical analgesia"
],
"offsets": [
[
0,
23
]
],
"normalized": []
}
] | [] | [] | [] |
80751 | 7410734 | [
{
"id": "80752",
"type": "document",
"text": [
"Scaling clinical judgments of symptom pathology by means of the psychophysiological method of magnitude estimation . Summing scores across heterogeneous symptom items without consideration of their differing psychopathological significance has been criticized as producing an inadequate picture of an individual 's clinical status . The purpose of this study was to derive symptom item weights representing clinically judged seriousness of each symptom through the application of Steven 's psychophysical method of magnitude estimation . A nationwide sample of 129 clinicians rated the pathological significance of 221 symptom items in a design such that every rater rated 121 items , 21 of which were rated by all raters and 100 of which were rated only by the A or B subgroup to which each rater was randomly assigned . Each item was rated as to the seriousness of the pathology it would represent if manifested by either a boy child , girl child , boy adolescent , or girl adolescent , with one-fourth of the raters assigned to each condition . The results of 211 two-way analyses of variance revealed that age and age and sex in interaction , but not sex alone , significantly influenced the clinical ratings . The resulting magnitude estimation ratings of symptom pathology ranged from 1.0 to 9.9 . They were demonstrated to have satisfactoy reliability and convergent validity and to have the psychophysical characteristics of a prothetic continuum ."
],
"offsets": [
[
0,
1456
]
]
}
] | [
{
"id": "80753",
"type": "Intervention_Educational",
"text": [
"Steven 's psychophysical method of magnitude estimation ."
],
"offsets": [
[
480,
537
]
],
"normalized": []
},
{
"id": "80754",
"type": "Outcome_Mental",
"text": [
"age and sex"
],
"offsets": [
[
1118,
1129
]
],
"normalized": []
},
{
"id": "80755",
"type": "Outcome_Mental",
"text": [
"magnitude estimation ratings of symptom pathology"
],
"offsets": [
[
1229,
1278
]
],
"normalized": []
}
] | [] | [] | [] |
80756 | 7429786 | [
{
"id": "80757",
"type": "document",
"text": [
"Liquid antacids : palatability and predictability study ."
],
"offsets": [
[
0,
57
]
]
}
] | [
{
"id": "80758",
"type": "Intervention_Pharmacological",
"text": [
"Liquid antacids"
],
"offsets": [
[
0,
15
]
],
"normalized": []
},
{
"id": "80759",
"type": "Participant_Condition",
"text": [
"antacids :"
],
"offsets": [
[
7,
17
]
],
"normalized": []
}
] | [] | [] | [] |
80760 | 7449282 | [
{
"id": "80761",
"type": "document",
"text": [
"Cardiac and haemodynamic measurements in hypertensive pregnancy . 1 . Haemodynamic and left ventricular variables were determined by M-mode echocardiography in 21 normotensive and 36 hypertensive patients during the last trimester of pregnancy . 2 . Blood pressure of hypertensive patients was lowered by bed rest only , or by oxprenolol or methyldopa , but remained elevated . 3 . Cardiac output was raised in the last trimester of pregnancy in both normotensive and hypertensive patients . 4 . Left ventricular mass was increased in normal pregnancy , but displayed an exaggerated increase in hypertensive patients . 5 . Total peripheral resistance was inappropriately elevated in hypertensive pregnancy , except in the oxprenolol-treated group . 6 . There ws no reduction in heart rate or cardiac output in the group treated with beta-adrenoreceptor blocking agents . These factors , in combination with normal peripheral resistance , may contribute to the improvement in foetal outcome described in maternal hypertension of pregnancy treated with oxprenolol ."
],
"offsets": [
[
0,
1063
]
]
}
] | [
{
"id": "80762",
"type": "Intervention_Pharmacological",
"text": [
"oxprenolol or methyldopa"
],
"offsets": [
[
327,
351
]
],
"normalized": []
},
{
"id": "80763",
"type": "Intervention_Pharmacological",
"text": [
"beta-adrenoreceptor blocking agents"
],
"offsets": [
[
833,
868
]
],
"normalized": []
},
{
"id": "80764",
"type": "Intervention_Pharmacological",
"text": [
"oxprenolol ."
],
"offsets": [
[
1051,
1063
]
],
"normalized": []
},
{
"id": "80765",
"type": "Outcome_Physical",
"text": [
"Blood pressure"
],
"offsets": [
[
250,
264
]
],
"normalized": []
},
{
"id": "80766",
"type": "Outcome_Physical",
"text": [
"Cardiac output"
],
"offsets": [
[
382,
396
]
],
"normalized": []
},
{
"id": "80767",
"type": "Outcome_Physical",
"text": [
"Left ventricular mass"
],
"offsets": [
[
496,
517
]
],
"normalized": []
},
{
"id": "80768",
"type": "Outcome_Physical",
"text": [
"Total peripheral resistance"
],
"offsets": [
[
623,
650
]
],
"normalized": []
},
{
"id": "80769",
"type": "Outcome_Physical",
"text": [
"heart rate"
],
"offsets": [
[
778,
788
]
],
"normalized": []
},
{
"id": "80770",
"type": "Outcome_Physical",
"text": [
"cardiac output"
],
"offsets": [
[
792,
806
]
],
"normalized": []
},
{
"id": "80771",
"type": "Participant_Condition",
"text": [
"hypertensive pregnancy"
],
"offsets": [
[
41,
63
]
],
"normalized": []
},
{
"id": "80772",
"type": "Participant_Sample-size",
"text": [
"21"
],
"offsets": [
[
160,
162
]
],
"normalized": []
},
{
"id": "80773",
"type": "Participant_Condition",
"text": [
"normotensive"
],
"offsets": [
[
163,
175
]
],
"normalized": []
},
{
"id": "80774",
"type": "Participant_Sample-size",
"text": [
"36"
],
"offsets": [
[
180,
182
]
],
"normalized": []
},
{
"id": "80775",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
41,
53
]
],
"normalized": []
},
{
"id": "80776",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
41,
53
]
],
"normalized": []
},
{
"id": "80777",
"type": "Participant_Condition",
"text": [
"normotensive"
],
"offsets": [
[
163,
175
]
],
"normalized": []
},
{
"id": "80778",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
41,
53
]
],
"normalized": []
},
{
"id": "80779",
"type": "Participant_Condition",
"text": [
"hypertensive"
],
"offsets": [
[
41,
53
]
],
"normalized": []
}
] | [] | [] | [] |
80780 | 7481533 | [
{
"id": "80781",
"type": "document",
"text": [
"A randomized surveillance study of patients with pedunculated and small sessile tubular and tubulovillous adenomas . The Funen Adenoma Follow-up Study . BACKGROUND We wanted to assess the influence of various surveillance intervals on the risk of new neoplasia after removal of pedunculated and small sessile tubular and tubulovillous adenomas . METHODS After initial colonoscopic polypectomy patients were randomized to surveillance with either 2 years ( group A ) or 4 years ( group B ) between colorectal examinations . RESULTS The cumulated risk of a patient having new adenomas was 35.0 % ( 28.7-41.4 % ) in group A and 35.5 % ( 28.4-42.7 % ) in group B after 48 months . The risk increased to 44.9 % ( 36.0-53.9 % ) and 60.1 % ( 48.5-71.7 % ) , respectively , after 96 months . The risk of significant neoplasia ( carcinoma or adenoma with villous structure , severe dysplasia , or diameter > 10 mm ) was 5.2 % ( 2.3-8.1 % ) and 8.6 % ( 3.8-13.3 % ) after 48 months and 8.6 % ( 4.2-13.0 % ) and 17.4 % ( 7.6-27.2 % ) after 96 months . More than one adenoma at first examination was associated with higher risk of new adenomas . Furthermore , we found a tendency for age above 60 years and male gender to be associated with higher risk of new adenomas . More than two adenomas at first examination was the only factor found to be associated with a higher risk of new significant neoplasia . One patient in group A and two patients in group B developed cancer , which is not significantly different from the number expected ( 3.43 ) in the average Danish population ( RR = 0.9 , 0.2-2.6 ) . CONCLUSION After colonoscopy with removal of all polyps , colorectal examination at 4 years resulted in a similar risk of new adenomas compared with examinations at 2 and 4 years . However , new significant neoplasia tended to be more frequent when first surveillance was at 4 years . Extending the surveillance to 8 years also tended to increase the risk more in the group being examined every 4 years , but reduction of the number of surveillance examinations by more than 50 % and a probable reduction of complications from surveillance examinations themselves may justify a recommendation for the longest interval ."
],
"offsets": [
[
0,
2214
]
]
}
] | [
{
"id": "80782",
"type": "Outcome_Physical",
"text": [
"risk of new neoplasia"
],
"offsets": [
[
239,
260
]
],
"normalized": []
},
{
"id": "80783",
"type": "Outcome_Physical",
"text": [
"risk of a patient having new adenomas"
],
"offsets": [
[
545,
582
]
],
"normalized": []
},
{
"id": "80784",
"type": "Outcome_Physical",
"text": [
"significant neoplasia ( carcinoma or adenoma with villous structure , severe dysplasia , or diameter > 10 mm"
],
"offsets": [
[
796,
904
]
],
"normalized": []
},
{
"id": "80785",
"type": "Outcome_Physical",
"text": [
"higher risk of new adenomas"
],
"offsets": [
[
1104,
1131
]
],
"normalized": []
},
{
"id": "80786",
"type": "Outcome_Physical",
"text": [
"adenomas"
],
"offsets": [
[
106,
114
]
],
"normalized": []
},
{
"id": "80787",
"type": "Outcome_Physical",
"text": [
"risk of new significant neoplasia"
],
"offsets": [
[
1360,
1393
]
],
"normalized": []
},
{
"id": "80788",
"type": "Outcome_Physical",
"text": [
"cancer"
],
"offsets": [
[
1457,
1463
]
],
"normalized": []
},
{
"id": "80789",
"type": "Outcome_Physical",
"text": [
"risk of new adenomas"
],
"offsets": [
[
1111,
1131
]
],
"normalized": []
},
{
"id": "80790",
"type": "Outcome_Physical",
"text": [
"neoplasia"
],
"offsets": [
[
251,
260
]
],
"normalized": []
},
{
"id": "80791",
"type": "Participant_Condition",
"text": [
"pedunculated and small sessile tubular and tubulovillous adenomas"
],
"offsets": [
[
49,
114
]
],
"normalized": []
},
{
"id": "80792",
"type": "Participant_Condition",
"text": [
"initial colonoscopic polypectomy"
],
"offsets": [
[
360,
392
]
],
"normalized": []
},
{
"id": "80793",
"type": "Participant_Age",
"text": [
"age above 60 years"
],
"offsets": [
[
1172,
1190
]
],
"normalized": []
},
{
"id": "80794",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
1195,
1199
]
],
"normalized": []
}
] | [] | [] | [] |
80795 | 7485923 | [
{
"id": "80796",
"type": "document",
"text": [
"[ Erythropoietin therapy during frequent autologous blood donations . Dose-finding study ] . Avoidance of homologous blood products and patients ' demand for preoperative autologous blood donation programs are increasing . As many of these patients are older , with a compromised cardiovascular system and a slow response of the erythropoietic system when anemia occurs , the feasibility and benefit of autologous blood donation is often limited . Augmentation of preoperative blood donation by therapy with recombinant human erythropoietin ( rHuEPO ) has been described in animal models and in patients . METHODS . In a multicenter , controlled , randomized trial , 49 patients scheduled for orthopaedic or vascular surgery received 0 ( control group , n = 9 ) , 200 ( n = 10 ) , 300 ( n = 11 ) , 400 ( n = 10 ) or 500 ( n = 9 ) U/kg rHuEPO ( Erypo , Cilag , Sulzbach , distributor Fresenius , Oberursel , Germany ) subcutaneously twice a week for 3 weeks while every week 450 ml blood was collected . Iron sulphate 100 mg was prescribed orally twice a day . Patients were ineligible if they had uncontrolled hypertension , recent myocardial infarction , haematological disorders or a history of seizures . Blood donation had to be cancelled if the haematocrit was below 30 % . RESULTS . There was a significant ( ANOVA ) drop of the haematocrit value only in the control group , and end-point values for haematocrit and haemoglobin were significantly elevated in the 400 and 500 U/kg groups compared with the control group ( Table 9 ) . DISCUSSION . The erythropoietic stimulus of phlebotomy for autologous blood donations is often not efficient enough to guarantee a constant haematocrit . Lowering of the preoperative haematocrit jeopardizes the aim of avoidance of homologous blood transfusions . rHuEPO increased the efficiency of autologous blood collections , as predonation haematocrit values could be preserved in the high-dosage groups . As a consequence , homologous transfusions could be avoided . However , there were broad interindividual differences in the erythropoietic response , possibly due to limitations in iron availability . Adverse effects of rHuEPO therapy , such as hypertension , thrombosis or neurologic disorders , are mostly reported in patients with terminal kidney failure . No such disturbances were observed in the present study . CONCLUSION . rHuEPO ameliorates the preoperative decrease of haemoglobin and haematocrit values due to autologous blood donations in a dose-related fashion . The individually adjusted dosage of rHuEPO and iron supplementation merits further investigation ."
],
"offsets": [
[
0,
2623
]
]
}
] | [
{
"id": "80797",
"type": "Intervention_Pharmacological",
"text": [
"Erythropoietin"
],
"offsets": [
[
2,
16
]
],
"normalized": []
},
{
"id": "80798",
"type": "Intervention_Pharmacological",
"text": [
"recombinant human erythropoietin"
],
"offsets": [
[
508,
540
]
],
"normalized": []
},
{
"id": "80799",
"type": "Intervention_Pharmacological",
"text": [
"rHuEPO"
],
"offsets": [
[
543,
549
]
],
"normalized": []
},
{
"id": "80800",
"type": "Intervention_Pharmacological",
"text": [
"Erypo"
],
"offsets": [
[
844,
849
]
],
"normalized": []
},
{
"id": "80801",
"type": "Intervention_Pharmacological",
"text": [
"Cilag"
],
"offsets": [
[
852,
857
]
],
"normalized": []
},
{
"id": "80802",
"type": "Intervention_Pharmacological",
"text": [
"Sulzbach"
],
"offsets": [
[
860,
868
]
],
"normalized": []
},
{
"id": "80803",
"type": "Intervention_Pharmacological",
"text": [
"distributor Fresenius"
],
"offsets": [
[
871,
892
]
],
"normalized": []
},
{
"id": "80804",
"type": "Intervention_Pharmacological",
"text": [
"Oberursel"
],
"offsets": [
[
895,
904
]
],
"normalized": []
},
{
"id": "80805",
"type": "Intervention_Pharmacological",
"text": [
"Iron sulphate 100 mg"
],
"offsets": [
[
1003,
1023
]
],
"normalized": []
},
{
"id": "80806",
"type": "Intervention_Pharmacological",
"text": [
"rHuEPO"
],
"offsets": [
[
543,
549
]
],
"normalized": []
},
{
"id": "80807",
"type": "Outcome_Other",
"text": [
"haematocrit value"
],
"offsets": [
[
1335,
1352
]
],
"normalized": []
},
{
"id": "80808",
"type": "Outcome_Other",
"text": [
"end-point values for haematocrit and haemoglobin"
],
"offsets": [
[
1385,
1433
]
],
"normalized": []
},
{
"id": "80809",
"type": "Outcome_Physical",
"text": [
"haematocrit"
],
"offsets": [
[
1250,
1261
]
],
"normalized": []
},
{
"id": "80810",
"type": "Outcome_Physical",
"text": [
"haematocrit"
],
"offsets": [
[
1250,
1261
]
],
"normalized": []
},
{
"id": "80811",
"type": "Outcome_Other",
"text": [
"efficiency"
],
"offsets": [
[
1823,
1833
]
],
"normalized": []
},
{
"id": "80812",
"type": "Outcome_Physical",
"text": [
"erythropoietic response"
],
"offsets": [
[
2073,
2096
]
],
"normalized": []
},
{
"id": "80813",
"type": "Outcome_Adverse-effects",
"text": [
"hypertension"
],
"offsets": [
[
1110,
1122
]
],
"normalized": []
},
{
"id": "80814",
"type": "Outcome_Adverse-effects",
"text": [
"thrombosis"
],
"offsets": [
[
2209,
2219
]
],
"normalized": []
},
{
"id": "80815",
"type": "Outcome_Adverse-effects",
"text": [
"neurologic disorders"
],
"offsets": [
[
2223,
2243
]
],
"normalized": []
},
{
"id": "80816",
"type": "Outcome_Physical",
"text": [
"terminal kidney failure ."
],
"offsets": [
[
2283,
2308
]
],
"normalized": []
},
{
"id": "80817",
"type": "Outcome_Physical",
"text": [
"ameliorates"
],
"offsets": [
[
2387,
2398
]
],
"normalized": []
},
{
"id": "80818",
"type": "Outcome_Physical",
"text": [
"haemoglobin and haematocrit values"
],
"offsets": [
[
2428,
2462
]
],
"normalized": []
},
{
"id": "80819",
"type": "Participant_Condition",
"text": [
"autologous blood donations"
],
"offsets": [
[
41,
67
]
],
"normalized": []
},
{
"id": "80820",
"type": "Participant_Age",
"text": [
"older"
],
"offsets": [
[
253,
258
]
],
"normalized": []
},
{
"id": "80821",
"type": "Participant_Condition",
"text": [
"compromised cardiovascular system"
],
"offsets": [
[
268,
301
]
],
"normalized": []
},
{
"id": "80822",
"type": "Participant_Sample-size",
"text": [
"49"
],
"offsets": [
[
667,
669
]
],
"normalized": []
},
{
"id": "80823",
"type": "Participant_Condition",
"text": [
"orthopaedic or vascular surgery"
],
"offsets": [
[
693,
724
]
],
"normalized": []
},
{
"id": "80824",
"type": "Participant_Condition",
"text": [
"terminal kidney failure"
],
"offsets": [
[
2283,
2306
]
],
"normalized": []
}
] | [] | [] | [] |
80825 | 7486842 | [
{
"id": "80826",
"type": "document",
"text": [
"Comparison of fluoxetine and placebo in the treatment of obesity . Our study aims at assessing the efficacy and safety of fluoxetine as compared with placebo in the treatment of obesity using a double-blind crossover design . We studied 42 obese women ( body mass index 35.9 +/- 5.3 kg/m2 ) . The obese patients were randomized to start treatment with fluoxetine ( group A ) or placebo ( group B ) for 3 months ( period 1 ) . After a 1-month washout period , treatment was crossed for the following 3 months ( period 2 ) . There was no significant difference in weight loss when the patients were treated with fluoxetine ( group A period 1 and group B period 2 ) as compared with patients treated with placebo ( group B period 1 and group A period 2 ) . There were no significant differences in monthly weight reduction during both treatments . In conclusion , we demonstrated that serotoninergic drugs such as fluoxetine need further investigation before being used indiscriminately in obese subjects ."
],
"offsets": [
[
0,
1003
]
]
}
] | [
{
"id": "80827",
"type": "Intervention_Pharmacological",
"text": [
"fluoxetine"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "80828",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
29,
36
]
],
"normalized": []
},
{
"id": "80829",
"type": "Intervention_Pharmacological",
"text": [
"fluoxetine"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "80830",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
29,
36
]
],
"normalized": []
},
{
"id": "80831",
"type": "Intervention_Pharmacological",
"text": [
"fluoxetine"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "80832",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
29,
36
]
],
"normalized": []
},
{
"id": "80833",
"type": "Intervention_Pharmacological",
"text": [
"fluoxetine"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "80834",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
29,
36
]
],
"normalized": []
},
{
"id": "80835",
"type": "Intervention_Pharmacological",
"text": [
"fluoxetine"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "80836",
"type": "Outcome_Physical",
"text": [
"obesity ."
],
"offsets": [
[
57,
66
]
],
"normalized": []
},
{
"id": "80837",
"type": "Outcome_Physical",
"text": [
"weight loss"
],
"offsets": [
[
562,
573
]
],
"normalized": []
},
{
"id": "80838",
"type": "Outcome_Physical",
"text": [
"monthly weight reduction"
],
"offsets": [
[
795,
819
]
],
"normalized": []
},
{
"id": "80839",
"type": "Participant_Condition",
"text": [
"obesity ."
],
"offsets": [
[
57,
66
]
],
"normalized": []
},
{
"id": "80840",
"type": "Participant_Sample-size",
"text": [
"42"
],
"offsets": [
[
237,
239
]
],
"normalized": []
}
] | [] | [] | [] |
80841 | 7488285 | [
{
"id": "80842",
"type": "document",
"text": [
"Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis . A prospective , randomized trial in sixty-two patients . OBJECTIVE To define the most effective treatment for severe polyarteritis nodosa ( PAN ) and Churg-Strauss syndrome ( CSS ) and to investigate the indication for plasma exchange treatment . METHODS We conducted a prospective , randomized , multicenter trial in which 62 patients were randomly assigned to receive either prednisone plus cyclophosphamide ( intravenous bolus ) ( group A ; n = 28 ) or prednisone plus cyclophosphamide ( intravenous bolus ) plus plasma exchanges ( group B ; n = 34 ) as first-line treatment for severe PAN or CSS . Factors predicting poor prognosis were renal symptoms , gastrointestinal tract involvement , cardiomyopathy , central nervous system involvement , weight loss > 10 % of body weight , and age > 50 years old . Patients with hepatitis B virus-related PAN were not included in this study . The end point of the study was control of the disease ( recovery or remission ) or death . RESULTS Clinical symptoms and laboratory findings did not differ significantly in the 2 groups . Initial control of the disease was similar in both groups . Relapse after initial control of the disease was observed in 7 patients ( 4 in group A and 3 in group B ) . The mean +/- SD followup period was 31.1 +/- 20 months for group A and 35.9 +/- 16.8 months for group B . At 5 years of followup , 38 patients ( 61.3 % ) were cured ( 16 in group A and 22 in group B ) , and 5 ( 8.1 % ) were in remission without treatment but had not yet completed the cure-defining period of 18 months ( 3 in group A and 2 in group B ) . Eight ( 12.9 % ) ( 2 in group A and 2 in group B ) were considered to be in clinical remission and required a maintenance regimen of low-dose corticosteroids . Eleven patients died during the study period ( 7 in group A [ 25 % ] , 4 in group B [ 11.8 % ] ) . Uncontrolled vasculitis was responsible for 4 deaths ( 2 in each group ) , and treatment side effects caused the death of 1 patient in group A . There was no significant difference between the 5-year cumulative survival rates of the 2 groups ( 75 % and 88 % , respectively ) . CONCLUSION Based on our data , combined treatment with prednisone , cyclophosphamide , and plasma exchanges is not superior to treatment with prednisone and cyclophosphamide alone , and plasma exchanges should not be systematically proposed for initial treatment of severe PAN or CSS ."
],
"offsets": [
[
0,
2660
]
]
}
] | [
{
"id": "80843",
"type": "Intervention_Pharmacological",
"text": [
"Corticosteroids plus pulse cyclophosphamide and plasma exchanges"
],
"offsets": [
[
0,
64
]
],
"normalized": []
},
{
"id": "80844",
"type": "Intervention_Pharmacological",
"text": [
"corticosteroids plus pulse cyclophosphamide alone"
],
"offsets": [
[
72,
121
]
],
"normalized": []
},
{
"id": "80845",
"type": "Intervention_Pharmacological",
"text": [
"prednisone plus cyclophosphamide ( intravenous bolus )"
],
"offsets": [
[
617,
671
]
],
"normalized": []
},
{
"id": "80846",
"type": "Intervention_Pharmacological",
"text": [
"prednisone plus cyclophosphamide ( intravenous bolus ) plus plasma exchanges"
],
"offsets": [
[
696,
772
]
],
"normalized": []
},
{
"id": "80847",
"type": "Intervention_Pharmacological",
"text": [
"prednisone , cyclophosphamide"
],
"offsets": [
[
2430,
2459
]
],
"normalized": []
},
{
"id": "80848",
"type": "Intervention_Pharmacological",
"text": [
"plasma exchanges"
],
"offsets": [
[
48,
64
]
],
"normalized": []
},
{
"id": "80849",
"type": "Intervention_Pharmacological",
"text": [
"prednisone"
],
"offsets": [
[
617,
627
]
],
"normalized": []
},
{
"id": "80850",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
27,
43
]
],
"normalized": []
},
{
"id": "80851",
"type": "Outcome_Physical",
"text": [
"Relapse"
],
"offsets": [
[
1376,
1383
]
],
"normalized": []
},
{
"id": "80852",
"type": "Outcome_Physical",
"text": [
"mean +/- SD followup"
],
"offsets": [
[
1488,
1508
]
],
"normalized": []
},
{
"id": "80853",
"type": "Outcome_Physical",
"text": [
"cured"
],
"offsets": [
[
1643,
1648
]
],
"normalized": []
},
{
"id": "80854",
"type": "Outcome_Physical",
"text": [
"clinical remission"
],
"offsets": [
[
1915,
1933
]
],
"normalized": []
},
{
"id": "80855",
"type": "Outcome_Other",
"text": [
"maintenance regimen of low-dose corticosteroids"
],
"offsets": [
[
1949,
1996
]
],
"normalized": []
},
{
"id": "80856",
"type": "Outcome_Mortality",
"text": [
"died"
],
"offsets": [
[
2015,
2019
]
],
"normalized": []
},
{
"id": "80857",
"type": "Outcome_Mortality",
"text": [
"deaths"
],
"offsets": [
[
2144,
2150
]
],
"normalized": []
},
{
"id": "80858",
"type": "Outcome_Adverse-effects",
"text": [
"treatment side effects"
],
"offsets": [
[
2177,
2199
]
],
"normalized": []
},
{
"id": "80859",
"type": "Outcome_Mortality",
"text": [
"death"
],
"offsets": [
[
1211,
1216
]
],
"normalized": []
},
{
"id": "80860",
"type": "Outcome_Mortality",
"text": [
"5-year cumulative survival rates"
],
"offsets": [
[
2291,
2323
]
],
"normalized": []
},
{
"id": "80861",
"type": "Participant_Condition",
"text": [
"severe polyarteritis nodosa ( PAN ) and Churg-Strauss syndrome ( CSS )"
],
"offsets": [
[
350,
420
]
],
"normalized": []
},
{
"id": "80862",
"type": "Participant_Sample-size",
"text": [
"62 patients"
],
"offsets": [
[
564,
575
]
],
"normalized": []
}
] | [] | [] | [] |
80863 | 7489845 | [
{
"id": "80864",
"type": "document",
"text": [
"Cholesterol-lowering therapy may retard the progression of diabetic nephropathy . There is experimental evidence to suggest that hypercholesterolaemia may play a pathogenetic role in progressive glomerular injury . We investigated the effect of cholesterol-lowering therapy on the progression of diabetic nephropathy in 34 patients with non-insulin-dependent diabetes mellitus . Patients were randomly assigned in a single-blind fashion to treatment with either lovastatin , an HMG CoA reductase inhibitor ( n = 16 ; mean dose 30.0 +/- 12.6 mg/day ) or placebo ( n = 18 ) for 2 years . Renal function was assessed by serially measuring the serum creatinine , glomerular filtration rate ( using Cr51-EDTA ) , and 24-h urinary protein excretion . Lovastatin treatment was associated with significant reductions in total cholesterol ( p < 0.001 ) , LDL-cholesterol ( p < 0.001 ) and apo B ( p < 0.01 ) , the reductions at 24 months being 26 , 30 and 18 % , respectively . Beneficial effects on serum triglyceride , HDL-cholesterol and apo A1 levels were also observed . Lp ( a ) showed no significant change in both groups . Glomerular filtration rate deteriorated significantly in the placebo group after 24 months ( p < 0.025 ) but showed no significant change in the lovastatin-treated patients . The increase in serum creatinine was statistically significant ( p < 0.02 ) in placebo-treated patients at 12 and 24 months , and in the lovastatin group after 24 months . Twenty-four hour urinary protein excretion increased in both groups ( p < 0.05 ) . Lovastatin treatment was not associated with significant elevations in liver or muscle enzymes . We conclude that effective normalisation of hypercholesterolaemia may retard the progression of diabetic nephropathy ."
],
"offsets": [
[
0,
1767
]
]
}
] | [
{
"id": "80865",
"type": "Intervention_Physical",
"text": [
"Cholesterol-lowering therapy"
],
"offsets": [
[
0,
28
]
],
"normalized": []
},
{
"id": "80866",
"type": "Intervention_Pharmacological",
"text": [
"lovastatin , an HMG CoA reductase inhibitor"
],
"offsets": [
[
462,
505
]
],
"normalized": []
},
{
"id": "80867",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
553,
560
]
],
"normalized": []
},
{
"id": "80868",
"type": "Outcome_Physical",
"text": [
"total cholesterol"
],
"offsets": [
[
812,
829
]
],
"normalized": []
},
{
"id": "80869",
"type": "Outcome_Physical",
"text": [
"LDL-cholesterol"
],
"offsets": [
[
846,
861
]
],
"normalized": []
},
{
"id": "80870",
"type": "Outcome_Physical",
"text": [
"apo B"
],
"offsets": [
[
880,
885
]
],
"normalized": []
},
{
"id": "80871",
"type": "Outcome_Physical",
"text": [
"serum triglyceride"
],
"offsets": [
[
991,
1009
]
],
"normalized": []
},
{
"id": "80872",
"type": "Outcome_Physical",
"text": [
"HDL-cholesterol"
],
"offsets": [
[
1012,
1027
]
],
"normalized": []
},
{
"id": "80873",
"type": "Outcome_Physical",
"text": [
"apo A1 levels"
],
"offsets": [
[
1032,
1045
]
],
"normalized": []
},
{
"id": "80874",
"type": "Outcome_Physical",
"text": [
"Lp ( a )"
],
"offsets": [
[
1067,
1075
]
],
"normalized": []
},
{
"id": "80875",
"type": "Outcome_Other",
"text": [
"no significant"
],
"offsets": [
[
1083,
1097
]
],
"normalized": []
},
{
"id": "80876",
"type": "Outcome_Other",
"text": [
"Glomerular filtration rate deteriorated significantly"
],
"offsets": [
[
1122,
1175
]
],
"normalized": []
},
{
"id": "80877",
"type": "Outcome_Other",
"text": [
"no significant change"
],
"offsets": [
[
1083,
1104
]
],
"normalized": []
},
{
"id": "80878",
"type": "Outcome_Physical",
"text": [
"increase in serum creatinine"
],
"offsets": [
[
1301,
1329
]
],
"normalized": []
},
{
"id": "80879",
"type": "Outcome_Other",
"text": [
"statistically significant"
],
"offsets": [
[
1334,
1359
]
],
"normalized": []
},
{
"id": "80880",
"type": "Outcome_Physical",
"text": [
"urinary protein excretion increased"
],
"offsets": [
[
1486,
1521
]
],
"normalized": []
},
{
"id": "80881",
"type": "Outcome_Other",
"text": [
"not associated"
],
"offsets": [
[
1577,
1591
]
],
"normalized": []
},
{
"id": "80882",
"type": "Outcome_Physical",
"text": [
"significant elevations"
],
"offsets": [
[
1597,
1619
]
],
"normalized": []
},
{
"id": "80883",
"type": "Outcome_Physical",
"text": [
"liver or muscle enzymes"
],
"offsets": [
[
1623,
1646
]
],
"normalized": []
},
{
"id": "80884",
"type": "Outcome_Physical",
"text": [
"hypercholesterolaemia"
],
"offsets": [
[
129,
150
]
],
"normalized": []
},
{
"id": "80885",
"type": "Outcome_Physical",
"text": [
"diabetic nephropathy"
],
"offsets": [
[
59,
79
]
],
"normalized": []
},
{
"id": "80886",
"type": "Participant_Condition",
"text": [
"diabetic nephropathy ."
],
"offsets": [
[
59,
81
]
],
"normalized": []
},
{
"id": "80887",
"type": "Participant_Condition",
"text": [
"progressive glomerular injury ."
],
"offsets": [
[
183,
214
]
],
"normalized": []
},
{
"id": "80888",
"type": "Participant_Sample-size",
"text": [
"34"
],
"offsets": [
[
320,
322
]
],
"normalized": []
},
{
"id": "80889",
"type": "Participant_Condition",
"text": [
"non-insulin-dependent diabetes mellitus"
],
"offsets": [
[
337,
376
]
],
"normalized": []
}
] | [] | [] | [] |
80890 | 7491394 | [
{
"id": "80891",
"type": "document",
"text": [
"A comparison of live and videotape ratings : clomipramine and haloperidol in autism . This study compared live ratings with ratings of videotapes and compared response to clomipramine with response to haloperidol in 8 subjects , mean age 5.62 years , who met criteria for autism . They were consecutive admissions to a pilot study of clomipramine ( n = 4 ) or a double-blind , placebo controlled study of haloperidol ( n = 4 ) . Live ratings were performed by two raters at the end of the pre-treatment placebo baseline period and at the end of the drug treatment period on the CPRS and the CGI and were videotaped . Employing the same instruments , these videotapes were rated by two raters who did not know the subjects and were blind to study design , treatment , and study phase . Ratings of videotapes significantly differed from live ratings . A treatment effect for haloperidol was detected only on live ratings and not on ratings of videotapes . No treatment effect was detected for clomipramine in either live or videotape ratings ."
],
"offsets": [
[
0,
1041
]
]
}
] | [
{
"id": "80892",
"type": "Intervention_Pharmacological",
"text": [
"clomipramine"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "80893",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
62,
73
]
],
"normalized": []
},
{
"id": "80894",
"type": "Intervention_Pharmacological",
"text": [
"clomipramine"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "80895",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
62,
73
]
],
"normalized": []
},
{
"id": "80896",
"type": "Intervention_Pharmacological",
"text": [
"clomipramine"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "80897",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
377,
384
]
],
"normalized": []
},
{
"id": "80898",
"type": "Intervention_Pharmacological",
"text": [
"haloperidol"
],
"offsets": [
[
62,
73
]
],
"normalized": []
},
{
"id": "80899",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
377,
384
]
],
"normalized": []
},
{
"id": "80900",
"type": "Intervention_Pharmacological",
"text": [
"clomipramine"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "80901",
"type": "Outcome_Other",
"text": [
"Ratings of videotapes"
],
"offsets": [
[
785,
806
]
],
"normalized": []
},
{
"id": "80902",
"type": "Outcome_Other",
"text": [
"live ratings"
],
"offsets": [
[
106,
118
]
],
"normalized": []
},
{
"id": "80903",
"type": "Outcome_Other",
"text": [
"live ratings"
],
"offsets": [
[
106,
118
]
],
"normalized": []
},
{
"id": "80904",
"type": "Outcome_Other",
"text": [
"ratings of videotapes"
],
"offsets": [
[
124,
145
]
],
"normalized": []
},
{
"id": "80905",
"type": "Outcome_Other",
"text": [
"live"
],
"offsets": [
[
16,
20
]
],
"normalized": []
},
{
"id": "80906",
"type": "Outcome_Other",
"text": [
"videotape ratings"
],
"offsets": [
[
25,
42
]
],
"normalized": []
},
{
"id": "80907",
"type": "Participant_Condition",
"text": [
"clomipramine"
],
"offsets": [
[
45,
57
]
],
"normalized": []
},
{
"id": "80908",
"type": "Participant_Condition",
"text": [
"haloperidol in autism"
],
"offsets": [
[
62,
83
]
],
"normalized": []
},
{
"id": "80909",
"type": "Participant_Sample-size",
"text": [
"8"
],
"offsets": [
[
216,
217
]
],
"normalized": []
},
{
"id": "80910",
"type": "Participant_Age",
"text": [
"5.62 years"
],
"offsets": [
[
238,
248
]
],
"normalized": []
}
] | [] | [] | [] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.